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Harlequin ichthyosis (HI), a rare severe form of congenital ichthyosis is caused by recessive mutations in the ABCA12 gene. At birth, affected neonates have widespread, grossly thickened skin, separated by deep red fissures, bilateral ectropion, eclabium and a rudimentary nose and ears. Previously, most babies died shortly after birth but with improved neonatal care and the early introduction of oral retinoids, there is now a cohort of HI survivors. 

ABCA12 mutation analysis was performed and bi-allelic mutations were identified in 14 out of 17 cases, 9 of which were novel. In one consanguineous case, reverse transcriptase PCR on a parental skin biopsy and copy number analysis were used to identify a multiple exon deletion, when standard techniques failed. 

A previous study showed that in ABCA12 deficiency, epidermal differentiation is dysregulated. Staining of skin biopsies with RXR-α and PPAR-δ showed that both of these nuclear hormone receptors are up-regulated in the spinous and granular cell layers of HI skin compared to normal skin while ABCA1 is down regulated in the basal layer. 
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The skin is the largest organ in the body. It has a complex structure comprising three layers. The outermost epidermis is a cellular layer that consists of stratified squamous epithelium. This overlies the dermis where connective tissue provides tensile strength and elasticity, followed by the subcutaneous layer that largely consists of adipose tissue. A vestigial layer of striated muscle separates the skin from the rest of the body.  

The epidermis is a layered structure that is mainly composed of keratinocytes. These cells are formed by a process of terminal differentiation from cells that originate in the basal layer of the epidermis and migrate upwards towards the surface. Other cells in the epidermis are the melanocytes that donate pigment to keratinocytes, dendritic Langerhans’ cells that have an immunological function and neuroendocrine Merkel cells. In addition, hair follicles and eccrine and apocrine sweat glands comprise the skin appendages. Collectively these features allow the skin to perform its multiple functions that include acting as a self- repairing barrier to the external environment; providing defence against ultraviolet radiation, microbes and excessive water loss or absorption; thermoregulation and as a site for vitamin D synthesis. The skin is also a sensory organ that allows one to feel painful stimuli, touch and temperature and is a site for antigen presentation and wound healing (Freinkel & Woodley, 2001).

There are regional variations in the thickness of the skin and the distribution of appendages. In humans, there are two main types of skin distinguished by the presence or absence of hair. Glabrous (non-hairy) skin has a thick epidermis with a compact stratum corneum, lacks hair follicles and sebaceous glands and has encapsulated sense organs. This type of skin is found on the palms, soles and lips. Hair bearing skin has both hair follicles and sebaceous glands but lacks encapsulated sense organs. Its structure can vary at different body sites, for example on the scalp there are many more hair follicles than at other sites (Wolff, et al., 2007). 





The epidermis is the outermost layer of the skin and is derived from the embryonic ectoderm. Keratinocytes comprise 95% of cells in the epidermis. They have a cytoskeleton that is made up of actin containing microfilaments, tubulin containing microtubules and keratin intermediate filaments. (Holbrook, 1991).  There are 54 known functioning keratin genes that are divided into two families: type I (basic) and type II (acidic). Mapping studies have shown that acidic-basic keratin pairs are co-expressed in a cell- and tissue-specific manner. Basal keratinocytes express keratin (K) 5 and K14 (Fuchs & Green, 1980) while in the suprabasal epidermis, K1 and K10 are characteristic of epidermal differentiation (Woodcock-Mitchell et al., 1982). K15 is expressed in basal keratinocytes of the hair follicle bulge region; K9 is restricted to palmoplantar epidermis and K2e to the superficial interfollicular epidermis. 

Once keratinocytes are committed to terminal differentiation, they migrate upwards through the epidermis and are eventually shed at the surface. This leads to the formation of four variably differentiated epidermal layers: the stratum basale, stratum spinosum, stratum granulosum and stratum corneum (Figure 1.1).

Stratum basale (basal layer)




Stratum spinosum (spinous layer)
The suprabasal spinous keratinocytes are polyhedral while those nearer the granular layer are more flattened and also contain organelles called lamellar bodies (LB). The proteins K1 and K10 are newly synthesised in the spinous layer and are characteristic of epidermal differentiation. Adjacent cells are joined by desmosomes that resemble tiny spine-like projections microscopically, giving the layer its name.

Stratum granulosum (granular layer)
This layer derives its name from the presence of keratohyaline granules within the keratinocytes. These structures are mainly composed of the protein profilaggrin, which when proteolytically cleaved yields filaggrin, a protein involved in epidermal cornification. The granules also contain loricrin, a protein that forms part of the cornified cell envelope and keratin intermediate filaments. The granular layer is also the primary site of activity of LB, specifically at the granular-cornified layer interface. In palmoplantar skin there is an additional zone between the granular layer and the stratum corneum named the stratum lucidum that contains cells that are still nucleated and are referred to as transitional cells.

Stratum corneum (SC)











1.2.2	Dermal-epidermal basement membrane zone 






The dermis is derived from the embryonic mesoderm and lies between the epidermis and the subcutaneous fat. It provides the epidermis with nutrients via the BMZ gives the skin elasticity and strength and also aids in thermoregulation and the detection of sensory stimuli. Unlike the epidermis it has a rich blood supply and nervous innervation. 

The dermis is divided into the upper papillary dermis and the lower reticular region. It is less cellular than the epidermis and is mainly composed of an amorphous ground substance in which proteins and polysaccharides combine to form hygroscopic proteoglycan macromolecules that strongly attract and retain water. Interspersed within this extracellular matrix are collagens that provide great tensile strength and elastic fibres such as elastin that confer flexibility and resiliance. Other dermal components include fibrillin, fibronectin and laminins. 











Regeneration of the skin and its appendages is facilitated by stem cells. These can be found in the basal layer of the interfollicular epidermis, the bulge area of hair follicles and at the base of sebaceous glands. Stem cells can both self renew and give rise to differentiating cells. In the epidermis it remains unclear what proportion of basal cells are stem cells and how many of these become committed to terminal differentiation. The longstanding theory divides basal keratinocytes into epidermal proliferation units. Within each unit a single stem cell divides to produce an equal number of stem daughter cells and non-stem committed progenitor cells named transient amplifying (TA) cells. These divide a small number of times before withdrawing from the cell cycle and undergoing terminal differentiation in the suprabasal layer. However, recent data challenges the existence of TA cells and instead proposes that basal layer stem cells can become spinous layer cells directly or by delaminating from the basal layer, depending on whether the orientation of the cell spindle is horizontal or vertical  ADDIN EN.CITE (Lechler & Fuchs, 2005). 


1.4	Pathogenesis of the skin barrier

The major function of the epidermis is to act as a barrier to the external environment. This is achieved by two independent mechanisms that result in the terminal differentiation of proliferative basal layer keratinocytes, into flattened enucleate and mitotically inactive squames and by the formation of extracellular lipid-enriched lamellar membranes in the SC. 






LB, also known as lamellar granules, keratinosomes, membrane coating granules and Odland bodies are specialised secretory granules that are thought to be essential in barrier formation and desquamation  ADDIN EN.CITE (Hayward, 1979; Odland, 1960). They measure 0.2-0.3 m in diameter (Schmitz & Muller, 1991) and are found in greatest numbers in the granular layer of the epidermis and to a lesser extent in the spinous layer. 

Landman (1986) proposed that LB were isolated vesicles formed via budding from the trans-golgi network of epidermal keratinocytes.  According to this theory, the vesicles were thought to contain multiple stacked flattened LB discs. Upon arrival at the stratum granulosum / SC interface, the LB would fuse with each other and the LB discs would form multilamellar membrane sheets in the SC intercellular space. However, Norlen (2001) considered it unnatural, time consuming and a waste of energy for a continuous membrane structure like the trans-golgi to be disrupted and then for another similar structure, the intercellular lipid lamellae of the SC to be reformed. According to the ‘membrane folding model’ (Norlen, 2001), LB are not discrete organelles, rather a branched system continuous with the trans-golgi , that unfold into the extracellular space in a non-energy dependant manner and where membrane continuity is preserved (Fartasch, 2004). 

LB contain the precursors of the SC lipid lamellae namely, phospholipids, glucosylceramides, sphingomyelin and cholesterol and their respective lipid processing enzymes: phospholipases, -glucocerebrosidase, acidic sphingomyelinase and steroid sulfatase (Elias and Feingold, 2006). The incorporation of these enzymes into LB requires the prior or concurrent delivery of lipid to the LB (Rassner et al., 1999). In the absence of lipids, these enzymes are not transported from the golgi to LB. Furthermore, the key lipids must all be present in appropriate amounts to synthesise LB and an excess or deficiency can lead to disturbed LB formation. To this end the lipid transporter ABCA12 may play a key role in lipid delivery to the LB and is thus crucial in LB formation. This will be discussed further in section 1.7.2.






The lipid lamellae of the SC are uniquely composed of 50% ceramides, 25% cholesterol and 15% free fatty acids (Feingold, 2007). These lipids are delivered to the SC in their precursor form via LB. On LB exocytosis the lipids are further metabolised by the enzymes that are co-secreted with them. In addition to providing the lipids needed for the extracellular matrix, the products of this processing also have other important effects. Glycerol that is formed by breakdown of phospholipids acts as a water holding agent that keeps the SC hydrated (Feingold, 2007) and free fatty acids contribute to the acidification of the SC  ADDIN EN.CITE (Fluhr, et al., 2001). A pH of 5-5.5 is needed for the efficient functioning of many of the enzymes in the SC such as -glucocerebrosidase and sphingomyelinase. Finally, the breakdown of cholesterol sulphate to cholesterol by steroid sulphatase plays an important role in controlling desquamation  ADDIN EN.CITE (Elias, et al., 1984).  

Many of the lipids destined for the SC are synthesised in the skin. The epidermis is an active site of cholesterol and fatty acid synthesis (Feingold, 1991)  and the latter serve as precursors for both phospholipids and ceramides. Ceramides are lipid molecules composed of the amino alcohol sphingosine and a fatty acid. Ceramides are synthesised from sphingomyelin hydrolysis, de novo synthesis from palmitate and serine or via the salvage pathway whereby complex sphingolipids are broken down into sphingosine that is then recycled to form ceramide. In addition to being a major constituent of the SC, ceramides are found in high concentrations in cell membranes and act as signalling molecules for a number of cellular functions.  Glucosylceramide is synthesised from ceramide by the action of glucosylceramide synthase, an enzyme that is predominantly localised in the outer epidermis (Chujor, et al., 1998). There is evidence to suggest that extracutaneous lipids also contribute to maintaining the epidermal barrier. For example systemically administered labelled cholesterol and fatty acids are delivered to the epidermis (Nikkari, et al., 1975)  and essential fatty acids, that by definition are only available form dietary sources, are present in large quantities in the SC (Elias & Brown, 1978). 






Endogenous intracellular lipids can exert effects on gene expression via their interaction with nuclear hormone receptors.  These receptors, (also termed liposensors as many of their ligands are lipid metabolites) are all characterised by a central DNA binding domain, which targets the receptor to specific DNA sequences (response elements). The DNA binding domain is composed of two highly conserved zinc fingers and the C-terminal domain of the receptor contains the ligand-binding site. Once bound, the ligand shifts the receptor to a transcriptionally active state which allows the DNA binding domain to regulate gene expression (Feingold & Jiang, 2011). In the skin, intracellular lipids interact with the peroxisome proliferator-activated receptors (PPAR), liver X receptors (LXR) and retinoid X receptor  (RXR) to facilitate epidermal development.

There are three PPAR isoforms, , / and . These receptors form heterodimers with RXR- to regulate gene expression and are activated by fatty acids, eicosanoids and other lipid metabolites  ADDIN EN.CITE (Chawla, et al., 2001; Kersten, et al., 2000; Mangelsdorf & Evans, 1995). All three isoforms are expressed in human epidermis (Rivier, et al., 1998) but PPAR/ is the most abundant  ADDIN EN.CITE (Westergaard, et al., 2003). LXRs are responsible for reverse cholesterol transport and regulate the genes involved in the cellular efflux of excess cholesterol and phospholipids (Edwards, et al., 2002). The two isoforms,  and  are both activated by the same oxysterol metabolites, they also form heterodimers with RXR-  ADDIN EN.CITE (Willy, et al., 1995) and have been localised in human skin  ADDIN EN.CITE (Russell, et al., 2007). 

Effects of PPAR and LXR on keratinocyte differentiation
Treatment of cultured keratinocytes and topical treatment of normal mouse skin with activators of PPAR, PPAR/, PPAR and LXR increase the mRNA and protein levels of markers of keratinocyte differentiation such as involucrin, filaggrin, loricrin and transglutaminase-1. In knockout mice deficient in any of these receptors, their respective activators do not induce the expression of differentiation markers indicating that this stimulation is receptor mediated  ADDIN EN.CITE (Komuves, et al., 2002; Mao-Qiang, et al., 2004; Schmuth, et al., 2004). Hence it is speculated that as intracellular lipid levels rise in preparation for LB synthesis, fatty acids and oxysterols (derived from increased cholesterol production) activate PPAR and LXR respectively, thus stimulating keratinocyte differentiation  ADDIN EN.CITE (Feingold, 2007; Schmuth, et al., 2008). The promoter regions of the genes for involucrin, loricrin and transglutaminase-1 have activator protein-1 (AP-1) biding sites. Increased AP-1 binding leads to enhanced gene expression. Mutations in the AP-1 site of the involucrin promoter prevent PPAR and LXR activators from increasing involucrin gene expression  ADDIN EN.CITE (Hanley, Komuves, et al., 2000; Hanley, Ng, et al., 2000) which suggests that activation of AP-1 transcription may be one pathway by which PPAR/LXR activators increase the expression of these differentiation related proteins.

Effects of PPAR and LXR on lamellar membrane formation
Topical treatment with PPAR, PPAR/, PPAR and LXR activators increases the synthesis of cholesterol, fatty acid and ceramide in mouse epidermis  ADDIN EN.CITE (Man, et al., 2006). This is most likely due to increased mRNA expression of the enzymes that synthesise these lipids. In human organotypic skin cultures PPAR activators increase the expression of enzymes needed for lipid synthesis including serine-palmitoyltransferase, long chain acyl-CoA synthase and HMG-CoA synthase  ADDIN EN.CITE (Rivier et al., 2000). In mouse skin treated with a PPAR/ activator, HMG Co-A synthase 2 is reported to be induced  ADDIN EN.CITE (Calleja, et al., 2006). 
The delivery of glucosylceramide into LB is facilitated by ABCA12. This is a key step in LB formation. In the absence of ABCA12 the number of LB are diminished and those that do form have an abnormal morphology  ADDIN EN.CITE (Akiyama, et al., 2005). PPAR/, PPAR and to a lesser extent LXR activators stimulate ABCA12 expression in keratinocytes in a dose- and time-dependent manner  ADDIN EN.CITE (Jiang, et al., 2008).

LB secretion is also influenced by NHR. In mice topically treated with activators of PPAR, PPAR/ and LXR, but not PPAR, there was accelerated and premature LB secretion in both the basal state and after barrier disruption  ADDIN EN.CITE (Man, et al., 2006). Receptor-deficient mouse models have shown that PPAR/ but not PPAR or PPAR is the key isoform involved in LB formation and secretion  ADDIN EN.CITE (Calleja, et al., 2006; Man, et al., 2008). Furthermore, genetic ablation of RXR or RXR/ shows a LB defect identical to PPAR/ knockout mice that is reversed with the addition of topical PPAR/ activators  ADDIN EN.CITE (Calleja, et al., 2006).






The ichthyoses are a clinically and aetiologically heterogeneous group of disorders that result from abnormal epidermal differentiation and desquamation, resulting in diffuse and persistent scaling (Oji & Traupe, 2006). In recent years the genes responsible for causing some of the ichthyoses have been identified and many encode proteins involved in lipid synthesis or desquamation.  






IV is the most common of the inherited ichthyoses with a prevalence of 1:250 (Oji & Traupe, 2006). It is characterised by fine scale that is most prominent on the extensor surfaces of the arms and lower legs with milder involvement of the trunk and lower abdomen. The flexural creases are characteristically spared, as is the nappy area. In addition there is palmoplantar hyperlinearity, keratosis pilaris and between 37-50% of patients have an atopic diathesis (Kuokkanen, 1969). IV is an autosomal dominant disorder caused by null mutations in the filaggrin gene (FLG)  ADDIN EN.CITE (Smith, et al., 2006). In keeping with this, IV patient’s skin shows a reduction in both the size and number, or complete absence of keratohyaline granules (Sybert et al., 1985). Furthermore, FLG mutations have also been associated with atopic dermatitis  ADDIN EN.CITE (Palmer, et al., 2006) and allergic phenotypes  ADDIN EN.CITE (Marenholz, et al., 2006). 

X-linked recessive ichthyosis (XLRI)
XLRI is caused by mutations in the steroid sulphatase gene (STS) (Webster et al., 1978). It can present as early as 1-3 weeks with fine peeling of the skin that later develops into dark polygonal scale, often with flexural involvement (Oji & Traupe, 2006). Steroid sulphatase is secreted from LB into the SC where it catalyses the degradation of cholesterol sulphate to cholesterol. In the absence of the enzyme, cholesterol sulphate accumulates and inhibits corneodesmosome degradation, leading to a failure of corneocyte desquamation (Elias et al., 2004). XLRI can be associated with birth complications (Traupe, 1989), testicular abnormalities and corneal opacities (Hernandez-Martin et al., 1999).
Congenital ichthyosiform erythroderma (CIE)
CIE, also known as non-bullous CIE, is a rare and severe autosomal recessive ichthyosis. Ninety percent of babies are born with a collodian membrane. This shiny tight translucent covering typically sheds within a few weeks to reveal generalised erythroderma covered with fine white scale. All areas are affected and there is associated palmoplantar hyperkeratosis / keratoderma, nail dystrophy and markedly reduced or absent sweating. 

Lamellar ichthyosis (LI)
LI is less common than CIE. Most babies are born with a collodian membrane that sheds to reveal skin that is less erythematous than in CIE. Generalised scaling occurs in the first month but in some cases may be localised to the scalp, abdomen and lower legs. The scales in LI are large, dark brown or grey and firmly adherent. In mild cases, there may be seasonal variation with an improvement in the summer months. 

Mutations in several genes have been identified that give rise to the CIE/LI phenotype. In about 35-40% of cases, there is a homozygous or compound heterozygous mutation in the transglutaminase 1 (TGM1) gene on chromosome 14  ADDIN EN.CITE (Huber, et al., 1995; L. J. Russell, et al., 1995). Mutations in a gene family encoding for the epidermal lipoxygenases ALOXE3 and ALOX12B were identified on chromosome 17 in 6 Mediterranean families affected by CIE  ADDIN EN.CITE (Jobard, et al., 2002). Furthermore, missense mutations in the gene encoding for the adenosine triphosphate (ATP) binding cassette (ABC) transporter protein ABCA12 on chromosome 2 were identified in a sub-set of patients with LI2 from Africa  ADDIN EN.CITE (Lefevre, et al., 2003) and also in several cases of CIE (Sakai, et al., 2009). Additional mutations have also been found in both CIE and LI patients in the ichthyin gene on chromosome 5  ADDIN EN.CITE (Lefevre, et al., 2004), CYP4F22, NIPAL4 and the P450 gene  ADDIN EN.CITE (Lefevre, et al., 2006).

Autosomal dominant LI
This is characterised by dark-grey LI-like scaling with PPK and lichenification of the dorsa of the hands and feet but exhibits clinical heterogeneity and variable penetrance (Oji & Traupe, 2006). The underlying gene defect is not yet known. 
Self-healing collodion baby
This is the eventual phenotype of about 10% of babies born with a collodian membrane. The skin heals with no or very mild ichthyosis. Mutations in TGM1 are thought to underlie the condition. It is hypothesised that in utero, the elevated hydrostatic pressure is thought to lock the mutated enzyme in an inactive cis confirmation. The change to a terrestrial environment after birth facilitates the conversion of the enzyme to its active trans form, resulting in a dramatic improvement in the phenotype (Raghunath, et al., 2003). 

Bathing suit ichthyosis
This variant of LI is caused by TGM1 mutations. It is characterised by pronounced scaling in the warmer areas of the skin with sparing of the extremities and central face. It is thought to be a temperature sensitive phenotype as an in situ assay of transglutaminase in the epidermis of patients revealed a marked decrease in enzyme activity when the temperature was increased from 25 to 37 C  ADDIN EN.CITE (Oji, et al., 2006). 

Bullous ichthyosiform erythroderma of Brocq (BIE)
BIE, also known as epidermolytic hyperkeratosis, is inherited in an autosomal dominant manner. Affected babies show generalised erythroderma at birth with widespread blistering or erosions. Hyperkeratosis appears later and persists throughout life, affecting the entire integument and there may be an associated PPK (Oji & Traupe, 2006). The disorder is caused by heterozygous mutations of KRT1 (keratin 1) and KRT10 (keratin 10)  ADDIN EN.CITE (Bonifas, et al., 1992; Compton, et al., 1992). KRT1 mutations are associated with PPK because K1 is the main expression partner of K9 in palmoplantar skin (Oji & Traupe, 2006). 

Ichthyosis bullosa of Siemans (IBS)
This has a milder phenotype than BIE and is distinguished from the latter by the lack of erythroderma and lichenified hyperkeratosis on the flexures, over joints and on the dorsa of the hands and feet (Oji & Traupe, 2006). Mutations in the keratin 2e underlie this disease  ADDIN EN.CITE (Kremer, et al., 1994; Rothnagel, et al., 1994). Microscopically, acanthokeratolysis is seen in the granular layer, which correlates with the expression pattern of this keratin. 
Ichthyosis hystrix Curth Macklin (IHCM)






This is a rare disease characterised by the triad of CIE, hair shaft anomalies and a severe atopic diathesis with raised IgE levels and eosinophilia. The skin changes usually evolve into ichthyosis linearis circumflexa, characterised by polycyclic migrating plaques with double-edged scales. Trichorrhexis invaginata is pathognomonic and is seen when the hair shaft is examined microscopically. The condition is caused by recessive mutations in the SPINK5 gene that encodes the serine protease inhibitor LEKTI  ADDIN EN.CITE (Chavanas, et al., 2000).

Dorfman Chanarin syndrome (DCS)
DCS is a neutral lipid storage disease due to impaired long-chain fatty acid oxidation. It is caused by autosomal recessive mutations in the CG1-58 gene  ADDIN EN.CITE (Lefevre, et al., 2001). At birth affected babies have skin that resembles CIE, with generalised white scaling and a variable degree of erythema. Associated features caused by widespread tissue deposition of neutral lipids include cataracts, hepatosplenomegaly, sensorineural deafness, myopathy and developmental delay. 

Gaucher syndrome type 2
Recessive mutations in the GBA gene encoding glucocerebrosidase cause this syndrome (Beutler, et al., 1994) and result in the accumulation of glucocerebrosides in phagocytes or the central nervous system. In type 2 disease there is almost complete loss of glucocerebrosidase activity that causes progressive neurological degeneration and death by the age of one year. Some babies are born with a collodion membrane.

Sjogren Larsson syndrome (SLS)
This recessive neurocutaneous syndrome is caused by a deficiency of the microsomal enzyme fatty aldehyde dehydrogenase  ADDIN EN.CITE (De Laurenzi, et al., 1996). Affected babies are often preterm and have cobblestone-like skin lichenification with severe pruritus, crystalline deposits in the retina and photophobia. With age the children develop generalised spasticity, become wheelchair bound and have mental impairment. 

Conradi-Hunermann-Happle syndrome
Alternatively known as chondrodysplasia punctata type 2, this X-linked dominant condition is lethal in most male embryos and shows variable expression amongst females due to differences in X-inactivation. Babies are born with a severe ichthyosiform erythroderma, which later evolves into striated hyperkeratosis following the lines of Blaschko (ichthyosis linearis). Associated findings include, follicular atrophoderma sectorial cataracts, (both of which are pathognomonic), scarring alopecia and skeletal dysplasia. The disease is caused by mutations in the EPB gene that codes for an enzyme involved in sterol metabolism, 8-7 sterol isomerase (Happle, 1979). 

CHILD syndrome
This acronym stands for congenital hemidysplasia with ichthyosiform naevus and limb defects. The naevus is very distinctive as it shows lateralisation with strict midline demarcation. It is an X-linked dominant disease caused by mutations in the NSDHL gene that encodes the enzyme 3-hydroxysteroid dehydrogenase (Konig, et al., 2000). 

Trichothiodystrophy
Trichothiodystrophy refers to a heterogeneous group of recessive disorders. At least two sub-types are associated with a congenital ichthyosis that can present at birth with a collodion membrane. Other features include brittle hair with abnormally low sulphur content of the hair shaft, intellectual impairment, decreased fertility and short stature. Recessive mutations in the XPD (Taylor, et al., 1997), XPB  ADDIN EN.CITE (Weeda, et al., 1997) and p8/TTDA  ADDIN EN.CITE (Giglia-Mari, et al., 2004) genes underlie the disease. 

IFAP syndrome
















Figure 1.2: Newborn baby with HI. The baby exhibits the typical features of HI with generalised fissured scale plates, bilateral ectropion, eclabium, flattened nose and ears and poorly formed digits.


1.6.2	Ultrastructural changes in HI 













ABCA12 consists of 53 exons with a total length of 7785 bp, which is translated into a 293 kDa protein of 2595 amino acids, with a 5’- untranslated region (UTR) of 220 bp and a 3’-UTR of 1092 bp. The coding region begins with an ATG codon at nucleotide residue 221 in exon 1  ADDIN EN.CITE (Lefevre, et al., 2003). The functional protein contains two transmembrane domains (TMD) containing six membrane spanning -helicies and two ATP-binding domains or nucleotide binding folds (NBF). The NBF contain three highly conserved sequence motifs: Walker A, Walker B domains  ADDIN EN.CITE (Walker, et al., 1982) and a signature C motif, located just upstream of the Walker B site  ADDIN EN.CITE (Hyde, et al., 1990). The Walker domains are involved in ATP binding and hydrolysis. More specifically Walker A displays a phosphate binding loop and Walker B a magnesium binding site. Both domains contain conserved consensus sequences that allow them to perform these functions. The NBF are located in the cytoplasm and transfer the energy needed to transport substrates across cell membranes (Dean, et al., 2001). 


1.7.2	ABCA12, lipids and lamellar bodies

ABCA12 is a member of a large superfamily of ABC transporters which bind and hydrolyse ATP to transport various molecules across a limiting membrane or into a vesicle (Borst & Elferink, 2002). The protein has been localised to LB in granular layer keratinocytes, where it acts as a transmembrane transporter, associated with lipid transfer in LB to the apical surface of granular layer cells  ADDIN EN.CITE (Akiyama, et al., 2005). The antibodies GM130 and anti-TGN-46, markers for the cis- and trans-Golgi respectively, have demonstrated that ABCA12 localises throughout the entire Golgi apparatus to LB at the cell periphery, suggesting that it works in the transport of lipids from the Golgi apparatus to LB in granular layer cells  ADDIN EN.CITE (Akiyama, et al., 2005).  However, ABCA12 is thought to distribute only very sparsely on the cell membrane as it fails to co-localise with transglutaminase-1, a membrane bound protein (Sakai, et al., 2007). Immunofluorescent double labelling reveals that the majority of ABCA12 co-localises with glucosylceramide in the cytoplasm within the upper spinous and granular layer cells (Sakai, et al., 2007).  In keeping with this it has also been shown that ABCA12 transports glucosylceramide to the inner leaflet of LB and that when it is deficient, glucosylceramide accumulation in LB is impaired (Mitsutake, et al., 2010). Indeed ceramide upregulates ABCA12 via a PPAR/ mediated pathway, thus providing a substrate driven, feed-forward mechanism for regulating the levels of this key lipid transporter  ADDIN EN.CITE (Jiang, et al., 2009). 

Models of HI have helped gain some insight into further functions of ABCA12. One of the clinical features of HI is an increased thickness of the SC and the epidermis as a whole (Milner, et al., 1992). This is most likely caused by aberrant desquamation when certain proteases that are expressed or activated as products of late differentiation are not transported to the SC because of an ineffective LB system  ADDIN EN.CITE (Thomas, et al., 2009). An in vitro model of HI skin produced using an ABCA12-ablated organotypic co-culture (OTCC) system, showed that the expression of the LB components kallikrein 5 (KLK-5) and cathepsin D (CTSD), proteases associated with desquamation, is dramatically reduced  ADDIN EN.CITE (A. C. Thomas, et al., 2009). KLK-5 is expressed in the granular layer and transported via LB to the SC where it is involved in a proteolytic cascade where it activates itself and KLK-7  ADDIN EN.CITE (Sondell, et al., 1995). Once active both these enzymes aid desquamation by digesting desmoglein 1, desmocolin 1 and corneodesmin  ADDIN EN.CITE (Caubet, et al., 2004; Descargues, et al., 2006; Simon, et al., 2001). CTSD on the other hand is activated by ceramides  ADDIN EN.CITE (Egberts, et al., 2004) and has a role in desquamation through corneodesmosome degradation (Igarashi, et al., 2004). Hence in the absence of these proteins, normal desquamation cannot occur, the SC remains abnormally thickened and in HI, this manifests as the retention of thick scale. 

The proteins lympho-epithelial Kazal-type-related inhibitor (LEKT1), KLK-7, KLK-5 and CTSD are all markers of the LB system  ADDIN EN.CITE (Ishida-Yamamoto, et al., 2005; 2004). While levels of KLK-5 and CTSD are reduced in ABCA12 deficiency, LEKT1 and KLK-7 levels are unchanged. Furthermore, there is some degree of co-localisation between ABCA12 and KLK-5 / CTSD while no such relationship is seen with KLK-7 / LEKT1  ADDIN EN.CITE (A. C. Thomas, et al., 2009). These authors therefore propose that KLK-7 and LEKT1 are separately localised to ABCA12 and are translocated within LB, suggesting that ABCA12 is important for the formation of some but not all parts of the LB system. Indeed some LB can be present in HI epidermis although they usually have an abnormal morphology. 


1.7.3	ABCA12 and keratinocyte differentiation






In addition to HI, mutations in ABCA12 also cause two other autosomal recessive congenital ichthyoses, type 2 lamellar ichthyosis  ADDIN EN.CITE (Lefevre, et al., 2003) and congenital ichthyosiform erythroderma (Sakai, et al., 2009). Genotype-phenotype correlations are discussed further in Chapter 3. 


1.8	Other ABC transporters 

The ABC transporter superfamily is the largest transporter gene family. The proteins translocate a wide variety of substrates including sugars, amino acids, metal ions, peptides, proteins, hydrophobic compounds and metabolites across extra- and intracellular cell membranes (Dean, et al., 2001). There are forty-eight known ABC genes that are divided into seven ABC subfamilies organised from A to G. The ABC genes are highly conserved between eukaryotic species. As with ABCA12, the proteins all contain two transmembrane domains and two NBF that bear the Walker A and B domains and a signature C motif. Table 1.1 lists the ABC genes, along with their known functions and disease associations.
1.8.1	The ABCA subfamily

The ABCA subfamily comprises 12 full transporters and one pseudogene (ABCA11) that are split into two subgroups. The first group (ABCA1-A4, A7, A12 and A13) includes seven genes that map to six different chromosomes that are dispersed across the genome (Dean, et al., 2001). They are all involved in lipid transport and secretion  ADDIN EN.CITE (Peelman, et al., 2003). The second group of ABCA genes (ABCA5, A6, A8-A10) is organised into a head-to-tail cluster on chromosome 17q24 (Dean, et al., 2001). The functions of the latter group are still unknown and as yet no diseases have been associated with them. The known disease associations of the ABCA genes are discussed below.

ABAC1 is involved in the efflux of cholesterol form cells. The gene is mutated in Tangier disease resulting in the accumulation of cholesterol in various tissues and very low blood levels of high-density lipoprotein  ADDIN EN.CITE (Brooks-Wilson, et al., 1999). ABCA1 is also mutated in familial hypoalphalipoproteinaemia  ADDIN EN.CITE (Brooks-Wilson, et al., 1999) and premature atherosclerosis  ADDIN EN.CITE (Clee, et al., 2000). The role of ABCA1 in the epidermis will be discussed further in Chapter 4. 








ABCA1	Cholesterol efflux onto HDL	Tangier disease  ADDIN EN.CITE (Brooks-Wilson, et al., 1999)Familial hypoapoproteinaemia  ADDIN EN.CITE (Brooks-Wilson, et al., 1999). Premature atherosclerosis  ADDIN EN.CITE (Clee, et al., 2000)
ABCA2	Drug resistance	Unknown
ABCA3	Unknown	Fatal surfactant deficiency (Shulenin, et al., 2004)







ABCA12	Lipid Transport	Harlequin ichthyosis  (Kelsell et al., 2005)Lamellar ichthyosis 2   ADDIN EN.CITE (Lefevre, et al., 2003)CIE  (Natsuga et al., 2007)




ABCB4	Bile-acid transport	Progressive familial intrahepatic cholestasis-3 (Deleuze, et al., 1996)
ABCB5	Unknown	Unknown
ABCB6	Iron transport	Unknown




ABCB11	Bile salt transport	Progressive familial intrahepatic cholestasis-2   ADDIN EN.CITE (Strautnieks, et al., 1998)
ABCC1	Drug resistance	Unknown




ABCC6	Organic anions	Pseudoxanthoma elasticum  (Le Saux, et al., 2000)
ABCC7	Chloride ion channel	Cystic fibrosis   ADDIN EN.CITE (Riordan, et al., 1989)














ABCG2	Toxin efflux, drug resistance	Unknown
ABCG4	Unknown	Unknown
ABCG5	Sterol transport	Sitosterolemia   ADDIN EN.CITE (M. H. Lee, et al., 2001)
ABCG8	Sterol transport	Sitosterolemia   ADDIN EN.CITE (Berge, et al., 2000)

Table 1.1: The ABC genes, known functions and disease associations to date. 


1.9	Aims of this study

(1)	To identify novel ABCA12 mutations in order to improve the understanding between genotype and phenotype in HI and to assist with prenatal diagnosis; and to develop alternative strategies of identifying mutations when standard techniques fail.

(2)	To examine the effect of the absence of ABCA12 on the nuclear hormone receptors PPAR/ and RXR and the lipid transporter ABCA1.


























2.1	DNA and RNA analysis

2.1.1	 DNA extraction from whole blood

DNA was extracted from 3-10 ml samples of whole blood using a Nucleon BACC Genomic DNA Extraction Kit (GE Healthcare, USA). Four times the volume of reagent A was added to the blood sample, rotary mixed for 4 min and then centrifuged at 1300 rpm for 5 min to lyse the cells. After discarding the supernatant, the pellet was re-suspended in 2 ml of reagent B and deproteinised by adding 500 l of sodium perchlorate solution. Once mixed, DNA was extracted by adding 2 ml of chloroform. Without remixing the phases, 300 l of Nucleon resin was added and the sample was centrifuged for 3 min at 1300 rpm. The clear upper phase was removed and 2 volumes of cold 100% ethanol were added to precipitate the DNA. The sample was centrifuged at 4000 rpm for 5 min to pellet the DNA, which was then washed in 2 ml of cold 70% ethanol. After re-centrifuging at 4000 rpm for 5 min, the supernatant was discarded and the pellet allowed to air dry for 15 min. The DNA was then re-dissolved in 200-500 l of distilled water. 




































































































Table 2.2: Primer sequences for ABCA12 intron 11 primers. Product size is shown in base pairs (bp) and annealing temperature (TA) in °C.


2.1.5	Polymerase chain reaction (PCR)

PCR reactions were carried out using Bio Taq Polymerase (Bioline, UK) with a total reaction volume of either 15 l. The reagents, concentrations and volumes used are shown below in Table 2.3.

10X NH2 Buffer 	1.5 l
10mM dNTP mix 	0.3 l
25mM MgCl2 	2.4
Bio Taq Polymerase (Bioline, UK)	0.1 l
5M Betaine	2.4 l
Forward primer (5 pmol/l)	0.6 l














Each reaction was carried out using a multiplex PCR master mix kit (Qiagen UK). This kit contained pre-optimised concentrations of MgCl2 (final concentration 3mM), dNTPs, buffer and Taq DNA polymerase. Following the addition of primers, DNA and water, the final reaction volume was 15 l. The concentrations and volumes of reagents used are shown in Table 2.4. Cycling conditions were the same as those previously described in section 2.1.5. 
 

2X Qiagen master mix	7.5 l
Forward primers (10 pmol/l)	1.5 l










DNA fragment size was measured using agarose gels made by dissolving 1-2% agarose in 1X TBE buffer (Table 2.5). The solution was heated in a standard microwave oven until the agarose had dissolved and then cooled before adding ethidium bromide to a final concentration of 0.5 g/ml. Once the gel had set, DNA products were loaded using 6X loading dye and run submerged in a  tank (Bio-Rad, USA) at a constant voltage of 120 volts. The size standard used was a 1Kb Plus DNA ladder (Invitrogen, USA). Products were visualised using an ultraviolet trans-illuminator and photographed for reference. The reagents used for agarose gel electrophoresis are shown in Table 2.5.

6X loading dye	1Kb DNA ladder	1X TBE
0.25% bromophenol blue	10% 1Kb ladder	45mM Tris-borate
15% Ficoll in H2O	16% 6X loading dye	2 mM EDTA
0.25% xylene cyanol FF	74% H2O	






Prior to sequencing PCR products were first purified using EXOSAP. The stock solution was made by combining 2 hydrolytic enzymes, Exonuclease 1 (Cambio Limited), with shrimp alkaline phosphatase (Amersham Pharmacia Biotech Limited, Sweden) in a ratio of 1:20. These enzymes removed unwanted primers and deoxynucleotides respectively. The EXOSAP stock solution was diluted 1 in 10 and 2 l of this was combined with 0.5 l of PCR product. The mixture was transferred to the thermocycler for incubation at 37°C for 15 min, 80°C for 15 min and then 4°C for 2 min. 






BigDye Terminator Master Mix v3.1	1 l
Better Buffer (Microzone)	3 l





Table 2.6: DNA sequencing reaction reagents











2.1.10	DNA sizing and quantification using the Agilent bioanalyser






2.2.1	RNA extraction from tissue
















RT-PCR primers were purchased from Sigma-Aldrich (St Louis, USA).  Primer pairs were designed to amplify coding regions of interest in ABCA12. The GC content of each pair was kept as close as possible and ranged from 55-62%. The oligonucleotide length varied from 19 – 22 bp. The annealing temperature (AT) of each primer was calculated using the following equation:

AT = 69.3 + (0.41 x GC%) – (650 / oligonucleotide length)

The lowest AT was used initially in PCR reactions and where necessary this was optimised. Primers that amplified the hypoxanthine phosphoribosyltransferase (HPRT) housekeeping gene were used as a control of cDNA abundance. The primers used in RT-PCR reactions are shown in Table 2.7.











Table 2.7: Primers used in RT-PCR reactions. The forward (f) and reverse (r) primers are shown along with the product size in base pairs (bp) and the annealing temperature (AT) in °C.

2.2.5	Reverse transcription polymerase chain reaction

PCR amplification of cDNA was performed as described in section 2.1.5 with modification of the reagent concentrations and volumes as shown in Table 2.8. Cycling conditions were unchanged with the exceptions that the denaturing and annealing time was reduced to 10 sec and the extension time was increased to 1 min 32 sec, based on the assumption that 1 min is required to amplify 1 Kb of sequence. A 1.5% agarose gel was made as described in section 2.1.7. DNA samples were mixed with loading dye in a ratio of 5:1 and electrophoresed at a constant voltage of 130 volts for 90 min. 


10X NH2 Buffer 	5.0 l
50X dNTP mix 	1.0 l
25mM MgCl2 	1.5 l
Bio Taq Polymerase (Bioline, UK)	0.5 l
Forward primer (20 pmol/l)	1.0 l





Table 2.8: Reagent concentrations and volumes used in RT-PCR reactions


2.2.6	DNA recovery from an agarose gel






2.2.7	Purification of RT-PCR products






Purified RT-PCR products were sequenced using the ABI BigDye Terminator version 3.1 (Applied Biosystems, UK), Better Buffer (Microzone, Canada), primer working solution and distilled water to a final volume of 10 l as shown in Table 2.9. The primer working solution was made by combining 2 l of primer at 10 pmol/l with 23 l of distilled water. Cycling conditions consisted of 25 cycles at 96°C for 10 sec, 50°C for 5 sec and 60°C for 4 min, followed by a final incubation at 4°C for 10 min. 


BigDye Terminator Master Mix v 3.1	2 l
Better Buffer 	1 l



































Primary antibody 	Antigen retrieval method	IHC dilution	ICC dilution	Western protocol	Source
Rabbit anti-PPAR/	Trypsin	1/100	1/100	1/200overnight at 4C	Abcam, UK
Rabbit anti- RXR	Trypsin	1/100	1/100	1/1000 overnight at 4C	Abcam, UK
Rabbit anti-ABCA1	Trypsin	1/200	1/100	1/500 overnight at 4C	Santa Cruz, USA
Rabbit anti-ABCA12	--	1/500	--	--	Harlen Sera Labs, UK
Mouse anti-GAPDH (Glyceraldehyde-3-phosphate dehydrogenase)	--	--	--	1/10000 overnight at 4C	Abcam, UK
Mouse anti-vinculin	--	--	--	1/40000 overnight at 4C	Sigma-Aldrich, UK
Secondary antibody 		IHC dilution	ICC dilution	Western protocol	Source
Alexa Fluor 488 goat anti-rabbit	--	1/800	1/800	--	Molecular Probes, USA
Rabbit anti-mouse HRP conjugated	--	--	--	1/1000 for 1 hour at room temperature	DakoCytomation, Denmark












Frozen slides were first air dried for 30 min and then fixed by placing them in chilled acetone for 10 min. This prevented removal of the section from the slide during subsequent washes. The slides were then washed in 1X TBS (0.05 M Tris-HCL pH 7.5 and 0.15 M NaCl) for 10 min and then blocked with 10% goat serum for 20 min. The primary antibody was diluted in 5% goat serum, applied to the blocked sections and incubated overnight in a humidified chamber at 4°C. Thereafter the slides were given 3 TBS washes for 5 min each. The secondary fluorescent antibody was diluted in TBS and then applied to the washed sections for 40 min at RT. After 3 further TBS washes, DAPI (4’, 6 diamidino-2-phenylindole) was applied for 5 min to counterstain the cell nuclei blue. Slides were then mounted in immunomount (Thermo Electron Corporation, USA) before visualisation under the fluorescent microscope.

Paraffin embedded sections (IHC-P)

Paraffin embedded sections were first dewaxed and then rehydrated by performing the following washes:
1.	Xylene: 5 min
2.	Xylene: 3 min
3.	100% ethanol: 3 min
4.	100% ethanol: 3 min
5.	90% ethanol: 3 min
6.	70% ethanol: 3 min
7.	Cold water: 5 min
Before proceeding with staining an antigen retrieval step was required to unmask antigenic sites that become hidden during the fixation process, due to the formation of methylene bridges that cross-link proteins. An enzymatic method involving trypsin was used. In brief, the sections were covered with trypsin working solution and incubated in a water bath at 37°C for 15 min. The reagents used are summarised in Table 2.11. After antigen retrieval the sections were allowed to cool at RT for 10 min before proceeding with staining as described above (IHC-F).


Trypsin stock solution (0.5%)	CaCl2 stock solution (1%)	Trypsin working solution (0.05%)
 50 mg trypsin (Sigma Aldrich, UK) 10 ml dH2O	100 mg CaCl210 ml dH2O	1 ml trypsin stock solution (0.5%)1 ml CaCl2 stock solution (1%)8ml dH2OMix and adjust to pH 7.8 with 0.1 M NAOH

































Ham’s F12 medium	25% (v/v)
10% FBS	
1% L-glutamine	





Adenine	1.8 x 10-4 M
Liothyronine	2 x 10-11 M
Epidermal growth factor	10 ng/ml

Table 2.12: Components of RM+ cell culture medium











Phoenix packaging cell line

The Phoenix amphotrophic retroviral packaging cell line (Orbigen, USA) was used as an expression system to generate viral particles. These cells are capable of producing all the necessary trans proteins, namely gag, pol and env that are required for packaging, processing, reverse transcription and integration of recombinant genomes. Phoenix cells were grown in DMEM supplemented with 10% FCS, 1% L-glutamine, 100 U/ml penicillin and 100 g/ml streptomycin. Cells were kept at 37°C with 10% CO2 unless retrovirus was being collected in which case the temperature was lowered to 32°C. Once the cells had reached approximately 80% confluency, they were split as described above, with the exception that 1X TE was used to detach the cells and DMEM was used in place of RM+.


2.4.3	Recovery of frozen cultured cells

Frozen cells were recovered by thawing cryovials quickly in a water bath at 37°C. The cell suspension was then slowly added to 10 ml of culture medium before centrifuging at 1200 RPM for 5 min. The cells were then resuspended in the appropriate medium and seeded in a tissue culture flask.  






Due to the paucity of HI skin biopsies the pSUPERIOR-retro-puro shRNA system (Oligoengine, USA) was used to suppress the expression of ABCA12 as described by Thomas et al (2009). This vector contained 59 mer pairs of oligonucleotides made up of a 19 nucleotide (nt) sequence in both the sense and antisense orientation, separated by a 9 nt spacer sequence. The 19 nt sequence was derived from the ABCA12 mRNA transcript. The resulting transcript of the recombinant vector was predicted to fold back on itself to form a 19 bp short hairpin RNA molecule (shRNA) that would then be processed into functional silencing RNA (siRNA) within target cells. The mechanism of RNA interference is such that the antisense strand of the siRNA duplex hybridises to the corresponding region of the ABCA12 mRNA. This mediates cleavage of the molecule and disrupts functional protein expression. Preformed vector containing the oligonucleotide sequences described in Table 2.13 were used for the ABCA12 knockdown experiments.












JM109 bacterial component cells (Stratagen, UK) were thawed on ice after which 75 l was mixed with 1 l of each vector and placed on ice for 20 min. Cells were then heat shocked at 42°C for 45 sec to allow the bacteria to take up the DNA and then cooled on ice for 2 min. To allow the cells to recover, 250 l of SOC medium (Invitrogen, USA) was added and samples were incubated at 37°C for 15 min with shaking. The bacterial cells were then diluted 1 in 50 in 200 l of Luria Broth (LBr) supplemented with ampicillin at a concentration of 1 l/ml. This antibiotic was chosen as the plasmid being used had an ampicillin resistance gene. Bacterial cells were then plated on agar plates containing ampicillin at a concentration of 50 l/ml and cultured overnight at 37°C. The following day plates were removed from the incubator and stored at 4°C until required. For each transformation reaction,  at least 5 colonies were picked and placed in a Falcon tube containing 5 ml of LBr/ampicillin and grown overnight at 37°C with shaking. 


2.5.3	Isolation of plasmid DNA from bacteria

Plasmid DNA was extracted from the bacterial cells using the QIAprep spin miniprep kit (Qiagen, UK) according to the manufacturer’s instructions. Using an alkaline lysis method, large bacterial chromosomal DNA was differentially precipitated from small plasmid DNA that remained in solution. Briefly, pelleted bacterial cells were resuspended in 250 l of buffer P1, then 250 l of buffer P2 and 350 l of buffer P3, mixing well each time. The mixture was centrifuged for 10 min at 13000 RPM. After applying the supernatant to a QIAprep spin column, the column was washed with 500 l of buffer PB and then 750 l of buffer PE. The plasmid DNA was then eluted in 50 l of sterile water. 


2.5.4	Transfection of Phoenix cells

Phoenix cells were seeded in 2 ml of DMEM at a density of 1 million cells per well of a 6-well plate and transfected 24 hours later using FuGENE 6 transfection reagent (Roche, Switzerland), at a ratio of 2.5:1 FuGene : plasmid DNA. To transfect, 20 l of FuGene was added drop wise to 100 l of DMEM serum-free medium and incubated at RT for 5 min. Eight micrograms of the specific plasmid DNA was then added to the tube and left at RT for 20 min. From the 6 well plate containing the Phoenix cells, 0.5 ml of media was removed from each well. The transfection mixture was then slowly applied to the cells in a drop wise manner. In addition to the 3 constructs described in Table 2.13, a vector only control (VOC) plasmid was added to 1 well and Phoenix cells without any DNA were left in another well. The cells were incubated at 37°C for 24 hours and then at 32°C for another 24 hours in 1.5 ml of fresh medium. 
2.5.5	Collection of retrovirus from Phoenix cells

After transfection, cells were selected with puromycin 1 g/ml for 10 days. In addition, puromycin was added to a well of untransfected cells as a control for cell death.  To harvest virus the medium was filtered to remove any cell debris and before being used in transduction experiments.


2.5.6	Retroviral transduction of NEB1 cells






Western blotting (WB) was used to compare protein levels between lysed cells. 

2.6.1 Cell lysis
NEB1 cells were grown to approximately 70% confluency before protein isolation.  Triton lysis buffer (TLB) was made as described in Table 2.14. For cell lysis, 10 l of protease inhibitor (Roche, UK) was mixed with 1 ml of TLB and added to cells that had been washed twice in PBS. After 20 min on ice, a cell scraper was used to detach the cells and the lysate was collected in a 1.5 ml tube. This was centrifuged for 15 min at 14000 RPM at 4°C. The supernatant was then collected and stored at -80°C until required. 

1X triton lysis buffer
20 mM Tris pH 7.4
2 M NaCl
2 mM EDTA pH 7.4
1% (v/v) Triton X-100
10% (v/v) Glycerol






The protein concentration of the lysate was determined using the DC Protein Assay (BioRad, UK) according to the manufacturer’s instructions. The optical density of samples was measured at 650 nm using an Ultraspec III spectrophotometer (Pharmacia, UK). Serial dilutions of bovine serum albumin were used as a protein standard to plot a calibration curve of absorbance versus protein concentration. The lysate protein concentration was extrapolated from this curve.


2.6.3	Buffers used for Western blotting

Several buffers were used for WB and the details of these are outlined in Tables 2.15-2.17 below. 
(i)	Laemmli buffer was used as a loading buffer and prepared at 2X concentration as described in Table 2.15. The buffer and lysate were mixed in a 1:1 ratio.
(ii)	Running buffer was made as described in Table 2.16 and used at 1X concentration.
(iii)	 Transfer buffer was made as described in Table 2.17. Two types of transfer buffer were made to accommodate small (<80 kDa) and large (>80 kDa) proteins. For the latter, sodium dodecyl sulphate (SDS) was added to discourage the precipitation of larger proteins in the gel. 

2X Laemmli buffer
4 % (v/w) SDS
10% (v/w) 2-mercaptoethanol
20% (v/v) glycerol
0.2% (v/w) bromophenol blue
0.1 M Tris HCL pH 6.8









Table 2.16: Reagents for running buffer


10X transfer buffer (for proteins < 80 kDa)	10X transfer buffer (for proteins > 80kDa)
0.3 M Tris base	0.48 M Tris base
0.25 M Glycine	0.30 M Glycine
20% Methanol to 1X transfer buffer before use	20% (v/v) Methanol to 1X transfer buffer before use
--	0.37% (v/w) SDS

Table 2.17: Composition of 10X transfer buffer for small and large proteins


2.6.4	SDS-polyacrylamide gel electrophoresis (PAGE) and transfer

All the protein samples were separated on SDS-polyacrylamide gels. A 6% gel was used for ABCA1 while a 12% gel was used for all the other (smaller) proteins. The composition of these gels is outlined in Table 2.18. The reagents were added in the order stated with TEMED always being added last. The resolving gel mixture was poured between 2 glass plates and 1.5 mm spacers in a gel electrophoresis apparatus (Biorad, UK). The gel mixture was overlaid with 1 ml of isopropanol and left to polymerise at RT for approximately 20 min. Once the gel had set, the isopropanol was washed away with ddH2O. A 5% stacking gel mixture was prepared (Table 2.18), cast with sample combs over the resolving gel and allowed to polymerise at RT for approximately 30 min. Protein lysates were mixed with an equivalent volume of laemmli buffer and denatured at 95°C for 5 min. Thereafter, 10-20 l of protein sample and 10 l of Full range Rainbow Molecular Weight marker (GE Healthcare, UK) were loaded onto the gel. The gel was run at a constant voltage of 100 volts until the desired separation was obtained. 

Following SDS-PAGE the proteins were transferred onto a Hybond-C nitrocellulose membrane (GE Healthcare, UK) in a wet transfer electrophoretic cell (Hoefer, USA). Briefly, the SDS-polyacrylamide gel and the nitrocellulose membrane were soaked in the appropriate 1X transfer buffer (Table 2.17) and sandwiched between 2 pieces of filter paper, which were in turn sandwiched between 2 sponges. This complex was placed in a cassette and then immersed in a tank containing the same transfer buffer. Proteins were transferred onto the gel from the membrane at a constant current of 300 mA for 1.5 – 2.5 hours. 

Gel reagent	6% resolving gel (15 ml)	12% resolving gel (15 ml)	5% stacking gel (3ml)
dH2O	7.9 ml	4.9 ml	2.1 ml
30% acrylamide mix	3.0 ml	6.0 ml	0.5 ml
1.5 M Tris (pH 8.8)	3.8 ml	3.8 ml	0.38 ml*
10% SDS	0.15 ml	0.15 ml	0.03 ml
10% ammonium persulphate	0.15 ml	0.15 ml	0.03 ml
TEMED	0.012 ml	0.006 ml	0.003 ml
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Mutations in ABCA12 have been described in three autosomal recessive congenital ichthyoses: HI  ADDIN EN.CITE (Akiyama, et al., 2005; Kelsell, et al., 2005), type 2 lamellar ichthyosis (LI2)  ADDIN EN.CITE (Lefevre, et al., 2003) and congenital ichthyosiform erythroderma (CIE) (Sakai, et al., 2009). Both LI2 and CIE have a much milder phenotype than HI, suggesting that the nature of the ABCA12 mutation has a major impact on the severity of the disease. Forty-four different mutations have been described to date in HI  ADDIN EN.CITE (Akiyama, et al., 2006; Akiyama, et al., 2005; Akiyama, et al., 2007; Castiglia, et al., 2009; Kelsell, et al., 2005; Rajpar et al., 2006; A. C. Thomas, et al., 2006; A. C. Thomas, et al., 2008). In contrast to CIE and LI2 where most mutations are homozygous missense, the majority of those in HI are homozygous or compound heterozygous nonsense substitutions, frameshift mutations, whole exon deletions, small deletions and insertions. They are all predicted to cause a truncated protein resulting in severe loss of function. Furthermore, while splice site mutations have also been described  ADDIN EN.CITE (A. C. Thomas, et al., 2008) missense substitutions are rare in HI.

The aim of this chapter is to identify novel ABCA12 mutations that cause HI, firstly to facilitate prenatal and pre-implantation diagnosis and also to investigate the relationship between genotype and phenotype. An indirect aim is to devise alternative strategies of finding mutations when standard PCR and sequencing techniques are ineffective. 






ABCA12 mutations were detected in both alleles in 14 out of 17 patients with clinically confirmed HI. These results are presented in section 3.2.1 and are divided into homozygous and compound heterozygous mutations. In the remaining 3 patients, no putative disease causing mutations could be found on either allele and this is discussed further in section 3.2.2. In the parental sample a disease causing mutation was not detected using standard techniques. Further analysis of this sample and strategies used to identify the missing mutation are discussed in section 3.2.3. The 3 clinically unconfirmed HI cases did not harbour ABCA12 mutations and this is discussed further in section 3.2.4. Prenatal genetic tests were successfully performed in 2 cases as outlined in section 3.2.5. Lastly, genotype-phenotype correlations are analysed in section 3.2.6.


3.2.1	ABCA12 mutation analysis 

Sequencing of all 53 ABCA12 exons using primers that flanked the exon-intron boundaries revealed the following results.
 
Homozygous mutations












A homozygous mutation c. 69+1G>C (AAAAGGCAGCCG(g/c)tgagttaa) was found in the splice donor site of intron 1 of a Mexican patient (0803) whose parents were not previously known to be consanguineous (Figure 3.3). To assess the potential effect of this mutation on ABCA12, the wildtype and mutated DNA sequences were compared by using an in silico splice site predictor program. The splice site predictor software Neural Network Splice Site Prediction Tool (Reese, et al., 1997) predicted that c. 69+1G>C would abolish the 5’ splice donor site. In the presence of this mutation, the splicing machinery uses an alternative splice downstream in the intron that is predicted to result in the insertion of a premature stop codon and thus a truncated protein. A second homozygous splice donor site mutation, c.3829+1G>A (GTCTTCCCAG(g/a)tatgaatg) was found in intron 26 of an Arab patient 0806 (Appendix A). This mutation is also predicted to alter the splice site resulting in a dysfunctional protein.
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Deletion of exons 52 and 53 was observed in a Palestinian patient (0910). Agarose gel electrophoresis of the ABCA12 PCR products revealed absent bands corresponding to exons 52 and 53 (Figure 3.4). All the other exons (1-51) amplified normally and no mutations were detected on sequencing. 


Figure 3.4: Agarose gel electrophoresis demonstrating deletion of exons 52 and 53 in patient 0910. Lanes 1-3 showing normal amplification of exons 11, 38 and 51 in the affected patient with absent bands in lanes 4 and 5, corresponding to the deleted exons 52 and 53 respectively. Lanes 6-9 showing normal amplification of exons 52 and 53 in both parents and positive and negative controls in lanes 10-13. 


The mutation was further verified with multiplex PCR and copy number analysis. Using the Lab-on-a-chip 2100 expert analysis software, individual exons were identified on an electropherogram by virtue of their differing heights, (measured in bp). As shown in Figure 3.5 in multiplex reactions containing the affected child’s DNA, exons 52 and 53 failed to amplify, while the other exons in the reaction amplified normally. In contrast, amplification peaks were seen for all the exons in the parental samples and the positive control. 





















































Figure 3.5: Lab-on-a-chip electropherogram showing deletion of exons 52 and 53. ABCA12 exons 8, 12/13, 25, 29 and 52 (upper trace) or 53 (lower trace) were simultaneously amplified by multiplex PCR. Individual exons were identified by peak size in bp and are labelled above their corresponding peaks, (i.e. exon 8: 459 bp; exon 12/13: 696 bp; exon 25: 288 bp; exon 29: 519 bp; exon 52 398 bp and exon 53 406bp). Traces for the father (blue), mother (green), affected child (red) and positive control, (cyan) were superimposed as shown above. The affected child did not have amplicons corresponding to exons 52 and 53 as indicated by the absence of red peaks. The negative control did not amplify.
Compound heterozygous mutations

Compound heterozygous mutations defined as different mutations on each allele were found as follows in two non-consanguineous families. 

(i)	Patient 0904 of British Caucasian origin had a paternal deletion mutation involving the 3’ end of exon 40 extending into intron 40, combined with a maternal single bp insertion in exon 44 (c. 6628insT / p. S2210fsX2223) causing a frameshift (Figure 3.6). The combined effects are expected to result in a truncated protein.




















Wildtype: …N  E  T  F  E  M  N  K  L  G  A  M  F  V  A  L  V  S  Q  G  T  M  F  F  S  L  R  L  L  I  N  E  S L  I  K  K  L  R  L  F  F  R  K  F  N  S  S  H  V  R  E  T  I  D  E  
Mutant:     …N  E  T  F  E  M  N  K  L  G  A  M  F  V  A  L  V  S  Q  G  T  M  F  F  S  L  R  L  L  I  N  E  FPDKETQAFLQKIX

Figure 3.6: Compound heterozygous mutations in patient 0904. (A) ABCA12 sequencing revealed a heterozygous paternal deletion of part of exon and intron 40 (shown in blue & by white arrow) & (B) maternal heterozygous frameshift mutation c. 6628insC in exon 44 (green arrow). (C) This frameshift mutation is predicted to result in the premature stop codon p. S2210fsX2223 and a truncated protein.






0804Turkish	NonsenseHomozygous	c. 4950C>A p. Y1650X	32
0905Turkish	NonsenseHomozygous	c. 2122C>G p. Y633X	15
0902*0903*  Balochistani *Siblings	NonsenseHomozygous	c. 1802G>A p. W601X	15
0803Mexican	Splice siteHomozygous	c. 69+1G>C AAAAGGCAGCCGg/ctgagttaa(Lower case denotes intron)	Intron 1
0806Arab other	Splice siteHomozygous	c. 3829+1G>AGTCTTCCCAGa/gtatgaatg(Lower case denotes intron)	Intron 26
0910Palestinian	Exon deletionHomozygous	Deletion of exons 52 and 53	52 & 53
0810Swedish Caucasian	MissenseSplice siteCompound heterozygous	c. 3265G>T / p. V1089Fc. 5128+3G>A (CAGAGATgtg/atgaatct)(Lower case denotes intron)	23Intron 33
0904British Caucasian	Exon and intron deletionFrameshiftCompound heterozygous	p.Q1974delc. 6628insT p. S2210fsX2223	4044

Table 3.1: ABCA12 mutations in 14 patients with clinically confirmed HI. Patients with mutations identified in both ABCA12 alleles by standard PCR and sequencing methods. X indicates the presence of a stop codon. Frameshift mutations are given with the predicted change at protein level. The cDNA reference sequence used was NM_173076 (NCBI) corresponding to full length ABCA12. 
3.2.2	Patients with unidentified mutations

ABCA12 mutations could not be identified in 3 patients with clinically confirmed HI using standard PCR and sequencing techniques. In all 3 cases the parents were known to be consanguineous (first cousins) so homozygous mutations were expected. There was no evidence of exon deletion on agarose gel electrophoresis of the PCR products and sequencing of the entire coding region did not reveal any disease associated mutations. 

The possibility of an alternative locus was therefore explored. In collaboration with Dr Charles Mein and Dr Richard Dobson, a genome wide search for regions of homozygosity was conducted using the Illumina HumanHap550v3_A Genotyping BeadChip SNP mapping array. DNA from patient 0811 showed a 14Mb block of homozygosity on chromosome 2q34-q36.3, consistent with linkage to ABCA12. 


















3.2.3	Use of RT-PCR and / or multiplex PCR to identify a complex mutation 

Analysis of DNA from first cousin consanguineous parents 0808a (father) and 0808b (mother) did not reveal any ABCA12 mutations using standard PCR and sequencing techniques. However both parents shared a common heterozygous SNP at position c. 3033 in exon 22. Further analysis was possible after the father consented to a skin biopsy. RT-PCR of total RNA extracted from this biopsy was used to look for the presence of mutant transcripts.

Exon 22 was further investigated initially. The reverse transcription product was amplified using primers where the forward primer started in exon 21 and the reverse primer in exon 23. Following sequencing, comparison was made of the morphology of the SNP in the blood and skin transcripts. However, as shown in Figure 3.8 there was no variation in the expression of the SNP between both sites eliminating it as a disease marker.

Figure 3.8: Exon 22 blood and skin transcripts from paternal sample 0808a. There is no variation in the expression of the SNP between the two sites.
RT-PCR was then performed on the whole gene with primers designed to start and end within exons. Amplification across exons 11 to 16 with primer pair ABCA12_Df/r showed the presence of more than one transcript in the paternal sample on agarose gel electrophoresis (Figure 3.9). 





Figure 3.9: RT-PCR analysis of parental sample 0808a. (A) RT-PCR using a primer pair that spanned exons 11-16 revealed 2 main products in the parental sample (WK), 1 product in the normal skin (NS) sample and no products from the genomic (Gn) DNA control. (B) The sizes of these products corresponded to the wildtype allele measuring 859 bp where all the exons were present and to the mutant allele measuring 190 bp in which there was a deletion of exons 12-15. (C) This was confirmed on sequencing. MW (molecular weight) refers to the size standard. 














































Figure 3.11: Agarose gel electrophoresis following amplification of ABCA12 exons 10-17 of an affected child and both parents. Amplicons corresponding to exons 10-17 can be identified in both parental samples and the positive control. In the affected child there are no products for exons 12-15. The negative control did not amplify. 


Deletion of exons 12-14 was confirmed using multiplex PCR. Five ABCA12 exons were simultaneously amplified. Each one could be discriminated on an electropherogram by virtue of their differing sizes measured in bp. Exon deletions were detected by assessing peak heights (Figure 3.12).  


Figure 3.12: Lab-on-a-chip electropherogram of multiplex PCR showing deletion of exons 12/13 and 14. ABCA12 exons 12/13, 14, 25, 27 and 29 were simultaneously amplified by multiplex PCR. Individual exons were identified by peak size in bp and are labelled above their corresponding peaks, (i.e. exon 12/13: 696 bp, exon 14: 395 bp, exon 25: 288 bp, exon 27: 519 bp and exon 29: 443 bp). Traces for the parental samples (dark blue and green respectively), affected child (red) and positive control, (light blue) were superimposed as shown above. The affected child did not have amplicons corresponding to exons 12/13 and 14 as indicated by the absence of red peaks. The negative control did not amplify.


3.2.4	ABCA12 analysis in suspected HI cases






Prenatal tests were performed in two families with a history of children with HI. In both cases the familial ABCA12 mutation was already known. DNA extracted from chorionic villus biopsy samples taken at 12-14 weeks gestation was analysed for the mutation p. Y1650X in exon 32 of family 1 and c. 7322delC in exon 49 of family 2. Sequencing analysis showed that the fetus in family 1 was a heterozygous carrier of the mutation and in family 2, the fetus was homozygous for the wildtype allele (Figure 3.13).












































Figure 3.13: Sequencing traces of ABCA12 mutation analysis for prenatal diagnosis in 2 different families. DNA extracted by chorionic villus biopsy was amplified using ABCA12 primers 32f/r and 49f/r in family 1 and 2 respectively. In family 1 the fetus (upper 2 traces in box 1) was a heterozygous carrier of the mutation p. Y1650X in exon 32. The affected sibling was homozygous for the mutation and control DNA showed the wildtype sequence. In family 2 the fetus was homozygous for the wildtype allele (upper trace) while both parents were heterozygous carriers. Arrows indicate the site of the mutation. 
3.2.6	Genotype-phenotype correlation






















The aims of this chapter were to identify new ABCA12 mutations and develop alternative strategies when standard techniques failed. This knowledge was then used for prenatal and pre-implantation diagnosis and to look for correlations between genotype and phenotype. 


3.3.1	ABCA12 mutations in HI

ABCA12 truncation mutations resulting in loss of function cause HI. Of the 44 reported mutations, 41% (18) are nonsense; 27% (25) are frameshift caused by insertions or small deletions; 16%  (7) affect the splice site; 9% (4) are missense and 7% (3) are due to whole exon deletions. During the course of this work, 14 different mutations were identified, 9 of which were novel. They were found in both alleles of 14 out of 17 patients and in keeping with previous reports each patient had at least one allele harbouring a truncation mutation. Most changes were homozygous reflecting the high level of parental consanguinity associated with this disease. 

The most common mutation, found exclusively in Pakistani families was c.7322delC in exon 49. This corroborated the findings of Thomas et al  ADDIN EN.CITE (2008), who previously reported this as a founder mutation after identifying it in 80% of patients from Pakistan. They also reported the mutation p. W601X in exon 15 of an Arab patient. During the current analysis, this latter mutation was identified in an unrelated sibling pair from Balochistan, a region inhabited by natives of Iranian, Pakistani and Afghani descent. Furthermore, the homozygous splice site mutation c.3829+1G>A in intron 26 found here in an Arab patient, was also identified by Thomas et al  ADDIN EN.CITE (2008) in an unrelated patient of possible Arab ancestry. Therefore, these two mutations may be additional founder mutations in Middle Eastern populations. Knowledge of recurring mutations is particularly useful when screening new cases, saving both time and resources if specific exons can be targeted from the outset. 

All the new mutations detected in this study are predicted to result in a truncated protein with the exception of an exon 23 heterozygous missense mutation in patient 0810. To date, the majority of ABCA12 missense mutations have been associated with LI2  ADDIN EN.CITE (Lefevre, et al., 2003) and CIE (Sakai, et al., 2009) where they are usually homozygous. Akiyama et al  ADDIN EN.CITE (2006) reported a case of HI of reduced clinical severity in a compound heterozygous patient with a missense mutation in exon 10 (c. 1160G>A) and a deletion mutation in exon 28 (c. 4158_4160delTAC). Exon 10 corresponds to the cytoplasmic domain of the protein. A missense mutation here would not affect any of the active transporter sites and this may account for the improved phenotype that was observed in the patient. The new missense substitution identified in the current study, (c. 3265G>T / p. V1089F) in exon 23, would cause a change in amino acid from valine, which is a hydrophobic residue to phenylalanine, which is an aromatic residue. This change lies in the cytoplasmic region between the first and second transmembrane domains. The valine residue is conserved amongst chimpanzee, dog, cow, mouse, chicken and zebrafish orthologues and is therefore likely to be functionally important. This may explain why patient 0810 did not exhibit a less severe phenotype unlike the previous report.

Two homozygous splice site mutations were identified in intron 1 and intron 26 of patient 0803 and 0806 respectively. In both cases, these changes are predicted to result in a truncated protein. Exon recognition is regulated via RNA-RNA, RNA-protein and protein-protein interactions involving the spliceosome (Nilsen, 1994) but the exact mechanism by which splice sites are selected is poorly understood. In mammals, the first 2 bases of the intron (GU) at the 5’ splice site are universally conserved (Aebi, et al., 1987) as is the dinucleotide AG at the 3’ end. A polypyrimidine tract and a branch site precede the latter, up to 100 nucleotides upstream of the 3’ splice site. As these splicing regulatory sequences are degenerate many others can be found in the genome that match the splice consensus sequence as well, or better than the real splice site, but are not actually involved in the process (Baralle & Baralle, 2005). Hence while the consensus elements are necessary for splicing, other factors must also be involved. Additional sequences located in exons and introns can enhance (exon/intron splice enhancers) or silence (exon or intron splice silencers) the recognition of adjacent splice sites by binding to regulatory proteins. Serine-arginine-rich SR proteins and heterogeneous ribonucleoproteins (hnRNPs) are thought to bind to these enhancer and silencer sequences respectively and help regulate splicing  ADDIN EN.CITE (Fairbrother & Chasin, 2000; Graveley, 2000). 

It has been estimated that up to 15% of all point mutations result in abnormal mRNA splicing (Krawczak, et al., 1992). However, in a study of ataxia telangiectasia (AT), where analysis was performed at both the DNA and RNA level, 48% of patients were found to have mutations that resulted in aberrant splicing, but less than half of these mutations involved the canonical splice sites  ADDIN EN.CITE (Teraoka, et al., 1999). Instead, mutations would have been incorrectly classified as simply frameshift, missense or nonsense if the analysis had been limited to the genomic sequence alone and their effect on splicing overlooked. Furthermore, some of the missense mutations could have been ignored, as the amino acid change may have been considered benign. It is postulated that these point mutations can interfere with splicing by affecting binding at nearby exon enhancer and silencer sequences or by nonsense-associated altered splicing (Maquat, 2001). 

HI is thought to be genetically homogeneous, as large series have reported a 100% mutation rate in one or both alleles of all families tested,  ADDIN EN.CITE (Akiyama, et al., 2005; Kelsell, et al., 2005; A. C. Thomas, et al., 2008). Indeed a genome wide search for regions of homozygosity in a patient with an unidentified mutation showed the largest block of homozygosity was consistent with linkage to ABCA12. Hence given the number of analyses to date, it seems unlikely that HI is also caused by mutations in another gene. In most cases conventional PCR and direct sequencing alone is successful. However, as this work has shown, as more cases are analysed, complex mutations are likely to be encountered that need alternative techniques. Thomas et al  ADDIN EN.CITE (2006) demonstrated the use of multiplex PCR and oligonucleotide array analysis to detect a heterozygous exon 8 deletion mutation in a patient with HI. In the current study, initial failure to find a mutation in a carrier parent’s DNA (sample 0808a), led us to sequence his cDNA extracted from a skin biopsy. This revealed a deletion of exons 12-15 that was later verified using copy number analysis. This mutation was not detected with the standard PCR reaction as amplicons generated from the normal allele masked the deletion in the abnormal one. Hence when looking for heterozygous mutations, skin biopsy material if available can be very useful. Patient 0910 also had exon deletions (52 and 53). These were identified immediately on agarose gel electrophoresis of the PCR products and further verified using copy number analysis. In both of these cases there were no mutations in the adjacent intronic sequences suggesting that the break point lies ‘deep’ in the intronic sequence. 

In this study mutations could not be identified on either allele in 6 patients. In 3 of these cases the diagnosis of HI proved to be incorrect. This is understandable as HI is very rare so an inexperienced clinician or histopathologist may make an incorrect diagnosis. Hence wherever possible, an expert should be involved before proceeding to mutation analysis. The other 3 patients had a reliable diagnosis of HI. All three sets of parents were consanguineous so homozygous mutations were expected. DNA was available from all the affected infants but direct sequencing of exons 1-53 and the intron/exon boundaries did not reveal any mutations and exon deletions were not seen on electrophoresis of the PCR products. Therefore, it is likely that these patients harbour mutations in an intron, promoter or other regulatory region of the gene. The availability of skin biopsy samples and high throughput sequencing technologies in the future may help elucidate these mutations.


3.3.2	ABCA12 and disease: genotype/phenotype correlation

Mutations in ABCA12 cause 3 clinically heterogeneous diseases. HI has the most severe phenotype. Newborns are encased in thick scale plates separated by deep red fissures which when shed, develops into a non-bullous congenital ichthyosiform erythroderma in survivors. Babies with CIE and LI2 are born with a collodian membrane. This is shed over a few weeks to leave generalised fine white scale against an erythrodermic background in CIE and widespread large dark pigmented scales without inflammation in LI2. Differences in the type and location of ABCA12 mutations can be seen between these 3 diseases. 

ABCA12 mutations in LI2 are thus far restricted to 9 families from North Africa  ADDIN EN.CITE (Lefevre, et al., 2003). Five different missense mutations were identified and they were homozygous in 8 consanguineous families and heterozygous in one non-consanguineous family. All 5 mutations occurred within exons 28-32 and 4 of them affected residues found in the 1st ATP binding cassette of the protein, which is a conserved functional domain. The most common mutation in LI2 is p. N1380S in exon 28 and haplotype analysis has confirmed that this is a founder mutation in patients from Algeria and Morocco.  

In CIE, 10 ABCA12 mutations have been identified and 7 of these are homozygous missense changes that are distributed throughout the gene. Interestingly, the same homozygous missense mutation in exon 30, c. 4541G>A / p. R1514H has been shown to result in both CIE (Sakai, et al., 2009) and LI2  ADDIN EN.CITE (Lefevre, et al., 2003). The mechanism for this remains unexplained. 

Three cases of CIE with compound heterozygous ABCA12 mutations have also been reported. In each case, one allele has harboured a nonsense mutation. Akiyama et al (2008) reported the case of a 2 year old child with CIE who had a nonsense mutation in exon 33, c. 5005C>T / p. Q1669X and a missense mutation, c. 3407G>A / p. G1136D in exon 24. The missense mutation would be expected to affect the intracytoplasmic region between the second and third transmembrane domains. The premature stop codon resulting form the nonsense mutation would eliminate the final 827 amino acids at the C-terminus of the peptide resulting in a truncated ABCA12 protein missing the second NBF and half of the transmembrane domains. Despite this critical effect on the protein, this child did not exhibit any of the phenotypic features of HI. 

Sakai et al (2009) also reported a compound heterozygous case of CIE with a nonsense mutation in exon 39: c. 5848C>T / p. R1950X and a missense mutation in exon 26: c. 3704G>C / p. W1235S. In this case the missense mutation would affect the intracytoplasmic region between the fifth and sixth transmembrane domains while the nonsense mutation would again result in the loss of the second NBF and half of the transmembrane domains. While no clinical information was given about this patient, Akiyama et al  ADDIN EN.CITE (2005) described a compound heterozygote with HI who harboured the same nonsense mutation combined with a splice site mutation in intron 23: c. 3295-2A>G. Similarly, a heterozygous nonsense mutation in exon 51: c. 7444C>T / p. R2482X was reported in a case of CIE where the second mutation was unidentified (Sakai, et al., 2009) and the same nonsense mutation has also been described in HI (Akiyama, 2010). 

This is interesting as in general any homozygous or compound heterozygous mutation, anywhere along the length of the gene leading to ABCA12 protein truncation will give rise to the HI phenotype. An explanation for this could be that the missense mutation only slightly impairs a functionally important part of the protein, such that despite the presence of a truncation mutation, the combined effect only results in a modest loss of ABCA12 function and a milder phenotype than HI. One further exception to this rule is c.3535G>A / p. G1179R in exon 24 which is a homozygous missense mutation reported in a patient with HI  ADDIN EN.CITE (A. C. Thomas, et al., 2006). In this case, the mutation lies within the first transmembrane domain of the protein and must cause significant disruption in its function. Functional studies need to be performed such as overexpressing wildtype and mutant ABCA12 to compare HI missense mutations with those found in CIE. 







Figure 3.14: ABCA12 mutations and their location within the gene. Adapted from Akiyama (2010). The structure of the predicted ABCA12 protein is illustrated with 2 transmembrane domains and 2 ATP binding cassettes. All the reported mutations have been grouped together according to their location within the gene. Mutations causing HI, CIE and LI2 are in black, red and blue respectively. Mutations resulting in more than one phenotype are in pink, namely p. R1514H results in  CIE and LI2 and both p. R1950X and p. R2482X cause HI and CIE. The cDNA reference sequence used was NM_173076 (NCBI). 1Mutations identified in this study; 2Thomas et al.,  ADDIN EN.CITE (2008); 3Thomas et al.,  ADDIN EN.CITE (2006); 4Castiglia et al., (2009); 5Natsuga et al., (2007); 6Akiyama et al.,  ADDIN EN.CITE (2006); 7Akiyama et al.,  ADDIN EN.CITE (2005); 8Kelsell et al.,  ADDIN EN.CITE (2005); 9Akiyama et al., (2008); 10Sakai et al., (2009); 11Akiyama et al.,  ADDIN EN.CITE (2007); 12Rajpar et al., (2006); 13Lefevre et al.,  ADDIN EN.CITE (2003).

3.3.3	Mutation type and effect on survival

This work has revealed that there may be a correlation between ABCA12 mutation type and survival in HI. Mortality was almost exclusively associated with homozygous mutations. The co-existence of other serious recessive diseases may be one explanation but it is also possible that being a compound heterozygote confers a survival advantage. Furthermore, ‘biallelic effects’, as described in xeroderma pigmentosum  ADDIN EN.CITE (Andressoo, et al., 2006), may also occur in HI where the interplay between two heterozygous mutations determines the severity of the disease.  One patient with a compound heterozygous mutation did not survive but this may have been due to other factors such as intractable sepsis, other co-morbidities or a palliative approach to care. 


3.3.4	Genetic testing in pregnancy





























3.4 	Summary and Conclusions

ABCA12 mutations cause three autosomal recessive congenital ichthyoses: HI, LI2 and CIE. Of these HI is the most severe. The 14 new mutations identified in this chapter are predicted to cause a truncated protein with severely disrupted function. The majority of mutations can be identified by standard PCR and sequencing techniques, but RT-PCR and copy number analysis are alternative ways of finding mutations when conventional methods prove ineffective.

Homozygous truncation mutations always result in HI and missense mutations are rare. Mutations are found throughout the gene and there are no genetic hotspots but ethnic variations do occur and cluster to specific exons. LI2 is caused by homozygous missense mutations in exons 28-32 while CIE results from at least one missense mutation and is occasionally associated with heterozygous truncation mutations.
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ABCA12 plays an essential role in the formation of a competent skin barrier. Complete deficiency, as in HI results in absent, reduced or abnormal LB and an inability to deliver lipids to the SC, resulting in a lack of interstitial lipid lamellae and barrier failure. However, the ichthyotic phenotype is also present in utero while the fetus is surrounded by amniotic fluid, suggesting that barrier defects alone probably do not account for the pathogenesis, at least during that period. Furthermore, babies with HI shed their thick scale soon after birth and there is a shift in phenotype to a congenital non-bullous ichthyosiform erythroderma. These observations suggest that in addition to its role in lipid transport, ABCA12 may be involved with processes that regulate keratinocyte differentiation. This may be via its interactions with PPAR/, a receptor that is known to have many differentiation related effects  ADDIN EN.CITE (Jiang, et al., 2008). 

ABCA12 transports glucosylceramide into LB but its expression is regulated by ceramide via activation of PPAR/  ADDIN EN.CITE (Jiang, et al., 2009). This feed-forward mechanism also controls the expression of another epidermal ABC transporter, ABCA1 that is involved in cholesterol efflux from cells. Cholesterol excess results in an increase in oxysterol levels that activate LXR, resulting in increased expression of ABCA1  ADDIN EN.CITE (Jiang, et al., 2008).  











4.2.1	PPAR/, RXR and ABCA1 staining in HI skin

A skin biopsy was taken from an adult patient with HI. Immunohistochemistry on frozen sections showed that there was no expression of ABCA12 (Figure 4.1) and analysis of the patient’s DNA identified potential deleterious mutations (Scott and Chronnell unpublished data). Thereafter the distribution and expression of PPAR/, RXR and ABCA1 in HI skin was investigated. The results of this immunostaining are illustrated in Figures 4.2-4.4 below. The staining was repeated and the same results were obtained in paraffin embedded sections of a skin biopsy taken from an independent HI patient, known to have the ABCA12 mutation c. 7322delC. These results are illustrated in Appendix B. 

PPAR/
IHC analysis with an antibody against PPAR/ showed that this nuclear hormone receptor was expressed throughout the epidermis but was most prominent in the basal and spinous layers. In HI skin the distribution was unchanged but the expression was reduced (Figure 4.2).  

RXR
Figure 4.3 illustrates RXR expression. This was also seen throughout the epidermis in both normal and HI skin. However on the basis of these results, it was difficult to ascertain whether there was any significant difference in expression. 

ABCA1



















Figure 4.3: RXR expression in normal skin and in HI. Normal skin (NS) and HI skin were stained for RXR and viewed with a confocal microscope at x40 magnification. The nuclei were stained blue with DAPI. RXR was expressed throughout the epidermis in both normal skin (NS) and HI skin. There was no obvious change although there may be reduced levels of expression in the basal cell population. 








The next set of experiments aimed to establish if there was a quantifiable difference in the expression of PPAR/, RXR and ABCA1 in HI. However, as the availability of patient skin was limited, an ABCA12 knock down was attempted using retrovirally transduced NEB1 cells containing shRNA constructs shown to be effective at reducing the expression of ABCA12 in this cell line. NEB1 cells were first stained with antibodies against PPAR/, RXR and ABCA1. The levels of these proteins in a NEB1 lysate were then assessed using Western blot analysis with the intention of repeating these experiments in the ABCA12 knockdown cells.  The results were as follows.


4.2.2	PPAR/, RXR and ABCA1 staining in NEB1 cells















Figure 4.5: Immunocytochemistry of PPAR/ in NEB1 keratinocytes.  NEB1 cells were stained for PPAR/ and viewed with a Leica microscope. The nuclei were stained blue with DAPI. PPAR/ appeared as small green globules in the cytoplasm, encircling the nucleus. 






























4.2.3	Western blot analysis of PPAR/, RXR and ABCA1



















4.2.4	ABCA12 knockdown studies 



































ABCA12 plays an integral role in forming and maintaining the barrier function of the epidermis. This is achieved through its action as a lipid transporter and also by mediating effects on keratinocyte differentiation. 

Among the abnormalities found in HI skin, an abnormal lipid profile is well recognised. The interstitial lamellae are composed of a complex mix of lipids of which ceramide is an important constituent. In an HI mouse model, the levels of the linoleic esters of omega-hydroxy long-chain ceramides were significantly reduced, with a corresponding increase in the intracellular levels of the glucosylated precursors of those same lipids (Zuo, et al., 2008). Similarly, in another mouse model, Smyth et al  ADDIN EN.CITE (2008) demonstrated that mice carrying a homozygous spontaneous missense ABCA12 mutation had severely impaired lipid efflux and intracellular accumulation of neutral lipids, while Yanagi et al  ADDIN EN.CITE (2008) noticed loss of ceramide staining in the SC of their ABCA12 deficient mice, as well as accumulation of glucosylceramide staining intracellularly. Furthermore, in vitro experiments of cultured keratinocytes from an HI patient showed defective glucosylceramide transport that was recoverable by corrective gene transfer  ADDIN EN.CITE (Akiyama, et al., 2005). 

As one would expect, lipids can influence the expression of ABAC12. Blocking the conversion of ceramide to glucosylceramide, inhibiting sphingomyelin synthesis from ceramides and blocking the hydrolysis of ceramides leads to a net increase in ceramide levels and a concomitant increase in ABCA12 mRNA. Similarly, an increase in endogenous ceramide levels or incubation of human keratinocytes with exogenous synthetic cell-permeable ceramides, results in increased ABCA12 mRNA and protein levels. This stimulation of ABCA12 gene expression in response to raised ceramide levels is mediated by PPAR/  ADDIN EN.CITE (Jiang, et al., 2009).  

In this chapter, the expression of PPAR/ was reduced on immunostaining of HI skin. As described above, glucosylceramide levels are elevated in HI keratinocytes. As this lipid accumulates, the levels of its precursor ceramide diminish and the feed forward stimulation of ABCA12 via PPAR/ would be removed, thus resulting in a reduction in the levels of the latter, which could explain the results seen here. RXR forms a heterodimer with PPAR/ so it is possible that the expression of RXR may also be reduced in HI, but this has not been demonstrated here. 

The interaction between ABCA12 and another lipid transporter, ABCA1 was also investigated. Cholesterol efflux to apolipoprotein A1 (ApoA1) is responsible for maintaining cellular cholesterol homeostasis and is controlled by ABCA1. However, Smyth et al showed in their HI mouse model that ABCA12 might also be involved in this pathway by regulating ABCA1. Skin fibroblasts from their mutant mice showed an impaired ability to maintain cholesterol efflux to ApoA1. They demonstrated that there was reduced transcription of ABCA1 in the mutant mice and speculated that a direct association between ABCA1 and ABCA12 may be required for functional stabilisation of ABAC1 and normal cholesterol efflux to ApoA1. In this chapter it has been demonstrated that ABCA1 expression is reduced on immunostaining of HI skin which is in keeping with the observations in the mouse model. However, the mechanism by which this occurs remains undetermined. 

Current evidence suggests that ABCA12 is largely involved with ceramide transport. In ABCA12 deficient mice, total cholesterol levels did not differ significantly from matched wildtype controls and the levels of phosphatidylcholine, phosphatidylethanolomine, phosphatidylserine, sphingomyelin and free fatty acids were also similar between the two groups (Zuo, et al., 2008).  































Lipid transport to the SC is a key step in establishing the barrier function of the skin and ABCA12 is an important keratinocyte lipid transporter protein. In its absence, there is a defect in lipid loading into LB which themselves do not form properly, if at all, resulting in a SC that is deficient in interstitial lipid lamellae. Ceramide, a key component of the lipid lamellae is formed from glucosylceramide delivered to the SC via LB. This transport pathway is regulated by a feed forward mechanism whereby ceramide stimulates ABCA12 expression via PPAR/. In HI skin, the levels of omega-hydroxy long-chain ceramides are profoundly reduced and there is a corresponding fall in the expression of PPAR/. Furthermore, ABCA12 may affect the expression of another lipid transporter, ABCA1 as the expression of this protein is also reduced in HI skin. 
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HI (MIM242500) is the most severe form of congenital ichthyosis. Affected babies are born with a characteristic clinical appearance as described in Section 1.6.1. As the entire skin barrier is severely compromised, there is a high risk of sepsis and dehydration and the disease is often fatal in the neonatal period. Treatment with oral retinoid drugs encourages shedding of the grossly thickened skin (Brecher & Orlow, 2003) and babies who survive into infancy and beyond develop skin changes resembling severe NBCIE (Haftek, et al., 1996).

A review of the literature revealed that no large case series of HI have ever been reported. Individual case reports have largely focused on infants and relatively little information is available on the outcome of older children and adult survivors. Therefore, the primary aim of this chapter was to determine the clinical outcomes of the HI cases referred to our centre for ABCA12 mutation analysis. 

Over 70 DNA samples have been analysed to date  ADDIN EN.CITE (Kelsell, et al., 2005; A. C. Thomas, et al., 2006; A. C. Thomas, et al., 2008). Using this database, a detailed, systems-based clinical questionnaire (Appendix C) was sent to 56 clinicians worldwide. With the patient(s) consent they were asked to complete the questionnaire retrospectively using the medical notes. Kelsell et al  ADDIN EN.CITE (2005) previously published limited clinical data regarding 12 babies with HI. This information was included if the child was deceased at the time of the original study or if no further information was made available. Furthermore, following kind permission from the authors (Professor AY Finlay and Dr GK Khan), the children’s/family or adult dermatology life quality index [(C/F)DLQI] questionnaires were sent to all surviving UK children and adults with HI (Appendix C). 








Clinical data was obtained for 45 patients (Appendix C). This consisted of 33 completed detailed questionnaires and 12 brief questionnaires. In total, there were 25 survivors (56%) and 20 deaths (44%). Sex was reported for 43 patients. The male to female ratio was almost equal with 20 (47%) males and 23 (53%) females. More male babies died accounting for 65% of all deaths. The ages of survivors ranged from 10 months to 25 years.












Prenatal ultrasonography was performed in 8 cases, all with previously affected children, and results were available for 6 of these. The scans were conducted late in the second and third trimesters, (22 weeks onwards). Routine fetal anomaly scans used in the early stages of pregnancy were not included. 






Of 45 babies, an oral retinoid drug was given to 24, and 20 (83%) survived. Among the 20 survivors, treatment was started within the first 3 days of life in 9 babies (45%) and between days 4 and 7 in 7 babies (35%) and was deferred until 2 years and 11 months in another case. One baby received a retinoid as a neonate and in 2 cases the start date was unknown. 
	
Four children died despite receiving a retinoid. Within this group, treatment was started by day three in 3 babies (75%). The fourth child received isotretinoin from day 19 onwards. Twenty-one babies did not receive a retinoid, and within this group 5 (23%) survived. Out of the 16 deaths, 10 (63%) occurred by day 3.
	




Figure 5.1: Duration of course of treatment with oral retinoid. At least one course of treatment was given to each of 20 survivors with the retinoid dose ranging from 0.5 – 2.5 mg/kg. 







All babies had the harlequin typical appearance at birth. Newborns were encased in thick white plate-like scales separated by deep red fissures. Bilateral ectropion and eclabium were universal. The ears and nose were buried in thick hyperkeratotic skin resulting in anteverted nares and ears lacking retroaural folds. Of 45 children, 5 developed autoamputation of some fingertips due to constricting bands of skin around the digits. One child who subsequently died underwent a fasciotomy for limb swelling due to constriction. 

Infancy and beyond
Babies who survived into infancy had a severe ichthyosiform erythroderma. Of 25 survivors, 13 (52%) had a palmoplantar keratoderma. Plantar changes were associated with pain on weight bearing and subsequent delay in walking. 

































Heat / cold intolerance	9 (36)




Table 5.1:  Cutaneous manifestations of 25 surviving children and adults with HI. *Caused infection in the skin and also the endotracheal tube tip. ‡Other refers to photosensitivity (n=1); widespread pigmented macules (n=1) and widespread sterile pustulation (n=1). 


5.2.5.2	Hair and nail problems

Generalised poor hair growth affected 16 of the 25 survivors (64%). In 1 patient this was limited to the parietal and occipital scalp and in another there was regression of all the hair margins. One child aged 7 years had no scalp hair. Nail deformities as outlined in Table 5.2 were observed in 16 of the 25 survivors (64%). Among these 16 patients, 11 (69%) had abnormally shaped or small nails, 8 (50%) had thickened nails, and in 1 case, surgical amputation of the terminal phalanges of 2 fingers was required because of onychogryphosis. 
  
Clinical feature	Number of patients 
Thickened nails	8 
Beaked / pinched / distally curved	8 




















Clinical feature	Number of surviving patients (%)
Persistent ectropion	16 (64)
Surgical correction of ectropion	5  (20)
Epiphora	12 (48)











Among the 25 survivors, problems maintaining weight despite high calorie supplements were reported in 11 (44%). Two children required nasogastric feeds in infancy and 1 child had overnight supplementary feeding via a gastrostomy tube, performed intermittently until the age of 6 years. This is probably an underestimate because the use of feeding tubes was not specified in the questionnaire. Chronic constipation requiring regular laxatives affected 7 out of the 25 children (28%). Three children were treated for gastroesophageal reflux. Finally, vitamin D deficiency causing rickets and osteomalacia was reported in 3 patients, and 1 patient developed scurvy during a 3-year period when the child was out of the country and lost to follow-up.


5.2.5.5	Height and weight abnormalities
















Respiratory problems were most common in the neonatal and early infancy periods and were a major cause of death in neonates. Out of the 25 children who survived, 3 (12%) required mechanical ventilation and 1 infant had intermittent episodes of oxygen desaturation in the first 2 weeks.  Another 3 patients (12%) had respiratory failure secondary to respiratory syncytial virus and 1 patient developed pulmonary interstitial fibrosis.


5.2.5.9	Ear nose and throat problems

Deafness was reported in 1 of 25 survivors. Six children experienced recurrent blockage of the external auditory canal and required regular microsuctioning to remove skin debris. 


5.2.5.10  Urological problems

Surgical correction of phimosis in 1 patient and urinary incontinence due to an unstable bladder in another patient were reported. One child underwent circumcision without any problems.


5.2.5.11  Biochemical problems

Hypernatraemia, hypocalcaemia and hypoglycaemia were reported separately in 3 of 25 patients in early infancy.


5.2.5.12  Miscellaneous problems


















































HI is a rare disease that is associated with substantial morbidity and mortality. Males and females are equally affected and the disease affects all racial groups but occurs more often in populations with high levels of parental consanguinity. 
	
Previous reports have shown that many babies die soon after birth (Akiyama, 1999) but in this series the survival rate is over 50%. Indeed most babies were born at or near term and they all weighed an appropriate weight for gestational age. Reasons for improved survival may include greater awareness of the condition, improved quality of care and possibly early treatment with oral retinoids. In the retinoid-treated group, 83% survived (20 of 24 patients) compared with a 24% survival rate in the untreated group (5 of 21 patients). More than half of the deaths in the untreated group (10 of 16 [63%]) occurred in the first 3 days of life. However, only 45% of treated survivors received a retinoid within this time. This suggests that many of the early deaths may have happened irrespective of treatment with a retinoid, especially if the baby had other complications. In some cases it may have been decided that palliative care was more appropriate and this may have contributed to some of the deaths. A previous study (Singh, et al., 2001) showed that 6 out of 7 cases of HI treated with an oral retinoid survived beyond 1 year. These results demonstrate that the majority of survivors were treated with a retinoid and 80% started treatment by day 7. Liquid acitretin is not widely available and may take several days to obtain. Hence one can postulate that the introduction of oral retinoids, as soon as possible after birth, probably improves survival. However, one can appreciate that a more active management approach overall also contributes to improved survival. 

Long-term treatment with oral retinoids can be associated with toxicity. The only potential retinoid related side effect in this study was the development of a cataract in a child treated with acitretin (0.5 mg/kg/day) for 4 months from birth. Retinoid associated cataracts have been reported in adults but not in children (Brecher & Orlow, 2003).
Musculoskeletal toxicity can also be associated with chronic treatment.  Reported side effects include premature epiphyseal closure in a patient on high dose isotretinoin (3.5 mg/kg/day) for 4 years (Milstone, et al., 1982) and in another child with lamellar ichthyosis treated with etretinate 2.5 mg/kg/day for 6 years (Prendiville, et al., 1986). Fractures as a result of minor trauma have also been reported (Prendiville, et al., 1986) as has periosteal thickening, periosteal bone resorption and osteoporosis in patients on high doses of oral retinoids (Halkier-Sorensen, et al., 1987). By contrast, other authors have shown no increased risk of bone toxicity with chronic oral retinoid use  ADDIN EN.CITE (Glover, et al., 1987; Paige, et al., 1992). Retinoid-associated skeletal side effects were not reported in this study. Although 7 children reported joint pain, none of them were being treated with a retinoid at the time.  Mucocutaneous side effects can also occur and etretinate and acitretin have comparable toxicities (Brecher & Orlow, 2003). However, diffuse hair thinning and brittleness of the nails is more common with acitretin (Shalita, 1987). The hair thinning and nail changes reported in this study were disease-related and not due to acitretin and no mucocutaneous side-effects were reported.

In order to minimise long-term toxicity, Brecher and Orlow (2003) recommended that the retinoid dose should be kept as low as possible, ideally close to 0.5 mg/kg/day. Serum lipids and liver function tests should be performed at baseline, 1 month after initiation of treatment and every 3 months thereafter. Symptoms suggestive of skeletal toxicity should be promptly investigated, particularly in those children receiving doses greater than 1.0 mg/kg/day.

The diagnosis of HI is usually clinical and management of the neonate is largely supportive but involves the input of a multidisciplinary team. Emollients and the early introduction of an oral retinoid at an initial dose of 1 mg/kg/day encourage shedding of the thick armour-like plates. It is important to keep invasive procedures to a minimum and to be vigilant for signs of sepsis to avoid skin infection. An ophthalmologist should be involved at an early stage to minimise complications caused by the ectropion and ENT specialists for aural toilet to remove debris from the ears. Plastic surgery input may be needed to treat digital contractures or necrosis. Baseline biochemical and haematological tests should be carried out and abnormalities corrected. The retinoid dose can usually be reduced and after 6 months should be guided by clinical response. 

Survivors will have a life-long skin disease that resembles NBCIE. The mechanism behind this phenotypic recovery remains unclear. Yanagi et al  ADDIN EN.CITE (2010) demonstrated disrupted keratinocyte differentiation in neonatal epidermis and primary-culture keratinocytes from an HI mouse model. With maturation however, both the skin graft and subcultured HI keratinocytes regained normal differentiation, suggesting that this may contribute to the improvement in an HI survivor’s skin. Patients will still require frequent maintenance application of emollients, intermittent courses of oral retinoids in some cases and protection from extremes of temperature. Vitamin D supplements will be required if skin exposure to sunshine is restricted. Patient support groups such as the Foundation for Ichthyosis and Related Skin Types (FIRST) (United States) (http://www.firstskinfoundation.org (​http:​/​​/​www.firstskinfoundation.org​)) and the Ichthyosis Support Group (United Kingdom) (http://www.ichthyosis.org.uk (​http:​/​​/​www.ichthyosis.org.uk​)) provide valuable help to families.

Preservation of visual function is crucial in survivors. Persistent ectropion is a frequent complication affecting 64% of patients. In this study 20% underwent surgical correction. The lack of intact donor skin for grafting makes this more challenging in HI. Full thickness autografts from the thigh (Chua & Ainsworth, 2001) and posterior auricular skin (Khan, et al., 2009) have been described in HI as well as one case using engineered human skin (Culican & Custer, 2002). The long-term outcome of surgery in these cases is not known but there is 1 report of epiphora post-operatively. Unfortunately, ectropion frequently recurs following surgical correction. An alternative approach is periocular topical retinoid application. 

Early input from a dietician is necessary. Infants may have difficulty sucking because the jaw is splinted by thick scale, necessitating nasogastric feeding. Breastfeeding should be encouraged not least to promote parental bonding. Young children may need feeding via gastrostomy to maintain their calorific intake whereas older children and adults are more likely to comply with high calorie dietary supplements. Moskowitz et al  ADDIN EN.CITE (2004) investigated the pathophysiological basis for growth failure in children with ichthyosis. While observing that in general weight at birth was appropriate for gestational age, it fell to a lower centile during early infancy. They hypothesise that the defective skin barrier in these patients results in the loss of water and calories, which in turn affects growth potential.

This is the first time HI has been associated with rickets although this has previously been reported in children with ichthyosiform dermatoses  ADDIN EN.CITE (Thacher, et al., 2004; Sethuraman, et al., 2008). Possible mechanisms include defective vitamin D synthesis in the diseased epidermis and avoidance of exposure to ultraviolet radiation due to the disease (Milstone, et al., 1992).

Juvenile idiopathic arthritis is a rare inflammatory arthritis affecting those under 16 years of age. In addition to the 3 cases reported herein another patient with HI aged 6 years is described in the literature who developed rheumatoid factor positive polyarthritis (Chan, et al., 2003). The co-existence of these two rare conditions suggests a common underlying aetiology that is not yet understood.

Motor developmental delay was reported in almost one third of the cases. Digital contractures and autoamputated fingertips can affect gross and fine motor skills, and thickened, fissured plantar skin may be painful and delay walking. Furthermore, many of the children have frequent hospital admissions in infancy and, because of their disease, may also have fewer interactions with other children and adults, which affects their speech, language and social skills. Significant mental impairment is not usually associated with HI.

The interest in lipid levels and a family history of dyslipidaemia and premature cardiovascular disease stems from the observation that fibroblasts from ABCA12 deficient mice show decreased transcription of ABCA1  ADDIN EN.CITE (Smyth, et al., 2008). The authors speculate that there might be a direct association between these 2 lipid transporters in the cholesterol efflux pathway. This has implications for the pathogenesis of atherosclerosis. The present study was unable to sufficiently address lipid abnormalities in HI patients and their families but this warrants further investigation in the future. 
The cause of death in HI is often speculative, since post mortems are not usually conducted. Review of the mortality data shows that respiratory failure causes death as commonly as sepsis. This may simply arise because the thickened skin restricts chest wall movements, or makes breathing too painful resulting in poor pulmonary ventilation. Opiate analgesia is given in the neonatal period to relieve this pain but may itself cause respiratory depression. Rajamani et al., (2000)  reported that aspiration of amniotic fluid rich in epithelial cells might have contributed to the development of pulmonary disease in a child with congenital ichthyosis.  This is also plausible in HI where the amniotic fluid is likely to contain numerous epithelial cells. Furthermore, it has been reported that apart from the skin, ABCA12 is expressed in the lungs, testis and placenta  ADDIN EN.CITE (Lefevre, et al., 2003). ABCA3 aids lipid secretion from type II alveolar cells via LBs  ADDIN EN.CITE (Yamano, et al., 2001). Ultrastructural analysis of these cells in an HI mouse model has shown that LB-like organelles lack the normal lamellar structure compared with wildtype mice. Furthermore, the ABCA12 deficient mice exhibited alveolar collapse and pulmonary congestion suggesting that ABCA12 protein may be involved in generating or transporting the lipid component of pulmonary surfactant  ADDIN EN.CITE (Yanagi, et al., 2008). This would support our observation of a high incidence of respiratory-related deaths in HI.

Prenatal diagnosis (PND) is available for HI as discussed in Section 3.3.4. However when genetic testing is not available or is declined, some families rely on prenatal ultrasonography. This is both technically challenging and operator dependent. Indeed, out of 6 mothers who had scans to specifically look for HI the diagnosis was only made in 50%. 
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ABCA12 mutations result in three autosomal recessive congenital ichthyoses of which HI is the most severe. Nine novel mutations were identified which increases the total number of reported ABCA12 mutations in HI to over 50. A small proportion of these were seen to occur more frequently in certain populations and knowledge of these recurring mutations was useful when screening new cases. Most mutations were identified with standard PCR and sequencing techniques but alternative strategies included copy number variation analysis and examination of cDNA (obtained from skin biopsy material) with RT-PCR. The results of these mutation analyses were used to perform two prenatal and one pre-implantation genetic diagnosis. 

The majority of ABCA12 mutations in HI caused a truncated protein and included nonsense, frameshift (both small insertions and deletions) and splice site mutations. Whole exon deletions were also found and in a small number of cases, missense mutations have been identified in one or both alleles. During the course of this work, the missense mutation p. V1089F affected a highly conserved residue within the protein. HI is thought to be genetically homogeneous. Hence in the few cases where ABCA12 mutations remained elusive, it was likely that the mutation was within an intron, promoter or other regulatory region of the gene or, that standard Sanger sequencing missed it. 

In addition to HI, ABCA12 mutations are also a minor cause of LI2 in Africa and of several cases of CIE in the Japanese population. In terms of genotype-phenotype correlation, it can be predicted that homozygous missense mutations will generally give rise to the LI2 or CIE phenotype; heterozygous missense mutations are more likely to result in CIE and in the presence of homozygous truncation mutations, the HI phenotype will always manifest. 

In the absence of ABCA12 the competency of the epidermis as a skin barrier is diminished and epidermal differentiation is dysregulated. As a lipid transporter it is not surprising that ABCA12 expression is regulated by ceramide and this is achieved via PPAR/. The expression of this nuclear hormone receptor was assessed and it was identified that it is down regulated in HI skin. PPAR/ forms a heterodimer with RXR and the expression of the latter may also be reduced in HI. These receptors influence keratinocyte differentiation and this may be the mechanism by which this process is affected in HI. Furthermore, ABCA1 expression was also observed to be down regulated in HI skin. The mechanism for this remains unclear but lack of ABCA1 would affect cholesterol efflux from cells and this may have atherogenic sequelae. 
















ABCA12 analysis has now been performed in over 70 families and in most cases the disease causing mutations have been identified in both alleles. In those cases where mutations have not been found by standard techniques, next generation sequencing is likely to play an important role. In a genome wide search for regions of homozygosity, the largest block was consistent with linkage to ABCA12, so it is highly unlikely that HI is caused by mutations in other genes. Next generation sequencing can be used to examine all the exons in the block of homozygosity and may therefore identify mutations in introns, the promoter or regulatory regions of the gene. Identifying mutations remains important firstly to assist prenatal testing and secondly as it will help our understanding of the relationship between genotype and phenotype. 

In chapter 3 it was identified that the mutations p. R1950X and p. R2482X can cause both HI and CIE and that some cases of HI result from missense mutations. This is unusual as truncation mutations generally result in severe loss of function and the HI phenotype while missense mutations produce a milder ichthyosis such as LI2 or CIE. It would be useful to perform over expression studies of wildtype and mutant ABCA12 to compare the functional effect of these mutations. 

As it was observed that PPAR/ and ABCA1 were down regulated in HI skin, future work could look at the expression of these proteins in LI and CIE and make a comparison with HI. Differences here may contribute to the observed variations in phenotype. Furthermore, these proteins may be suitable therapeutic targets, such that PPAR/ and RXR agonists may be useful in the treatment of congenital ichthyoses. In addition, there is a marked change in the appearance of babies born with HI compared with older survivors. The mechanism for this phenotypic recovery remains unexplained. Comparison of skin biopsies from babies, children and adults, looking specifically at the expression of differentiation markers, nuclear hormone receptors and the composition of epidermal lipids may help elucidate this. 

Skin biopsy material is however difficult to obtain, not least due to the rarity and mortality associated with the disease. In the past an organotypic co-culture system was used as an in vitro model of HI  ADDIN EN.CITE (A. C. Thomas, et al., 2009). However, as illustrated in chapter 4, it has proved difficult to establish an ABCA12 knockdown. Hence once an HI skin biopsy is available it would be pertinent to establish an ABCA12-null cell line. Since the completion of this thesis such a cell line has been established and immortalised with HPV E6/E7 cells. 

Skin scrapings and tape strippings are easier to obtain and can be used for epidermal lipid analysis. While current evidence suggests that ABAC12 acts as a transporter for glucosylceramide, it would be important to assess the effect on other epidermal lipids when ABCA12 is absent. Similarly, the potential interaction between ABCA12 and ABCA1 could have an effect on blood lipids, which is an important consideration when the treatment for HI involves agents such as retinoids that are pro-atherogenic. 






































Appendix A: ABCA12 mutations in HI patients

Patient 0901: c. 5058delCAGA in exon 33


Figure A1: Frameshift mutation in patient 0901. (A) ABCA12 screening revealed a homozygous 4 bp deletion in exon 33, c. 5058delCAGA  (upper panel) with heterozygous changes noted in both carrier parents (middle and lower panels). The mutation results in a premature stop codon: D1707fsX1712.


Patient 0809: c. 450insC in exon 5

Figure A2: Frameshift mutation in patient 0809. ABCA12 screening revealed the homozygous single bp insertion in exon 5: c. 450insC (upper trace) while the normal exon is shown below. This is predicted to result in the premature stop codon G151fsX186.
Patients 0802 and 0807: c. 7322delC in exon 49
















Patient 0804: c.4950C>A in exon 32

Figure A4: Nonsense mutation in patient 0804. ABCA12 screening revealed a homozygous A to C mutation in exon 32 of this patient (lower trace) resulting in the premature stop codon p. Y1650X. The normal exon is shown in the upper trace. 


Patient 0905: c. 2122C>G in exon 15

Figure A5: Nonsense mutation in patient 0905. ABCA12 screening revealed a homozygous C to G mutation in the patient (lower trace) with corresponding heterozygous changes in both parents (upper and middle traces). Arrows indicate the site of the mutation. This is predicted to result in the premature stop codon p. Y633X. 
Patient 0806 


























A   c. 5128+3G>A in 5’ splice site of intron 33

B   c. 3265G>T in exon 23
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Appendix C        Summary of the demographic, clinical and mutation analysis data collected for HI patients in this study
Ethnicity 	PS	Sex	Gestation at birth (weeks)	Birth Wt (g)	Retinoid if used / age started / dose (mg/kg)	PND 	Outcome	Age 	Mutation	Exon
British Bangladeshi	Y	F	35	2500	Acitretin / D1 / 0.5	No 	Alive	7y	Deletion x231	23
British white	N	F	36	2381	Acitretin / D2 / 1.2, reduced to 0.5 mg/kg @ 4 weeks	No	Alive	13y	c. 2025delG2 † 	16
British white	N	F	35	2394	Acitretin / D1 / 1.0	USS - HI features	Alive	5y	c. 2025delG2 † 	16
British Indian	Y	F	37	2600	Acitretin / D4 / 0.5	USS - normal	Alive	12y	c. 7322delC1 	49
British white	N	F	35+3/7	1825	Acitretin / D3 / 1.0	No	Alive	8y	Deletion x82†	8
British Pakistani	Y	F	34	1750	Etretinate / acitretin – from neonate – 17y intermittently	No	Alive	25y	c. 7322delC1 	49
British Pakistani	Y	M	36	2600	Acitretin / D4 / 0.5	No	Alive	7y	c. 7322 delC1	49
British Somali	Y	F	36+3/7	2480	Acitretin / D2  / 0.5	No	Alive	1y	Unknown	
Bangladeshi	N	M	38	2800	Acitretin / 2y 11/12 / 10 mg od; again aged 5y 2 months 10 mg od	No	Alive	17	c. 6378delGC1	42
Appendix C        Summary of the demographic, clinical and mutation analysis data collected for HI patients in this study (cont)
British Pakistani	Y	M	37		Acitretin / D2 / 0.5; again @ 2.5y – 1 mg/kg	No	Alive	8y	p. W1294X3	27
Israeli		F	34	2340	Acitretin / D7 / 2.5	No	Alive	7y	p. Q354X2†	9
Jamaican / Eritrean	N	M	36+6/7	2590	Acitretin / D2 / 0.5	No	Alive	4y	Splice site mutation4†	37
North American	N	M	32	2190	None	USS – HI features 	Alive	3.5y	p. Y377X & p. Q2161X2	10/44
North American		F	36	2816	Acitretin / unknown / 1.0	No	Alive	12y	c. 2274insT2†	17
Egyptian		F			None	No	Alive	>20y	p. R1881X2	37
British white	N	F	37	2400	None	No	Alive	16y	c. 2025delG & p. R1297X2	16/27
British white	N	F			Unknown	No	Alive	18y	c. 2025delG & p. R1297X2	16/27
Hmong / Laotian			29	1525	Isotretinoin / unknown / unknown	No	Alive	1.5y	p. G1179R2	24
Balochistani	Y	F	34	2180	Etretinate / D2 / 1.4	USS @ 30 weeks	Alive	15y	p. W601X5	15
Balochistani	Y	M	35	2160	Etretinate / D7 / 2.3	No	Alive	16y	p. W601X5	15
Swedish white	N	F	34	2330	Acitretin / D3 / 1.0	No	Alive	2y	p. V1089F & c. 5128+3G>A5	23 / intron 33
British Somali	Y	F	37+6/7	2600	Acitretin / D14 / 1.0	Late 2nd trimester USS normal	Alive	18 mo	Unknown	
Appendix C        Summary of the demographic, clinical and mutation analysis data collected for HI patients in this study (cont)
Swedish white	N	F	33	2100	None	No	Alive	13y	Unknown	
Kosovan	N	F	32	2800	Acitretin / day 7 / 2.0; reduced to 1.0 on day 12 & 0.33 at 18 months	No	Alive	10y	2 heterozygous nonsense mutations – no further details	








British Pakistani		F	33+6	2025	Acitretin / D1 / 1.0	No	Died	D13	c. 7322delC1	49
Irish white		M		2900	Acitretin / D3 / 0.5	No	Died	2 mo	p. W199X2	6
Swiss white		F	39	2840	None	No	Died	D2	c. 528delT2	6
Swiss white 		F	30+5	1630	None	No	Died	D2	528delTb	6
Iranian		M	36	2980	Isotretinoin / D19 / 2.0	No	Died	4 mo	Splice site mutation intron 42a	Intron 42
Appendix C        Summary of the demographic, clinical and mutation analysis data collected for HI patients in this study (cont)




Iranian	Y	M	39	2752	None	USS – results unavailable	Died	D52	c. 450insC5	5
Arab other	Y	M			None	No	Died	D2	c. 3829+1G>A5	Intron 26
British Somali	Y	M	32	1890	None	USS – small for dates @ 24 weeks	Died	D3	Unknown	
British Pakistani	Y	M	34	1900	Acitretin / D2 / 0.5	No	Died	D17	Unknown	


















Prenatal testing performed? (amniocentesis / ultrasound)
Gestational age at birth 
Birth weight (e.g. ?intra-uterine growth retardation / low birth weight)
Classical Harlequin Ichthyosis at birth – Yes / No

Treatment with retinoids
Has the patient ever been treated with a retinoid?  
If yes - which one (acitretin or isotretinoin)?
Age of starting retinoid therapy 
Retinoid dose
Continuous or intermittent use?
Duration of retinoid therapy (approximate date / age when stopped)?
Skin




Recurrent skin infections (specify)		
Hair thinning 		
Nail deformities (specify)		








Clinical feature	Tick any that apply	Comments
Persistent ectropion		
Surgical correction of ectropion		
Epiphora (xs tears)		
Problems with vision  (specify)		
Recurrent conjunctivitis		









Acid reflux / other		
Locomotor
Clinical feature	Tick any that apply	Comments
Joint pain (specify joints affected)		
Proven inflammatory arthritis (specify type)		
Osteoporosis		
Autoamputation of digits		
Acitretin related problems 		
Other problems






Ear, nose and throat problems		
Psychiatric problems		
Lipids / cholesterol and cardiovascular disease
Has the patient’s lipid profile ever been checked?	Yes	No
		
Has the lipid profile ever been abnormal	Yes (please give details)	No
		
If abnormal, was the patient concomitantly on a retinoid?	Yes	No	N/A
			
Is there a family history of dyslipidaemia?	Yes (please give details)	No
		
Is there a family history of cardiovascular disease, sudden death < 50y or stroke?	Yes (please give details)	No
		
Social history
Children <2years old 
Has there has been any delay in achieving developmental milestones?

Children at school 
Is the child attending a mainstream school?  Has the child required statementing? How is the child progressing educationally –e.g. SATs / GCSEs / A/AS level exams done? Have there been any other school related issues, e.g. bullying?










Thank-you for your help and support






The aim of this questionnaire is to measure how much your skin problem has affected your life OVER THE LAST WEEK.  Please tick one box for each question.

	Over the last week, how itchy, sore, painful or stinging has your skin been?	Very muchA lotA littleNot at all		
	Over the last week, how embarrassed or self conscious have you been because of your skin?	Very muchA lotA littleNot at all		
	Over the last week, how much has your skin interfered with you going shopping or looking after your home or garden?	Very muchA lotA littleNot at all		Not relevant 
	Over the last week, how much has your skin influenced the clothes you wear?	Very muchA lotA littleNot at all		Not relevant 
	Over the last week, how much has your skin affected any social or leisure activities?				Very muchA lotA littleNot at all		Not relevant 
	Over the last week, how much has your skin made it difficult for you to do any sport?	Very muchA lotA littleNot at all		Not relevant 
	Over the last week, has your skin prevented you from working or studying?	yesno		Not relevant 
	If "No", over the last week how much has your skin been a problem at work or studying?	A lotA littleNot at all 		
	Over the last week, how much has your 	skin created problems with your partner or any of your close friends or relatives? 		Very muchA lotA littleNot at all		Not relevant 
	Over the last week, how much has your 	skin caused any sexual difficulties?		Very muchA lotA littleNot at all		Not relevant 
	Over the last week, how much of a problem has the treatment for your skin been, for example by making your home messy, or by taking up time?	Very muchA lotA littleNot at all		Not relevant 







                


The Family Dermatology Life Quality Index ( FDLQI )
                                  

Name:                                       ……………………………            FDLQI Score   
Relationship with patient:  ...………………………..




	The questions relate to the impact of your relative/partner’s skin disease on your quality of life over the last month.
	 Please read the questions carefully and tick one box for each.


1.   Over the last month how much emotional distress have you experienced due to your relative/partner’s skin disease (e.g. worry, depression, embarrassment, frustration)?  
Not at all/Not relevant              A little          Quite a lot           Very much     
            

2.  Over the last month how much has your relative/partner’s skin disease affected your physical well-being (e.g. tiredness, exhaustion, contribution to poor health, sleep/rest disturbance)? 
Not at all/Not relevant              A little          Quite a lot           Very much    


3.  Over the last month how much has your relative/partner’s skin disease affected your personal relationships with him/her or with other people?
Not at all/Not relevant              A little          Quite a lot           Very much    


4.   Over the last month how much have you been having problems with other peoples’ reactions due to your relative/partner’s skin disease (e.g. bullying, staring, need to explain to others about his/her skin problem)?
Not at all/Not relevant              A little         Quite a lot            Very much  


5.  Over the last month how much has your relative/partner’s skin disease affected your social life (e.g. going out, visiting or inviting people, attending social gatherings)?
Not at all/Not relevant              A little          Quite a lot           Very much 
 

                                                                                                            (Please turn over)                                                                                                                                                                                                                                        
6.  Over the last month how much has your relative/partner’s skin disease affected your recreation/leisure activities (e.g. holidays, personal hobbies, gym, sports, swimming, watching TV)?
Not at all/Not relevant              A little          Quite a lot         Very much   
               

7.  Over the last month how much time have you spent on looking after your relative/partner (e.g. putting on creams, giving medicines or looking after their skin)?
Not at all/Not relevant              A little          Quite a lot        Very much     

               
8.  Over the last month how much extra house-work have you had to do because of your relative/partner’s skin disease (e.g. cleaning, vacuuming, washing, cooking)? 
Not at all/Not relevant              A little          Quite a lot         Very much    
  
             
9.  Over the last month how much has your relative/partner’s skin disease affected your job/study (e.g. need to take time off, not able to work, decrease in the number of hours worked, having problems with people at work)?
Not at all/Not relevant              A little          Quite a lot         Very much    

            
10.  Over the last month how much has your relative/partner’s skin disease increased your routine household expenditure (e.g. travel costs, buying special products, creams, cosmetics)?
Not at all/Not relevant              A little          Quite a lot         Very much    

             






































ReferencesAebi, M., Hornig, H., & Weissmann, C. (1987). 5' cleavage site in eukaryotic pre-mRNA splicing is determined by the overall 5' splice region, not by the conserved 5' GU. Cell, 50(2), 237-246.Akiyama, M. (1999). The pathogenesis of severe congenital ichthyosis of the neonate. J Dermatol Sci, 21(2), 96-104.Akiyama, M. (2010). ABCA12 mutations and autosomal recessive congenital ichthyosis: a review of genotype/phenotype correlations and of pathogenetic concepts. Hum Mutat, 31(10), 1090-1096.Akiyama, M., Sakai, K., Hatamochi, A., Yamazaki, S., McMillan, J. R., & Shimizu, H. (2008). Novel compound heterozygous nonsense and missense ABCA12 mutations lead to nonbullous congenital ichthyosiform erythroderma. Br J Dermatol, 158(4), 864-867.Akiyama, M., Sakai, K., Sugiyama-Nakagiri, Y., Yamanaka, Y., McMillan, J. R., Sawamura, D., et al. (2006). Compound heterozygous mutations including a de novo missense mutation in ABCA12 led to a case of harlequin ichthyosis with moderate clinical severity. J Invest Dermatol, 126(7), 1518-1523.Akiyama, M., Shimizu, H., Yoneda, K., & Nishikawa, T. (1997). Collodion baby: ultrastructure and distribution of cornified cell envelope proteins and keratins. Dermatology, 195(2), 164-168.Akiyama, M., Sugiyama-Nakagiri, Y., Sakai, K., McMillan, J. R., Goto, M., Arita, K., et al. (2005). Mutations in lipid transporter ABCA12 in harlequin ichthyosis and functional recovery by corrective gene transfer. J Clin Invest, 115(7), 1777-1784.Akiyama, M., Titeux, M., Sakai, K., McMillan, J. R., Tonasso, L., Calvas, P., et al. (2007). DNA-based prenatal diagnosis of harlequin ichthyosis and characterization of ABCA12 mutation consequences. J Invest Dermatol, 127(3), 568-573.Akiyama, M., Yoneda, K., Kim, S. Y., Koyama, H., & Shimizu, H. (1996). Cornified cell envelope proteins and keratins are normally distributed in harlequin ichthyosis. J Cutan Pathol, 23(6), 571-575.Allikmets, R. (2000). Simple and complex ABCR: genetic predisposition to retinal disease. The American Journal of Human Genetics, 67(4), 793-799.Allikmets, R., Shroyer, N. F., Singh, N., Seddon, J. M., Lewis, R. A., Bernstein, P. S., et al. (1997). Mutation of the Stargardt disease gene (ABCR) in age-related macular degeneration. Science, 277(5333), 1805-1807.Andressoo, J. O., Jans, J., de Wit, J., Coin, F., Hoogstraten, D., van de Ven, M., et al. (2006). Rescue of progeria in trichothiodystrophy by homozygous lethal Xpd alleles. PLoS Biol, 4(10), e322.Baralle, D., & Baralle, M. (2005). Splicing in action: assessing disease causing sequence changes. J Med Genet, 42(10), 737-748.Berg, C., Geipel, A., Kohl, M., Krokowski, M., Baschat, A. A., Germer, U., et al. (2003). Prenatal sonographic features of Harlequin ichthyosis. Arch Gynecol Obstet, 268(1), 48-51.Berge, K. E., Tian, H., Graf, G. A., Yu, L., Grishin, N. V., Schultz, J., et al. (2000). Accumulation of dietary cholesterol in sitosterolemia caused by mutations in adjacent ABC transporters. Science, 290(5497), 1771-1775.Beutler, E., Demina, A., & Gelbart, T. (1994). Glucocerebrosidase mutations in Gaucher disease. Mol Med, 1(1), 82-92.Bongain, A., Benoit, B., Ejnes, L., Lambert, J. C., & Gillet, J. Y. (2002). Harlequin fetus: three-dimensional sonographic findings and new diagnostic approach. Ultrasound Obstet Gynecol, 20(1), 82-85.Bonifas, J. M., Bare, J. W., Chen, M. A., Lee, M. K., Slater, C. A., Goldsmith, L. A., et al. (1992). Linkage of the epidermolytic hyperkeratosis phenotype and the region of the type II keratin gene cluster on chromosome 12. J Invest Dermatol, 99(5), 524-527.Borradori, L., & Sonnenberg, A. (1999). Structure and function of hemidesmosomes: more than simple adhesion complexes. J Invest Dermatol, 112(4), 411-418.Borst, P., & Elferink, R. O. (2002). Mammalian ABC transporters in health and disease. Annu Rev Biochem, 71, 537-592.Brecher, A. R., & Orlow, S. J. (2003). Oral retinoid therapy for dermatologic conditions in children and adolescents. J Am Acad Dermatol, 49(2), 171-182; quiz 183-176.Brooks-Wilson, A., Marcil, M., Clee, S. M., Zhang, L. H., Roomp, K., van Dam, M., et al. (1999). Mutations in ABC1 in Tangier disease and familial high-density lipoprotein deficiency. Nat Genet, 22(4), 336-345.Buxman, M. M., Goodkin, P. E., Fahrenbach, W. H., & Dimond, R. L. (1979). Harlequin ichthyosis with epidermal lipid abnormality. Arch Dermatol, 115(2), 189-193.Calleja, C., Messaddeq, N., Chapellier, B., Yang, H., Krezel, W., Li, M., et al. (2006). Genetic and pharmacological evidence that a retinoic acid cannot be the RXR-activating ligand in mouse epidermis keratinocytes. Genes Dev, 20(11), 1525-1538.Castiglia, D., Castori, M., Pisaneschi, E., Sommi, M., Covaciu, C., Zambruno, G., et al. (2009). Trisomic rescue causing reduction to homozygosity for a novel ABCA12 mutation in harlequin ichthyosis. Clinical genetics, 76(4), 392-397.Caubet, C., Jonca, N., Brattsand, M., Guerrin, M., Bernard, D., Schmidt, R., et al. (2004). Degradation of corneodesmosome proteins by two serine proteases of the kallikrein family, SCTE/KLK5/hK5 and SCCE/KLK7/hK7. J Invest Dermatol, 122(5), 1235-1244.Chan, Y. C., Tay, Y. K., Tan, L. K., Happle, R., & Giam, Y. C. (2003). Harlequin ichthyosis in association with hypothyroidism and juvenile rheumatoid arthritis. Pediatr Dermatol, 20(5), 421-426.Chavanas, S., Bodemer, C., Rochat, A., Hamel-Teillac, D., Ali, M., Irvine, A. D., et al. (2000). Mutations in SPINK5, encoding a serine protease inhibitor, cause Netherton syndrome. Nat Genet, 25(2), 141-142.Chawla, A., Repa, J. J., Evans, R. M., & Mangelsdorf, D. J. (2001). Nuclear receptors and lipid physiology: opening the X-files. Science, 294(5548), 1866-1870.Chua, C. N., & Ainsworth, J. (2001). Ocular management of harlequin syndrome. Arch Ophthalmol, 119(3), 454-455.Chujor, C. S., Feingold, K. R., Elias, P. M., & Holleran, W. M. (1998). Glucosylceramide synthase activity in murine epidermis: quantitation, localization, regulation, and requirement for barrier homeostasis. J Lipid Res, 39(2), 277-285.Clee, S. M., Kastelein, J. J., van Dam, M., Marcil, M., Roomp, K., Zwarts, K. Y., et al. (2000). Age and residual cholesterol efflux affect HDL cholesterol levels and coronary artery disease in ABCA1 heterozygotes. J Clin Invest, 106(10), 1263-1270.Clement, S. A., Burrows, N. P., Sansome, A., Hazleman, B. L., & Ostor, A. J. (2007). Harlequin ichthyosis and juvenile idiopathic arthritis: a rare combination. Clin Rheumatol, 26(3), 460-462.Coldiron, B. M., & Bergstresser, P. R. (1989). Prevalence and clinical spectrum of skin disease in patients infected with human immunodeficiency virus. Archives of dermatology, 125(3), 357.Compton, J. G., DiGiovanna, J. J., Santucci, S. K., Kearns, K. S., Amos, C. I., Abangan, D. L., et al. (1992). Linkage of epidermolytic hyperkeratosis to the type II keratin gene cluster on chromosome 12q. Nat Genet, 1(4), 301-305.Culican, S. M., & Custer, P. L. (2002). Repair of cicatricial ectropion in an infant with harlequin ichthyosis using engineered human skin. Am J Ophthalmol, 134(3), 442-443.Dale, B. A., Holbrook, K. A., Fleckman, P., Kimball, J. R., Brumbaugh, S., & Sybert, V. P. (1990). Heterogeneity in harlequin ichthyosis, an inborn error of epidermal keratinization: variable morphology and structural protein expression and a defect in lamellar granules. J Invest Dermatol, 94(1), 6-18.Dale, B. A., Holbrook, K. A., Kimball, J. R., Hoff, M., & Sun, T. T. (1985). Expression of epidermal keratins and filaggrin during human fetal skin development. J Cell Biol, 101(4), 1257-1269.De Laurenzi, V., Rogers, G. R., Hamrock, D. J., Marekov, L. N., Steinert, P. M., Compton, J. G., et al. (1996). Sjogren-Larsson syndrome is caused by mutations in the fatty aldehyde dehydrogenase gene. Nat Genet, 12(1), 52-57.Dean, M., Hamon, Y., & Chimini, G. (2001). The human ATP-binding cassette (ABC) transporter superfamily. J Lipid Res, 42(7), 1007-1017.Deleuze, J. F., Jacquemin, E., Dubuisson, C., Cresteil, D., Dumont, M., Erlinger, S., et al. (1996). Defect of multidrug-resistance 3 gene expression in a subtype of progressive familial intrahepatic cholestasis. Hepatology, 23(4), 904-908.Descargues, P., Deraison, C., Prost, C., Fraitag, S., Mazereeuw-Hautier, J., D'Alessio, M., et al. (2006). Corneodesmosomal cadherins are preferential targets of stratum corneum trypsin- and chymotrypsin-like hyperactivity in Netherton syndrome. J Invest Dermatol, 126(7), 1622-1632.Edwards, P. A., Kennedy, M. A., & Mak, P. A. (2002). LXRs; oxysterol-activated nuclear receptors that regulate genes controlling lipid homeostasis. Vascul Pharmacol, 38(4), 249-256.Egberts, F., Heinrich, M., Jensen, J. M., Winoto-Morbach, S., Pfeiffer, S., Wickel, M., et al. (2004). Cathepsin D is involved in the regulation of transglutaminase 1 and epidermal differentiation. J Cell Sci, 117(Pt 11), 2295-2307.Elias, P. M., & Brown, B. E. (1978). The mammalian cutaneous permeability barrier: defective barrier function is essential fatty acid deficiency correlates with abnormal intercellular lipid deposition. Lab Invest, 39(6), 574-583.Elias, P. M., Crumrine, D., Rassner, U., Hachem, J. P., Menon, G. K., Man, W., et al. (2004). Basis for abnormal desquamation and permeability barrier dysfunction in RXLI. J Invest Dermatol, 122(2), 314-319.Elias, P. M., & Feingold, K. R. (2006). Skin barrier. New York, N.Y. ; London: Taylor & Francis.Elias, P. M., Williams, M. L., Maloney, M. E., Bonifas, J. A., Brown, B. E., Grayson, S., et al. (1984). Stratum corneum lipids in disorders of cornification. Steroid sulfatase and cholesterol sulfate in normal desquamation and the pathogenesis of recessive X-linked ichthyosis. J Clin Invest, 74(4), 1414-1421.Estines, O., Grosieux-Dauger, C., Derancourt, C., Patey, M., Durlach, A., & Bernard, P. (2001). [Paraneoplastic acquired ichthyosis revealing non-Hodgkin's lymphoma]. Ann Dermatol Venereol, 128(1), 31-34.Fairbrother, W. G., & Chasin, L. A. (2000). Human genomic sequences that inhibit splicing. Mol Cell Biol, 20(18), 6816-6825.Fartasch, M. (2004). The epidermal lamellar body: a fascinating secretory organelle. J Invest Dermatol, 122(5), XI-XII.Feingold, K. R. (1991). The regulation and role of epidermal lipid synthesis. Adv Lipid Res, 24, 57-82.Feingold, K. R. (2007). Thematic review series: skin lipids. The role of epidermal lipids in cutaneous permeability barrier homeostasis. J Lipid Res, 48(12), 2531-2546.Feingold, K. R., & Jiang, Y. J. The mechanisms by which lipids coordinately regulate the formation of the protein and lipid domains of the stratum corneum: Role of fatty acids, oxysterols, cholesterol sulfate and ceramides as signaling molecules. Dermatoendocrinol, 3(2), 113-118.Fleckman, P., Dale, B. A., & Holbrook, K. A. (1985). Profilaggrin, a high-molecular-weight precursor of filaggrin in human epidermis and cultured keratinocytes. J Invest Dermatol, 85(6), 507-512.Flint, G. L., Flam, M., & Soter, N. A. (1975). Acquired ichthyosis. A sign of nonlymphoproliferative malignant disorders. Arch Dermatol, 111(11), 1446-1447.Fluhr, J. W., Kao, J., Jain, M., Ahn, S. K., Feingold, K. R., & Elias, P. M. (2001). Generation of free fatty acids from phospholipids regulates stratum corneum acidification and integrity. J Invest Dermatol, 117(1), 44-51.Freinkel, R. K., & Woodley, D. (2001). The biology of the skin: Parthenon Pub. Group.Fuchs, E., & Green, H. (1980). Changes in keratin gene expression during terminal differentiation of the keratinocyte. Cell, 19(4), 1033-1042.Giglia-Mari, G., Coin, F., Ranish, J. A., Hoogstraten, D., Theil, A., Wijgers, N., et al. (2004). A new, tenth subunit of TFIIH is responsible for the DNA repair syndrome trichothiodystrophy group A. Nat Genet, 36(7), 714-719.Glover, M. T., Peters, A. M., & Atherton, D. J. (1987). Surveillance for skeletal toxicity of children treated with etretinate. Br J Dermatol, 116(5), 609-614.Graveley, B. R. (2000). Sorting out the complexity of SR protein functions. RNA, 6(9), 1197-1211.Grubauer, G., Elias, P. M., & Feingold, K. R. (1989). Transepidermal water loss: the signal for recovery of barrier structure and function. J Lipid Res, 30(3), 323-333.Haftek, M., Cambazard, F., Dhouailly, D., Reano, A., Simon, M., Lachaux, A., et al. (1996). A longitudinal study of a harlequin infant presenting clinically as non-bullous congenital ichthyosiform erythroderma. Br J Dermatol, 135(3), 448-453.Halkier-Sorensen, L., Laurberg, G., & Andresen, J. (1987). Bone changes in children on long-term treatment with etretinate. J Am Acad Dermatol, 16(5 Pt 1), 999-1006.Hanley, K., Komuves, L. G., Ng, D. C., Schoonjans, K., He, S. S., Lau, P., et al. (2000). Farnesol stimulates differentiation in epidermal keratinocytes via PPARalpha. J Biol Chem, 275(15), 11484-11491.Hanley, K., Ng, D. C., He, S. S., Lau, P., Min, K., Elias, P. M., et al. (2000). Oxysterols induce differentiation in human keratinocytes and increase Ap-1-dependent involucrin transcription. J Invest Dermatol, 114(3), 545-553.Happle, R. (1979). X-linked dominant chondrodysplasia punctata. Review of literature and report of a case. Hum Genet, 53(1), 65-73.Hayward, A. F. (1979). Membrane-coating granules. Int Rev Cytol, 59, 97-127.Hernandez-Martin, A., Gonzalez-Sarmiento, R., & De Unamuno, P. (1999). X-linked ichthyosis: an update. Br J Dermatol, 141(4), 617-627.Hoffjan, S., & Stemmler, S. (2007). On the role of the epidermal differentiation complex in ichthyosis vulgaris, atopic dermatitis and psoriasis. Br J Dermatol, 157(3), 441-449.Holbrook, K. A. (1991). Structure and function of the developing human skin. In: Goldsmith L.A. ed. Physiology, biochemistry, and molecular biology of the skin, vol 1. Oxford University Press: 63-110.Hsu, W. Y., Chen, J. Y., Lin, W. L., & Tsay, C. H. (1989). [Harlequin fetus--a case report]. Zhonghua Yi Xue Za Zhi (Taipei), 43(1), 63-66.Huber, M., Rettler, I., Bernasconi, K., Frenk, E., Lavrijsen, S. P., Ponec, M., et al. (1995). Mutations of keratinocyte transglutaminase in lamellar ichthyosis. Science, 267(5197), 525-528.Hyde, S. C., Emsley, P., Hartshorn, M. J., Mimmack, M. M., Gileadi, U., Pearce, S. R., et al. (1990). Structural model of ATP-binding proteins associated with cystic fibrosis, multidrug resistance and bacterial transport. Nature, 346(6282), 362-365.Igarashi, S., Takizawa, T., Yasuda, Y., Uchiwa, H., Hayashi, S., Brysk, H., et al. (2004). Cathepsin D, but not cathepsin E, degrades desmosomes during epidermal desquamation. Br J Dermatol, 151(2), 355-361.Ishida-Yamamoto, A., Deraison, C., Bonnart, C., Bitoun, E., Robinson, R., O'Brien, T. J., et al. (2005). LEKTI is localized in lamellar granules, separated from KLK5 and KLK7, and is secreted in the extracellular spaces of the superficial stratum granulosum. J Invest Dermatol, 124(2), 360-366.Ishida-Yamamoto, A., Richard, G., Takahashi, H., & Iizuka, H. (2003). In vivo studies of mutant keratin 1 in ichthyosis hystrix Curth-Macklin. J Invest Dermatol, 120(3), 498-500.Ishida-Yamamoto, A., Simon, M., Kishibe, M., Miyauchi, Y., Takahashi, H., Yoshida, S., et al. (2004). Epidermal lamellar granules transport different cargoes as distinct aggregates. J Invest Dermatol, 122(5), 1137-1144.Jiang, Y. J., Lu, B., Kim, P., Paragh, G., Schmitz, G., Elias, P. M., et al. (2008). PPAR and LXR activators regulate ABCA12 expression in human keratinocytes. J Invest Dermatol, 128(1), 104-109.Jiang, Y. J., Uchida, Y., Lu, B., Kim, P., Mao, C., Akiyama, M., et al. (2009). Ceramide stimulates ABCA12 expression via peroxisome proliferator-activated receptor {delta} in human keratinocytes. J Biol Chem, 284(28), 18942-18952.Jobard, F., Lefevre, C., Karaduman, A., Blanchet-Bardon, C., Emre, S., Weissenbach, J., et al. (2002). Lipoxygenase-3 (ALOXE3) and 12(R)-lipoxygenase (ALOX12B) are mutated in non-bullous congenital ichthyosiform erythroderma (NCIE) linked to chromosome 17p13.1. Hum Mol Genet, 11(1), 107-113.Kalinin, A., Marekov, L. N., & Steinert, P. M. (2001). Assembly of the epidermal cornified cell envelope. J Cell Sci, 114(Pt 17), 3069-3070.Kelsell, D. P., Norgett, E. E., Unsworth, H., Teh, M. T., Cullup, T., Mein, C. A., et al. (2005). Mutations in ABCA12 underlie the severe congenital skin disease harlequin ichthyosis. Am J Hum Genet, 76(5), 794-803.Kersten, S., Desvergne, B., & Wahli, W. (2000). Roles of PPARs in health and disease. Nature, 405(6785), 421-424.Khan, R., Arora, S., El-Hindy, N., & Chang, B. Y. (2009). Repair of cicatricial ectropion in a harlequin baby. J AAPOS, 13(4), 415-416.Knight, H., Pickard, B., Maclean, A., Malloy, M., Soares, D., McRae, A., et al. (2009). A Cytogenetic Abnormality and Rare Coding Variants Identify ABCA13 as a Candidate Gene in Schizophrenia, Bipolar Disorder, and Depression. American journal of human genetics.Komuves, L. G., Schmuth, M., Fowler, A. J., Elias, P. M., Hanley, K., Man, M. Q., et al. (2002). Oxysterol stimulation of epidermal differentiation is mediated by liver X receptor-beta in murine epidermis. J Invest Dermatol, 118(1), 25-34.Konig, A., Happle, R., Bornholdt, D., Engel, H., & Grzeschik, K. H. (2000). Mutations in the NSDHL gene, encoding a 3beta-hydroxysteroid dehydrogenase, cause CHILD syndrome. Am J Med Genet, 90(4), 339-346.Krawczak, M., Reiss, J., & Cooper, D. N. (1992). The mutational spectrum of single base-pair substitutions in mRNA splice junctions of human genes: causes and consequences. Hum Genet, 90(1-2), 41-54.Kremer, H., Zeeuwen, P., McLean, W. H., Mariman, E. C., Lane, E. B., van de Kerkhof, C. M., et al. (1994). Ichthyosis bullosa of Siemens is caused by mutations in the keratin 2e gene. J Invest Dermatol, 103(3), 286-289.Kuokkanen, K. (1969). Ichthyosis vulgaris. A clinical and histopathological study of patients and their close relatives in the autosomal dominant and sex-linked forms of the disease. Acta Derm Venereol Suppl (Stockh), 62, 1-72.Landmann, L. (1986). Epidermal permeability barrier: transformation of lamellar granule-disks into intercellular sheets by a membrane-fusion process, a freeze-fracture study. J Invest Dermatol, 87(2), 202-209.Le Saux, O., Urban, Z., Tschuch, C., Csiszar, K., Bacchelli, B., Quaglino, D., et al. (2000). Mutations in a gene encoding an ABC transporter cause pseudoxanthoma elasticum. Nature genetics, 25(2), 223-227.Lechler, T., & Fuchs, E. (2005). Asymmetric cell divisions promote stratification and differentiation of mammalian skin. Nature, 437(7056), 275-280.Lee, M. H., Lu, K., Hazard, S., Yu, H., Shulenin, S., Hidaka, H., et al. (2001). Identification of a gene, ABCG5, important in the regulation of dietary cholesterol absorption. Nat Genet, 27(1), 79-83.Lee, S. H., Elias, P. M., Proksch, E., Menon, G. K., Mao-Quiang, M., & Feingold, K. R. (1992). Calcium and potassium are important regulators of barrier homeostasis in murine epidermis. J Clin Invest, 89(2), 530-538.Lefevre, C., Audebert, S., Jobard, F., Bouadjar, B., Lakhdar, H., Boughdene-Stambouli, O., et al. (2003). Mutations in the transporter ABCA12 are associated with lamellar ichthyosis type 2. Hum Mol Genet, 12(18), 2369-2378.Lefevre, C., Bouadjar, B., Ferrand, V., Tadini, G., Megarbane, A., Lathrop, M., et al. (2006). Mutations in a new cytochrome P450 gene in lamellar ichthyosis type 3. Hum Mol Genet, 15(5), 767-776.Lefevre, C., Bouadjar, B., Karaduman, A., Jobard, F., Saker, S., Ozguc, M., et al. (2004). Mutations in ichthyin a new gene on chromosome 5q33 in a new form of autosomal recessive congenital ichthyosis. Hum Mol Genet, 13(20), 2473-2482.Lefevre, C., Jobard, F., Caux, F., Bouadjar, B., Karaduman, A., Heilig, R., et al. (2001). Mutations in CGI-58, the gene encoding a new protein of the esterase/lipase/thioesterase subfamily, in Chanarin-Dorfman syndrome. Am J Hum Genet, 69(5), 1002-1012.Man, M. Q., Barish, G. D., Schmuth, M., Crumrine, D., Barak, Y., Chang, S., et al. (2008). Deficiency of PPARbeta/delta in the epidermis results in defective cutaneous permeability barrier homeostasis and increased inflammation. J Invest Dermatol, 128(2), 370-377.Man, M. Q., Choi, E. H., Schmuth, M., Crumrine, D., Uchida, Y., Elias, P. M., et al. (2006). Basis for improved permeability barrier homeostasis induced by PPAR and LXR activators: liposensors stimulate lipid synthesis, lamellar body secretion, and post-secretory lipid processing. J Invest Dermatol, 126(2), 386-392.Manabe, M., Sanchez, M., Sun, T. T., & Dale, B. A. (1991). Interaction of filaggrin with keratin filaments during advanced stages of normal human epidermal differentiation and in ichthyosis vulgaris. Differentiation, 48(1), 43-50.Mangelsdorf, D. J., & Evans, R. M. (1995). The RXR heterodimers and orphan receptors. Cell, 83(6), 841-850.Mao-Qiang, M., Fowler, A. J., Schmuth, M., Lau, P., Chang, S., Brown, B. E., et al. (2004). Peroxisome-proliferator-activated receptor (PPAR)-gamma activation stimulates keratinocyte differentiation. J Invest Dermatol, 123(2), 305-312.Maquat, L. E. (2001). The power of point mutations. Nat Genet, 27(1), 5-6.Marenholz, I., Nickel, R., Ruschendorf, F., Schulz, F., Esparza-Gordillo, J., Kerscher, T., et al. (2006). Filaggrin loss-of-function mutations predispose to phenotypes involved in the atopic march. J Allergy Clin Immunol, 118(4), 866-871.Milner, M. E., O'Guin, W. M., Holbrook, K. A., & Dale, B. A. (1992). Abnormal lamellar granules in harlequin ichthyosis. J Invest Dermatol, 99(6), 824-829.Milstone, L. M., Ellison, A. F., & Insogna, K. L. (1992). Serum parathyroid hormone level is elevated in some patients with disorders of keratinization. Arch Dermatol, 128(7), 926-930.Milstone, L. M., McGuire, J., & Ablow, R. C. (1982). Premature epiphyseal closure in a child receiving oral 13-cis-retinoic acid. J Am Acad Dermatol, 7(5), 663-666.Mitsutake, S., Suzuki, C., Akiyama, M., Tsuji, K., Yanagi, T., Shimizu, H., et al. (2010). ABCA12 dysfunction causes a disorder in glucosylceramide accumulation during keratinocyte differentiation. J Dermatol Sci, 60(2), 128-129.Morley, S. M., Dundas, S. R., James, J. L., Gupta, T., Brown, R. A., Sexton, C. J., et al. (1995). Temperature sensitivity of the keratin cytoskeleton and delayed spreading of keratinocyte lines derived from EBS patients. J Cell Sci, 108 ( Pt 11), 3463-3471.Moskowitz, D. G., Fowler, A. J., Heyman, M. B., Cohen, S. P., Crumrine, D., Elias, P. M., et al. (2004). Pathophysiologic basis for growth failure in children with ichthyosis: an evaluation of cutaneous ultrastructure, epidermal permeability barrier function, and energy expenditure. J Pediatr, 145(1), 82-92.Mosser, J., Douar, A. M., Sarde, C. O., Kioschis, P., Feil, R., Moser, H., et al. (1993). Putative X-linked adrenoleukodystrophy gene shares unexpected homology with ABC transporters. Nature, 361(6414), 726-730.Natsuga, K., Akiyama, M., Kato, N., Sakai, K., Sugiyama-Nakagiri, Y., Nishimura, M., et al. (2007). Novel ABCA12 mutations identified in two cases of non-bullous congenital ichthyosiform erythroderma associated with multiple skin malignant neoplasia. J Invest Dermatol, 127(11), 2669-2673.Nemes, Z., & Steinert, P. M. (1999). Bricks and mortar of the epidermal barrier. Exp Mol Med, 31(1), 5-19.Nikkari, T., Schreibman, P. H., & Ahrens, E. H., Jr. (1975). Isotope kinetics of human skin cholesterol secretion. J Exp Med, 141(3), 620-634.Nilsen, T. W. (1994). RNA-RNA interactions in the spliceosome: unraveling the ties that bind. Cell, 78(1), 1-4.Norlen, L. (2001). Skin barrier formation: the membrane folding model. J Invest Dermatol, 117(4), 823-829.Odland, G. F. (1960). A submicroscopic granular component in human epidermis. J Invest Dermatol, 34, 11-15.Oeffner, F., Fischer, G., Happle, R., Konig, A., Betz, R. C., Bornholdt, D., et al. (2009). IFAP syndrome is caused by deficiency in MBTPS2, an intramembrane zinc metalloprotease essential for cholesterol homeostasis and ER stress response. Am J Hum Genet, 84(4), 459-467.Oji, V., Hautier, J. M., Ahvazi, B., Hausser, I., Aufenvenne, K., Walker, T., et al. (2006). Bathing suit ichthyosis is caused by transglutaminase-1 deficiency: evidence for a temperature-sensitive phenotype. Hum Mol Genet, 15(21), 3083-3097.Oji, V., & Traupe, H. (2006). Ichthyoses: differential diagnosis and molecular genetics. Eur J Dermatol, 16(4), 349-359.Paige, D. G., Judge, M. R., Shaw, D. G., Atherton, D. J., & Harper, J. I. (1992). Bone changes and their significance in children with ichthyosis on long-term etretinate therapy. Br J Dermatol, 127(4), 387-391.Palmer, C. N., Irvine, A. D., Terron-Kwiatkowski, A., Zhao, Y., Liao, H., Lee, S. P., et al. (2006). Common loss-of-function variants of the epidermal barrier protein filaggrin are a major predisposing factor for atopic dermatitis. Nat Genet, 38(4), 441-446.Peelman, F., Labeur, C., Vanloo, B., Roosbeek, S., Devaud, C., Duverger, N., et al. (2003). Characterization of the ABCA transporter subfamily: identification of prokaryotic and eukaryotic members, phylogeny and topology. J Mol Biol, 325(2), 259-274.Prendiville, J., Bingham, E. A., & Burrows, D. (1986). Premature epiphyseal closure--a complication of etretinate therapy in children. J Am Acad Dermatol, 15(6), 1259-1262.Raghunath, M., Hennies, H. C., Ahvazi, B., Vogel, M., Reis, A., Steinert, P. M., et al. (2003). Self-healing collodion baby: a dynamic phenotype explained by a particular transglutaminase-1 mutation. J Invest Dermatol, 120(2), 224-228.Rajamani, S., Birnkrant, D. J., & Rodgers, M. (2000). Use of bronchoalveolar lavage to demonstrate squamous epithelial aspiration in congenital icthyosis: a case report. J Perinatol, 20(5), 329-330.Rajpar, S. F., Cullup, T., Kelsell, D. P., & Moss, C. (2006). A novel ABCA12 mutation underlying a case of Harlequin ichthyosis. Br J Dermatol, 155(1), 204-206.Rassner, U., Feingold, K. R., Crumrine, D. A., & Elias, P. M. (1999). Coordinate assembly of lipids and enzyme proteins into epidermal lamellar bodies. Tissue Cell, 31(5), 489-498.Reese, M. G., Eeckman, F. H., Kulp, D., & Haussler, D. (1997). Improved splice site detection in Genie. J Comput Biol, 4(3), 311-323.Riordan, J. R., Rommens, J. M., Kerem, B., Alon, N., Rozmahel, R., Grzelczak, Z., et al. (1989). Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science, 245(4922), 1066-1073.Rivier, M., Castiel, I., Safonova, I., Ailhaud, G., & Michel, S. (2000). Peroxisome proliferator-activated receptor-alpha enhances lipid metabolism in a skin equivalent model. J Invest Dermatol, 114(4), 681-687.Rivier, M., Safonova, I., Lebrun, P., Griffiths, C. E., Ailhaud, G., & Michel, S. (1998). Differential expression of peroxisome proliferator-activated receptor subtypes during the differentiation of human keratinocytes. J Invest Dermatol, 111(6), 1116-1121.Rothnagel, J. A., Traupe, H., Wojcik, S., Huber, M., Hohl, D., Pittelkow, M. R., et al. (1994). Mutations in the rod domain of keratin 2e in patients with ichthyosis bullosa of Siemens. Nat Genet, 7(4), 485-490.Russell, L. E., Harrison, W. J., Bahta, A. W., Zouboulis, C. C., Burrin, J. M., & Philpott, M. P. (2007). Characterization of liver X receptor expression and function in human skin and the pilosebaceous unit. Exp Dermatol, 16(10), 844-852.Russell, L. J., DiGiovanna, J. J., Rogers, G. R., Steinert, P. M., Hashem, N., Compton, J. G., et al. (1995). Mutations in the gene for transglutaminase 1 in autosomal recessive lamellar ichthyosis. Nat Genet, 9(3), 279-283.Sakai, K., Akiyama, M., Sugiyama-Nakagiri, Y., McMillan, J. R., Sawamura, D., & Shimizu, H. (2007). Localization of ABCA12 from Golgi apparatus to lamellar granules in human upper epidermal keratinocytes. Exp Dermatol, 16(11), 920-926.Sakai, K., Akiyama, M., Yanagi, T., McMillan, J. R., Suzuki, T., Tsukamoto, K., et al. (2009). ABCA12 is a major causative gene for non-bullous congenital ichthyosiform erythroderma. J Invest Dermatol, 129(9), 2306-2309.Schmitz, G., & Muller, G. (1991). Structure and function of lamellar bodies, lipid-protein complexes involved in storage and secretion of cellular lipids. J Lipid Res, 32(10), 1539-1570.Schmuth, M., Haqq, C. M., Cairns, W. J., Holder, J. C., Dorsam, S., Chang, S., et al. (2004). Peroxisome proliferator-activated receptor (PPAR)-beta/delta stimulates differentiation and lipid accumulation in keratinocytes. J Invest Dermatol, 122(4), 971-983.Schmuth, M., Jiang, Y. J., Dubrac, S., Elias, P. M., & Feingold, K. R. (2008). Thematic review series: skin lipids. Peroxisome proliferator-activated receptors and liver X receptors in epidermal biology. J Lipid Res, 49(3), 499-509.Sethuraman, G., Khaitan, B. K., Dash, S. S., Chandramohan, K., Sharma, V. K., Kabra, M., et al. (2008). Ichthyosiform erythroderma with rickets: report of five cases. Br J Dermatol, 158(3), 603-606.Shalita, A. R. (1987). Mucocutaneous and systemic toxicity of retinoids: monitoring and management. Dermatologica, 175 Suppl 1, 151-157.Shulenin, S., Nogee, L. M., Annilo, T., Wert, S. E., Whitsett, J. A., & Dean, M. (2004). ABCA3 gene mutations in newborns with fatal surfactant deficiency. N Engl J Med, 350(13), 1296-1303.Simon, M., Jonca, N., Guerrin, M., Haftek, M., Bernard, D., Caubet, C., et al. (2001). Refined characterization of corneodesmosin proteolysis during terminal differentiation of human epidermis and its relationship to desquamation. J Biol Chem, 276(23), 20292-20299.Singh, S., Bhura, M., Maheshwari, A., Kumar, A., Singh, C. P., & Pandey, S. S. (2001). Successful treatment of harlequin ichthyosis with acitretin. Int J Dermatol, 40(7), 472-473.Smith, F. J., Irvine, A. D., Terron-Kwiatkowski, A., Sandilands, A., Campbell, L. E., Zhao, Y., et al. (2006). Loss-of-function mutations in the gene encoding filaggrin cause ichthyosis vulgaris. Nat Genet, 38(3), 337-342.Smyth, I., Hacking, D. F., Hilton, A. A., Mukhamedova, N., Meikle, P. J., Ellis, S., et al. (2008). A mouse model of harlequin ichthyosis delineates a key role for Abca12 in lipid homeostasis. PLoS Genet, 4(9), e1000192.Sneddon, I. B. (1955). Acquired ichthyosis in Hodgkin's disease. Br Med J, 1(4916), 763-764.Sondell, B., Thornell, L. E., & Egelrud, T. (1995). Evidence that stratum corneum chymotryptic enzyme is transported to the stratum corneum extracellular space via lamellar bodies. J Invest Dermatol, 104(5), 819-823.Stefkova, J., Poledne, R., & Hubacek, J. A. (2004). ATP-binding cassette (ABC) transporters in human metabolism and diseases. Physiol Res, 53(3), 235-243.Steinert, P. M., Cantieri, J. S., Teller, D. C., Lonsdale-Eccles, J. D., & Dale, B. A. (1981). Characterization of a class of cationic proteins that specifically interact with intermediate filaments. Proc Natl Acad Sci U S A, 78(7), 4097-4101.Steven, A. C., & Steinert, P. M. (1994). Protein composition of cornified cell envelopes of epidermal keratinocytes. J Cell Sci, 107 ( Pt 2), 693-700.Strautnieks, S. S., Bull, L. N., Knisely, A. S., Kocoshis, S. A., Dahl, N., Arnell, H., et al. (1998). A gene encoding a liver-specific ABC transporter is mutated in progressive familial intrahepatic cholestasis. Nat Genet, 20(3), 233-238.Sybert, V. P., Dale, B. A., & Holbrook, K. A. (1985). Ichthyosis vulgaris: identification of a defect in synthesis of filaggrin correlated with an absence of keratohyaline granules. J Invest Dermatol, 84(3), 191-194.Taylor, E. M., Broughton, B. C., Botta, E., Stefanini, M., Sarasin, A., Jaspers, N. G., et al. (1997). Xeroderma pigmentosum and trichothiodystrophy are associated with different mutations in the XPD (ERCC2) repair/transcription gene. Proc Natl Acad Sci U S A, 94(16), 8658-8663.Teraoka, S. N., Telatar, M., Becker-Catania, S., Liang, T., Onengut, S., Tolun, A., et al. (1999). Splicing defects in the ataxia-telangiectasia gene, ATM: underlying mutations and consequences. Am J Hum Genet, 64(6), 1617-1631.Thacher, T. D., Fischer, P. R., Pettifor, J. M., & Darmstadt, G. L. (2004). Nutritional rickets in ichthyosis and response to calcipotriene. Pediatrics, 114(1), e119-123.Thomas, A. C., Cullup, T., Norgett, E. E., Hill, T., Barton, S., Dale, B. A., et al. (2006). ABCA12 is the major harlequin ichthyosis gene. J Invest Dermatol, 126(11), 2408-2413.Thomas, A. C., Sinclair, C., Mahmud, N., Cullup, T., Mellerio, J. E., Harper, J., et al. (2008). Novel and recurring ABCA12 mutations associated with harlequin ichthyosis: implications for prenatal diagnosis. Br J Dermatol, 158(3), 611-613.Thomas, A. C., Tattersall, D., Norgett, E. E., O'Toole, E. A., & Kelsell, D. P. (2009). Premature terminal differentiation and a reduction in specific proteases associated with loss of ABCA12 in Harlequin ichthyosis. Am J Pathol, 174(3), 970-978.Thomas, P. M., Cote, G. J., Wohllk, N., Haddad, B., Mathew, P. M., Rabl, W., et al. (1995). Mutations in the sulfonylurea receptor gene in familial persistent hyperinsulinemic hypoglycemia of infancy. Science, 268(5209), 426-429.Traupe, H. (1989). The ichthyoses : a guide to clinical diagnosis, genetic counseling, and therapy. Berlin ; New York: Springer-Verlag.Uitto, J., Pfendner, E., & Jackson, L. G. (2003). Probing the fetal genome: progress in non-invasive prenatal diagnosis. Trends Mol Med, 9(8), 339-343.Vohra, N., Rochelson, B., & Smith-Levitin, M. (2003). Three-dimensional sonographic findings in congenital (harlequin) ichthyosis. J Ultrasound Med, 22(7), 737-739.Wada, M., Toh, S., Taniguchi, K., Nakamura, T., Uchiumi, T., Kohno, K., et al. (1998). Mutations in the canilicular multispecific organic anion transporter (cMOAT) gene, a novel ABC transporter, in patients with hyperbilirubinemia II/Dubin-Johnson syndrome. Hum Mol Genet, 7(2), 203-207.Walker, J. E., Saraste, M., Runswick, M. J., & Gay, N. J. (1982). Distantly related sequences in the alpha- and beta-subunits of ATP synthase, myosin, kinases and other ATP-requiring enzymes and a common nucleotide binding fold. EMBO J, 1(8), 945-951.Waring, J. I. (1932). Early mention of a Harlequin fetus in America. Archives of Pediatrics and Adolescent Medicine, 43(2), 442.Webster, D., France, J. T., Shapiro, L. J., & Weiss, R. (1978). X-linked ichthyosis due to steroid-sulphatase deficiency. Lancet, 1(8055), 70-72.Weeda, G., Eveno, E., Donker, I., Vermeulen, W., Chevallier-Lagente, O., Taieb, A., et al. (1997). A mutation in the XPB/ERCC3 DNA repair transcription gene, associated with trichothiodystrophy. Am J Hum Genet, 60(2), 320-329.Westergaard, M., Henningsen, J., Johansen, C., Rasmussen, S., Svendsen, M. L., Jensen, U. B., et al. (2003). Expression and localization of peroxisome proliferator-activated receptors and nuclear factor kappaB in normal and lesional psoriatic skin. J Invest Dermatol, 121(5), 1104-1117.Willy, P. J., Umesono, K., Ong, E. S., Evans, R. M., Heyman, R. A., & Mangelsdorf, D. J. (1995). LXR, a nuclear receptor that defines a distinct retinoid response pathway. Genes Dev, 9(9), 1033-1045.Wolff, K., Goldsmith, L. A., Goldsmith, L., Gilchrest, B., Katz, S., Paller, A., et al. (2007). Fitzpatrick's Dermatology In General Medicine, Seventh Edition: Two Volumes: McGraw-Hill Companies,Inc.Woodcock-Mitchell, J., Eichner, R., Nelson, W. G., & Sun, T. T. (1982). Immunolocalization of keratin polypeptides in human epidermis using monoclonal antibodies. J Cell Biol, 95(2 Pt 1), 580-588.Yamano, G., Funahashi, H., Kawanami, O., Zhao, L. X., Ban, N., Uchida, Y., et al. (2001). ABCA3 is a lamellar body membrane protein in human lung alveolar type II cells. FEBS Lett, 508(2), 221-225.Yanagi, T., Akiyama, M., Nishihara, H., Ishikawa, J., Sakai, K., Miyamura, Y., et al. (2010). Self-improvement of keratinocyte differentiation defects during skin maturation in ABCA12-deficient harlequin ichthyosis model mice. Am J Pathol, 177(1), 106-118.Yanagi, T., Akiyama, M., Nishihara, H., Sakai, K., Nishie, W., Tanaka, S., et al. (2008). Harlequin ichthyosis model mouse reveals alveolar collapse and severe fetal skin barrier defects. Hum Mol Genet, 17(19), 3075-3083.Zuo, Y., Zhuang, D., Han, R., Isaac, G., Tobin, J., McKee, M., et al. (2008). ABCA12 maintains the epidermal lipid permeability barrier by facilitating formation of ceramide linoleic esters. Journal of Biological Chemistry, 283(52), 36624.

Aebi, M., Hornig, H., & Weissmann, C. (1987). 5' cleavage site in eukaryotic pre-mRNA splicing is determined by the overall 5' splice region, not by the conserved 5' GU. Cell, 50(2), 237-246.
Akiyama, M. (1999). The pathogenesis of severe congenital ichthyosis of the neonate. J Dermatol Sci, 21(2), 96-104.
Akiyama, M. (2010). ABCA12 mutations and autosomal recessive congenital ichthyosis: a review of genotype/phenotype correlations and of pathogenetic concepts. Hum Mutat, 31(10), 1090-1096.
Akiyama, M., Sakai, K., Hatamochi, A., Yamazaki, S., McMillan, J. R., & Shimizu, H. (2008). Novel compound heterozygous nonsense and missense ABCA12 mutations lead to nonbullous congenital ichthyosiform erythroderma. Br J Dermatol, 158(4), 864-867.
Akiyama, M., Sakai, K., Sugiyama-Nakagiri, Y., Yamanaka, Y., McMillan, J. R., Sawamura, D., et al. (2006). Compound heterozygous mutations including a de novo missense mutation in ABCA12 led to a case of harlequin ichthyosis with moderate clinical severity. J Invest Dermatol, 126(7), 1518-1523.
Akiyama, M., Shimizu, H., Yoneda, K., & Nishikawa, T. (1997). Collodion baby: ultrastructure and distribution of cornified cell envelope proteins and keratins. Dermatology, 195(2), 164-168.
Akiyama, M., Sugiyama-Nakagiri, Y., Sakai, K., McMillan, J. R., Goto, M., Arita, K., et al. (2005). Mutations in lipid transporter ABCA12 in harlequin ichthyosis and functional recovery by corrective gene transfer. J Clin Invest, 115(7), 1777-1784.
Akiyama, M., Titeux, M., Sakai, K., McMillan, J. R., Tonasso, L., Calvas, P., et al. (2007). DNA-based prenatal diagnosis of harlequin ichthyosis and characterization of ABCA12 mutation consequences. J Invest Dermatol, 127(3), 568-573.
Akiyama, M., Yoneda, K., Kim, S. Y., Koyama, H., & Shimizu, H. (1996). Cornified cell envelope proteins and keratins are normally distributed in harlequin ichthyosis. J Cutan Pathol, 23(6), 571-575.
Allikmets, R. (2000). Simple and complex ABCR: genetic predisposition to retinal disease. The American Journal of Human Genetics, 67(4), 793-799.
Allikmets, R., Shroyer, N. F., Singh, N., Seddon, J. M., Lewis, R. A., Bernstein, P. S., et al. (1997). Mutation of the Stargardt disease gene (ABCR) in age-related macular degeneration. Science, 277(5333), 1805-1807.
Andressoo, J. O., Jans, J., de Wit, J., Coin, F., Hoogstraten, D., van de Ven, M., et al. (2006). Rescue of progeria in trichothiodystrophy by homozygous lethal Xpd alleles. PLoS Biol, 4(10), e322.
Baralle, D., & Baralle, M. (2005). Splicing in action: assessing disease causing sequence changes. J Med Genet, 42(10), 737-748.
Berg, C., Geipel, A., Kohl, M., Krokowski, M., Baschat, A. A., Germer, U., et al. (2003). Prenatal sonographic features of Harlequin ichthyosis. Arch Gynecol Obstet, 268(1), 48-51.
Berge, K. E., Tian, H., Graf, G. A., Yu, L., Grishin, N. V., Schultz, J., et al. (2000). Accumulation of dietary cholesterol in sitosterolemia caused by mutations in adjacent ABC transporters. Science, 290(5497), 1771-1775.
Beutler, E., Demina, A., & Gelbart, T. (1994). Glucocerebrosidase mutations in Gaucher disease. Mol Med, 1(1), 82-92.
Bongain, A., Benoit, B., Ejnes, L., Lambert, J. C., & Gillet, J. Y. (2002). Harlequin fetus: three-dimensional sonographic findings and new diagnostic approach. Ultrasound Obstet Gynecol, 20(1), 82-85.
Bonifas, J. M., Bare, J. W., Chen, M. A., Lee, M. K., Slater, C. A., Goldsmith, L. A., et al. (1992). Linkage of the epidermolytic hyperkeratosis phenotype and the region of the type II keratin gene cluster on chromosome 12. J Invest Dermatol, 99(5), 524-527.
Borradori, L., & Sonnenberg, A. (1999). Structure and function of hemidesmosomes: more than simple adhesion complexes. J Invest Dermatol, 112(4), 411-418.
Borst, P., & Elferink, R. O. (2002). Mammalian ABC transporters in health and disease. Annu Rev Biochem, 71, 537-592.
Brecher, A. R., & Orlow, S. J. (2003). Oral retinoid therapy for dermatologic conditions in children and adolescents. J Am Acad Dermatol, 49(2), 171-182; quiz 183-176.
Brooks-Wilson, A., Marcil, M., Clee, S. M., Zhang, L. H., Roomp, K., van Dam, M., et al. (1999). Mutations in ABC1 in Tangier disease and familial high-density lipoprotein deficiency. Nat Genet, 22(4), 336-345.
Buxman, M. M., Goodkin, P. E., Fahrenbach, W. H., & Dimond, R. L. (1979). Harlequin ichthyosis with epidermal lipid abnormality. Arch Dermatol, 115(2), 189-193.
Calleja, C., Messaddeq, N., Chapellier, B., Yang, H., Krezel, W., Li, M., et al. (2006). Genetic and pharmacological evidence that a retinoic acid cannot be the RXR-activating ligand in mouse epidermis keratinocytes. Genes Dev, 20(11), 1525-1538.
Castiglia, D., Castori, M., Pisaneschi, E., Sommi, M., Covaciu, C., Zambruno, G., et al. (2009). Trisomic rescue causing reduction to homozygosity for a novel ABCA12 mutation in harlequin ichthyosis. Clinical genetics, 76(4), 392-397.
Caubet, C., Jonca, N., Brattsand, M., Guerrin, M., Bernard, D., Schmidt, R., et al. (2004). Degradation of corneodesmosome proteins by two serine proteases of the kallikrein family, SCTE/KLK5/hK5 and SCCE/KLK7/hK7. J Invest Dermatol, 122(5), 1235-1244.
Chan, Y. C., Tay, Y. K., Tan, L. K., Happle, R., & Giam, Y. C. (2003). Harlequin ichthyosis in association with hypothyroidism and juvenile rheumatoid arthritis. Pediatr Dermatol, 20(5), 421-426.
Chavanas, S., Bodemer, C., Rochat, A., Hamel-Teillac, D., Ali, M., Irvine, A. D., et al. (2000). Mutations in SPINK5, encoding a serine protease inhibitor, cause Netherton syndrome. Nat Genet, 25(2), 141-142.
Chawla, A., Repa, J. J., Evans, R. M., & Mangelsdorf, D. J. (2001). Nuclear receptors and lipid physiology: opening the X-files. Science, 294(5548), 1866-1870.
Chua, C. N., & Ainsworth, J. (2001). Ocular management of harlequin syndrome. Arch Ophthalmol, 119(3), 454-455.
Chujor, C. S., Feingold, K. R., Elias, P. M., & Holleran, W. M. (1998). Glucosylceramide synthase activity in murine epidermis: quantitation, localization, regulation, and requirement for barrier homeostasis. J Lipid Res, 39(2), 277-285.
Clee, S. M., Kastelein, J. J., van Dam, M., Marcil, M., Roomp, K., Zwarts, K. Y., et al. (2000). Age and residual cholesterol efflux affect HDL cholesterol levels and coronary artery disease in ABCA1 heterozygotes. J Clin Invest, 106(10), 1263-1270.
Clement, S. A., Burrows, N. P., Sansome, A., Hazleman, B. L., & Ostor, A. J. (2007). Harlequin ichthyosis and juvenile idiopathic arthritis: a rare combination. Clin Rheumatol, 26(3), 460-462.
Coldiron, B. M., & Bergstresser, P. R. (1989). Prevalence and clinical spectrum of skin disease in patients infected with human immunodeficiency virus. Archives of dermatology, 125(3), 357.
Compton, J. G., DiGiovanna, J. J., Santucci, S. K., Kearns, K. S., Amos, C. I., Abangan, D. L., et al. (1992). Linkage of epidermolytic hyperkeratosis to the type II keratin gene cluster on chromosome 12q. Nat Genet, 1(4), 301-305.
Culican, S. M., & Custer, P. L. (2002). Repair of cicatricial ectropion in an infant with harlequin ichthyosis using engineered human skin. Am J Ophthalmol, 134(3), 442-443.
Dale, B. A., Holbrook, K. A., Fleckman, P., Kimball, J. R., Brumbaugh, S., & Sybert, V. P. (1990). Heterogeneity in harlequin ichthyosis, an inborn error of epidermal keratinization: variable morphology and structural protein expression and a defect in lamellar granules. J Invest Dermatol, 94(1), 6-18.
Dale, B. A., Holbrook, K. A., Kimball, J. R., Hoff, M., & Sun, T. T. (1985). Expression of epidermal keratins and filaggrin during human fetal skin development. J Cell Biol, 101(4), 1257-1269.
De Laurenzi, V., Rogers, G. R., Hamrock, D. J., Marekov, L. N., Steinert, P. M., Compton, J. G., et al. (1996). Sjogren-Larsson syndrome is caused by mutations in the fatty aldehyde dehydrogenase gene. Nat Genet, 12(1), 52-57.
Dean, M., Hamon, Y., & Chimini, G. (2001). The human ATP-binding cassette (ABC) transporter superfamily. J Lipid Res, 42(7), 1007-1017.
Deleuze, J. F., Jacquemin, E., Dubuisson, C., Cresteil, D., Dumont, M., Erlinger, S., et al. (1996). Defect of multidrug-resistance 3 gene expression in a subtype of progressive familial intrahepatic cholestasis. Hepatology, 23(4), 904-908.
Descargues, P., Deraison, C., Prost, C., Fraitag, S., Mazereeuw-Hautier, J., D'Alessio, M., et al. (2006). Corneodesmosomal cadherins are preferential targets of stratum corneum trypsin- and chymotrypsin-like hyperactivity in Netherton syndrome. J Invest Dermatol, 126(7), 1622-1632.
Edwards, P. A., Kennedy, M. A., & Mak, P. A. (2002). LXRs; oxysterol-activated nuclear receptors that regulate genes controlling lipid homeostasis. Vascul Pharmacol, 38(4), 249-256.
Egberts, F., Heinrich, M., Jensen, J. M., Winoto-Morbach, S., Pfeiffer, S., Wickel, M., et al. (2004). Cathepsin D is involved in the regulation of transglutaminase 1 and epidermal differentiation. J Cell Sci, 117(Pt 11), 2295-2307.
Elias, P. M., & Brown, B. E. (1978). The mammalian cutaneous permeability barrier: defective barrier function is essential fatty acid deficiency correlates with abnormal intercellular lipid deposition. Lab Invest, 39(6), 574-583.
Elias, P. M., Crumrine, D., Rassner, U., Hachem, J. P., Menon, G. K., Man, W., et al. (2004). Basis for abnormal desquamation and permeability barrier dysfunction in RXLI. J Invest Dermatol, 122(2), 314-319.
Elias, P. M., & Feingold, K. R. (2006). Skin barrier. New York, N.Y. ; London: Taylor & Francis.
Elias, P. M., Williams, M. L., Maloney, M. E., Bonifas, J. A., Brown, B. E., Grayson, S., et al. (1984). Stratum corneum lipids in disorders of cornification. Steroid sulfatase and cholesterol sulfate in normal desquamation and the pathogenesis of recessive X-linked ichthyosis. J Clin Invest, 74(4), 1414-1421.
Estines, O., Grosieux-Dauger, C., Derancourt, C., Patey, M., Durlach, A., & Bernard, P. (2001). [Paraneoplastic acquired ichthyosis revealing non-Hodgkin's lymphoma]. Ann Dermatol Venereol, 128(1), 31-34.
Fairbrother, W. G., & Chasin, L. A. (2000). Human genomic sequences that inhibit splicing. Mol Cell Biol, 20(18), 6816-6825.
Fartasch, M. (2004). The epidermal lamellar body: a fascinating secretory organelle. J Invest Dermatol, 122(5), XI-XII.
Feingold, K. R. (1991). The regulation and role of epidermal lipid synthesis. Adv Lipid Res, 24, 57-82.
Feingold, K. R. (2007). Thematic review series: skin lipids. The role of epidermal lipids in cutaneous permeability barrier homeostasis. J Lipid Res, 48(12), 2531-2546.
Feingold, K. R., & Jiang, Y. J. The mechanisms by which lipids coordinately regulate the formation of the protein and lipid domains of the stratum corneum: Role of fatty acids, oxysterols, cholesterol sulfate and ceramides as signaling molecules. Dermatoendocrinol, 3(2), 113-118.
Fleckman, P., Dale, B. A., & Holbrook, K. A. (1985). Profilaggrin, a high-molecular-weight precursor of filaggrin in human epidermis and cultured keratinocytes. J Invest Dermatol, 85(6), 507-512.
Flint, G. L., Flam, M., & Soter, N. A. (1975). Acquired ichthyosis. A sign of nonlymphoproliferative malignant disorders. Arch Dermatol, 111(11), 1446-1447.
Fluhr, J. W., Kao, J., Jain, M., Ahn, S. K., Feingold, K. R., & Elias, P. M. (2001). Generation of free fatty acids from phospholipids regulates stratum corneum acidification and integrity. J Invest Dermatol, 117(1), 44-51.
Freinkel, R. K., & Woodley, D. (2001). The biology of the skin: Parthenon Pub. Group.
Fuchs, E., & Green, H. (1980). Changes in keratin gene expression during terminal differentiation of the keratinocyte. Cell, 19(4), 1033-1042.
Giglia-Mari, G., Coin, F., Ranish, J. A., Hoogstraten, D., Theil, A., Wijgers, N., et al. (2004). A new, tenth subunit of TFIIH is responsible for the DNA repair syndrome trichothiodystrophy group A. Nat Genet, 36(7), 714-719.
Glover, M. T., Peters, A. M., & Atherton, D. J. (1987). Surveillance for skeletal toxicity of children treated with etretinate. Br J Dermatol, 116(5), 609-614.
Graveley, B. R. (2000). Sorting out the complexity of SR protein functions. RNA, 6(9), 1197-1211.
Grubauer, G., Elias, P. M., & Feingold, K. R. (1989). Transepidermal water loss: the signal for recovery of barrier structure and function. J Lipid Res, 30(3), 323-333.
Haftek, M., Cambazard, F., Dhouailly, D., Reano, A., Simon, M., Lachaux, A., et al. (1996). A longitudinal study of a harlequin infant presenting clinically as non-bullous congenital ichthyosiform erythroderma. Br J Dermatol, 135(3), 448-453.
Halkier-Sorensen, L., Laurberg, G., & Andresen, J. (1987). Bone changes in children on long-term treatment with etretinate. J Am Acad Dermatol, 16(5 Pt 1), 999-1006.
Hanley, K., Komuves, L. G., Ng, D. C., Schoonjans, K., He, S. S., Lau, P., et al. (2000). Farnesol stimulates differentiation in epidermal keratinocytes via PPARalpha. J Biol Chem, 275(15), 11484-11491.
Hanley, K., Ng, D. C., He, S. S., Lau, P., Min, K., Elias, P. M., et al. (2000). Oxysterols induce differentiation in human keratinocytes and increase Ap-1-dependent involucrin transcription. J Invest Dermatol, 114(3), 545-553.
Happle, R. (1979). X-linked dominant chondrodysplasia punctata. Review of literature and report of a case. Hum Genet, 53(1), 65-73.
Hayward, A. F. (1979). Membrane-coating granules. Int Rev Cytol, 59, 97-127.
Hernandez-Martin, A., Gonzalez-Sarmiento, R., & De Unamuno, P. (1999). X-linked ichthyosis: an update. Br J Dermatol, 141(4), 617-627.
Hoffjan, S., & Stemmler, S. (2007). On the role of the epidermal differentiation complex in ichthyosis vulgaris, atopic dermatitis and psoriasis. Br J Dermatol, 157(3), 441-449.
Holbrook, K. A. (1991). Structure and function of the developing human skin. In: Goldsmith L.A. ed. Physiology, biochemistry, and molecular biology of the skin, vol 1. Oxford University Press: 63-110.
Hsu, W. Y., Chen, J. Y., Lin, W. L., & Tsay, C. H. (1989). [Harlequin fetus--a case report]. Zhonghua Yi Xue Za Zhi (Taipei), 43(1), 63-66.
Huber, M., Rettler, I., Bernasconi, K., Frenk, E., Lavrijsen, S. P., Ponec, M., et al. (1995). Mutations of keratinocyte transglutaminase in lamellar ichthyosis. Science, 267(5197), 525-528.
Hyde, S. C., Emsley, P., Hartshorn, M. J., Mimmack, M. M., Gileadi, U., Pearce, S. R., et al. (1990). Structural model of ATP-binding proteins associated with cystic fibrosis, multidrug resistance and bacterial transport. Nature, 346(6282), 362-365.
Igarashi, S., Takizawa, T., Yasuda, Y., Uchiwa, H., Hayashi, S., Brysk, H., et al. (2004). Cathepsin D, but not cathepsin E, degrades desmosomes during epidermal desquamation. Br J Dermatol, 151(2), 355-361.
Ishida-Yamamoto, A., Deraison, C., Bonnart, C., Bitoun, E., Robinson, R., O'Brien, T. J., et al. (2005). LEKTI is localized in lamellar granules, separated from KLK5 and KLK7, and is secreted in the extracellular spaces of the superficial stratum granulosum. J Invest Dermatol, 124(2), 360-366.
Ishida-Yamamoto, A., Richard, G., Takahashi, H., & Iizuka, H. (2003). In vivo studies of mutant keratin 1 in ichthyosis hystrix Curth-Macklin. J Invest Dermatol, 120(3), 498-500.
Ishida-Yamamoto, A., Simon, M., Kishibe, M., Miyauchi, Y., Takahashi, H., Yoshida, S., et al. (2004). Epidermal lamellar granules transport different cargoes as distinct aggregates. J Invest Dermatol, 122(5), 1137-1144.
Jiang, Y. J., Lu, B., Kim, P., Paragh, G., Schmitz, G., Elias, P. M., et al. (2008). PPAR and LXR activators regulate ABCA12 expression in human keratinocytes. J Invest Dermatol, 128(1), 104-109.
Jiang, Y. J., Uchida, Y., Lu, B., Kim, P., Mao, C., Akiyama, M., et al. (2009). Ceramide stimulates ABCA12 expression via peroxisome proliferator-activated receptor {delta} in human keratinocytes. J Biol Chem, 284(28), 18942-18952.
Jobard, F., Lefevre, C., Karaduman, A., Blanchet-Bardon, C., Emre, S., Weissenbach, J., et al. (2002). Lipoxygenase-3 (ALOXE3) and 12(R)-lipoxygenase (ALOX12B) are mutated in non-bullous congenital ichthyosiform erythroderma (NCIE) linked to chromosome 17p13.1. Hum Mol Genet, 11(1), 107-113.
Kalinin, A., Marekov, L. N., & Steinert, P. M. (2001). Assembly of the epidermal cornified cell envelope. J Cell Sci, 114(Pt 17), 3069-3070.
Kelsell, D. P., Norgett, E. E., Unsworth, H., Teh, M. T., Cullup, T., Mein, C. A., et al. (2005). Mutations in ABCA12 underlie the severe congenital skin disease harlequin ichthyosis. Am J Hum Genet, 76(5), 794-803.
Kersten, S., Desvergne, B., & Wahli, W. (2000). Roles of PPARs in health and disease. Nature, 405(6785), 421-424.
Khan, R., Arora, S., El-Hindy, N., & Chang, B. Y. (2009). Repair of cicatricial ectropion in a harlequin baby. J AAPOS, 13(4), 415-416.
Knight, H., Pickard, B., Maclean, A., Malloy, M., Soares, D., McRae, A., et al. (2009). A Cytogenetic Abnormality and Rare Coding Variants Identify ABCA13 as a Candidate Gene in Schizophrenia, Bipolar Disorder, and Depression. American journal of human genetics.
Komuves, L. G., Schmuth, M., Fowler, A. J., Elias, P. M., Hanley, K., Man, M. Q., et al. (2002). Oxysterol stimulation of epidermal differentiation is mediated by liver X receptor-beta in murine epidermis. J Invest Dermatol, 118(1), 25-34.
Konig, A., Happle, R., Bornholdt, D., Engel, H., & Grzeschik, K. H. (2000). Mutations in the NSDHL gene, encoding a 3beta-hydroxysteroid dehydrogenase, cause CHILD syndrome. Am J Med Genet, 90(4), 339-346.
Krawczak, M., Reiss, J., & Cooper, D. N. (1992). The mutational spectrum of single base-pair substitutions in mRNA splice junctions of human genes: causes and consequences. Hum Genet, 90(1-2), 41-54.
Kremer, H., Zeeuwen, P., McLean, W. H., Mariman, E. C., Lane, E. B., van de Kerkhof, C. M., et al. (1994). Ichthyosis bullosa of Siemens is caused by mutations in the keratin 2e gene. J Invest Dermatol, 103(3), 286-289.
Kuokkanen, K. (1969). Ichthyosis vulgaris. A clinical and histopathological study of patients and their close relatives in the autosomal dominant and sex-linked forms of the disease. Acta Derm Venereol Suppl (Stockh), 62, 1-72.
Landmann, L. (1986). Epidermal permeability barrier: transformation of lamellar granule-disks into intercellular sheets by a membrane-fusion process, a freeze-fracture study. J Invest Dermatol, 87(2), 202-209.
Le Saux, O., Urban, Z., Tschuch, C., Csiszar, K., Bacchelli, B., Quaglino, D., et al. (2000). Mutations in a gene encoding an ABC transporter cause pseudoxanthoma elasticum. Nature genetics, 25(2), 223-227.
Lechler, T., & Fuchs, E. (2005). Asymmetric cell divisions promote stratification and differentiation of mammalian skin. Nature, 437(7056), 275-280.
Lee, M. H., Lu, K., Hazard, S., Yu, H., Shulenin, S., Hidaka, H., et al. (2001). Identification of a gene, ABCG5, important in the regulation of dietary cholesterol absorption. Nat Genet, 27(1), 79-83.
Lee, S. H., Elias, P. M., Proksch, E., Menon, G. K., Mao-Quiang, M., & Feingold, K. R. (1992). Calcium and potassium are important regulators of barrier homeostasis in murine epidermis. J Clin Invest, 89(2), 530-538.
Lefevre, C., Audebert, S., Jobard, F., Bouadjar, B., Lakhdar, H., Boughdene-Stambouli, O., et al. (2003). Mutations in the transporter ABCA12 are associated with lamellar ichthyosis type 2. Hum Mol Genet, 12(18), 2369-2378.
Lefevre, C., Bouadjar, B., Ferrand, V., Tadini, G., Megarbane, A., Lathrop, M., et al. (2006). Mutations in a new cytochrome P450 gene in lamellar ichthyosis type 3. Hum Mol Genet, 15(5), 767-776.
Lefevre, C., Bouadjar, B., Karaduman, A., Jobard, F., Saker, S., Ozguc, M., et al. (2004). Mutations in ichthyin a new gene on chromosome 5q33 in a new form of autosomal recessive congenital ichthyosis. Hum Mol Genet, 13(20), 2473-2482.
Lefevre, C., Jobard, F., Caux, F., Bouadjar, B., Karaduman, A., Heilig, R., et al. (2001). Mutations in CGI-58, the gene encoding a new protein of the esterase/lipase/thioesterase subfamily, in Chanarin-Dorfman syndrome. Am J Hum Genet, 69(5), 1002-1012.
Man, M. Q., Barish, G. D., Schmuth, M., Crumrine, D., Barak, Y., Chang, S., et al. (2008). Deficiency of PPARbeta/delta in the epidermis results in defective cutaneous permeability barrier homeostasis and increased inflammation. J Invest Dermatol, 128(2), 370-377.
Man, M. Q., Choi, E. H., Schmuth, M., Crumrine, D., Uchida, Y., Elias, P. M., et al. (2006). Basis for improved permeability barrier homeostasis induced by PPAR and LXR activators: liposensors stimulate lipid synthesis, lamellar body secretion, and post-secretory lipid processing. J Invest Dermatol, 126(2), 386-392.
Manabe, M., Sanchez, M., Sun, T. T., & Dale, B. A. (1991). Interaction of filaggrin with keratin filaments during advanced stages of normal human epidermal differentiation and in ichthyosis vulgaris. Differentiation, 48(1), 43-50.
Mangelsdorf, D. J., & Evans, R. M. (1995). The RXR heterodimers and orphan receptors. Cell, 83(6), 841-850.
Mao-Qiang, M., Fowler, A. J., Schmuth, M., Lau, P., Chang, S., Brown, B. E., et al. (2004). Peroxisome-proliferator-activated receptor (PPAR)-gamma activation stimulates keratinocyte differentiation. J Invest Dermatol, 123(2), 305-312.
Maquat, L. E. (2001). The power of point mutations. Nat Genet, 27(1), 5-6.
Marenholz, I., Nickel, R., Ruschendorf, F., Schulz, F., Esparza-Gordillo, J., Kerscher, T., et al. (2006). Filaggrin loss-of-function mutations predispose to phenotypes involved in the atopic march. J Allergy Clin Immunol, 118(4), 866-871.
Milner, M. E., O'Guin, W. M., Holbrook, K. A., & Dale, B. A. (1992). Abnormal lamellar granules in harlequin ichthyosis. J Invest Dermatol, 99(6), 824-829.
Milstone, L. M., Ellison, A. F., & Insogna, K. L. (1992). Serum parathyroid hormone level is elevated in some patients with disorders of keratinization. Arch Dermatol, 128(7), 926-930.
Milstone, L. M., McGuire, J., & Ablow, R. C. (1982). Premature epiphyseal closure in a child receiving oral 13-cis-retinoic acid. J Am Acad Dermatol, 7(5), 663-666.
Mitsutake, S., Suzuki, C., Akiyama, M., Tsuji, K., Yanagi, T., Shimizu, H., et al. (2010). ABCA12 dysfunction causes a disorder in glucosylceramide accumulation during keratinocyte differentiation. J Dermatol Sci, 60(2), 128-129.
Morley, S. M., Dundas, S. R., James, J. L., Gupta, T., Brown, R. A., Sexton, C. J., et al. (1995). Temperature sensitivity of the keratin cytoskeleton and delayed spreading of keratinocyte lines derived from EBS patients. J Cell Sci, 108 ( Pt 11), 3463-3471.
Moskowitz, D. G., Fowler, A. J., Heyman, M. B., Cohen, S. P., Crumrine, D., Elias, P. M., et al. (2004). Pathophysiologic basis for growth failure in children with ichthyosis: an evaluation of cutaneous ultrastructure, epidermal permeability barrier function, and energy expenditure. J Pediatr, 145(1), 82-92.
Mosser, J., Douar, A. M., Sarde, C. O., Kioschis, P., Feil, R., Moser, H., et al. (1993). Putative X-linked adrenoleukodystrophy gene shares unexpected homology with ABC transporters. Nature, 361(6414), 726-730.
Natsuga, K., Akiyama, M., Kato, N., Sakai, K., Sugiyama-Nakagiri, Y., Nishimura, M., et al. (2007). Novel ABCA12 mutations identified in two cases of non-bullous congenital ichthyosiform erythroderma associated with multiple skin malignant neoplasia. J Invest Dermatol, 127(11), 2669-2673.
Nemes, Z., & Steinert, P. M. (1999). Bricks and mortar of the epidermal barrier. Exp Mol Med, 31(1), 5-19.
Nikkari, T., Schreibman, P. H., & Ahrens, E. H., Jr. (1975). Isotope kinetics of human skin cholesterol secretion. J Exp Med, 141(3), 620-634.
Nilsen, T. W. (1994). RNA-RNA interactions in the spliceosome: unraveling the ties that bind. Cell, 78(1), 1-4.
Norlen, L. (2001). Skin barrier formation: the membrane folding model. J Invest Dermatol, 117(4), 823-829.
Odland, G. F. (1960). A submicroscopic granular component in human epidermis. J Invest Dermatol, 34, 11-15.
Oeffner, F., Fischer, G., Happle, R., Konig, A., Betz, R. C., Bornholdt, D., et al. (2009). IFAP syndrome is caused by deficiency in MBTPS2, an intramembrane zinc metalloprotease essential for cholesterol homeostasis and ER stress response. Am J Hum Genet, 84(4), 459-467.
Oji, V., Hautier, J. M., Ahvazi, B., Hausser, I., Aufenvenne, K., Walker, T., et al. (2006). Bathing suit ichthyosis is caused by transglutaminase-1 deficiency: evidence for a temperature-sensitive phenotype. Hum Mol Genet, 15(21), 3083-3097.
Oji, V., & Traupe, H. (2006). Ichthyoses: differential diagnosis and molecular genetics. Eur J Dermatol, 16(4), 349-359.
Paige, D. G., Judge, M. R., Shaw, D. G., Atherton, D. J., & Harper, J. I. (1992). Bone changes and their significance in children with ichthyosis on long-term etretinate therapy. Br J Dermatol, 127(4), 387-391.
Palmer, C. N., Irvine, A. D., Terron-Kwiatkowski, A., Zhao, Y., Liao, H., Lee, S. P., et al. (2006). Common loss-of-function variants of the epidermal barrier protein filaggrin are a major predisposing factor for atopic dermatitis. Nat Genet, 38(4), 441-446.
Peelman, F., Labeur, C., Vanloo, B., Roosbeek, S., Devaud, C., Duverger, N., et al. (2003). Characterization of the ABCA transporter subfamily: identification of prokaryotic and eukaryotic members, phylogeny and topology. J Mol Biol, 325(2), 259-274.
Prendiville, J., Bingham, E. A., & Burrows, D. (1986). Premature epiphyseal closure--a complication of etretinate therapy in children. J Am Acad Dermatol, 15(6), 1259-1262.
Raghunath, M., Hennies, H. C., Ahvazi, B., Vogel, M., Reis, A., Steinert, P. M., et al. (2003). Self-healing collodion baby: a dynamic phenotype explained by a particular transglutaminase-1 mutation. J Invest Dermatol, 120(2), 224-228.
Rajamani, S., Birnkrant, D. J., & Rodgers, M. (2000). Use of bronchoalveolar lavage to demonstrate squamous epithelial aspiration in congenital icthyosis: a case report. J Perinatol, 20(5), 329-330.
Rajpar, S. F., Cullup, T., Kelsell, D. P., & Moss, C. (2006). A novel ABCA12 mutation underlying a case of Harlequin ichthyosis. Br J Dermatol, 155(1), 204-206.
Rassner, U., Feingold, K. R., Crumrine, D. A., & Elias, P. M. (1999). Coordinate assembly of lipids and enzyme proteins into epidermal lamellar bodies. Tissue Cell, 31(5), 489-498.
Reese, M. G., Eeckman, F. H., Kulp, D., & Haussler, D. (1997). Improved splice site detection in Genie. J Comput Biol, 4(3), 311-323.
Riordan, J. R., Rommens, J. M., Kerem, B., Alon, N., Rozmahel, R., Grzelczak, Z., et al. (1989). Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science, 245(4922), 1066-1073.
Rivier, M., Castiel, I., Safonova, I., Ailhaud, G., & Michel, S. (2000). Peroxisome proliferator-activated receptor-alpha enhances lipid metabolism in a skin equivalent model. J Invest Dermatol, 114(4), 681-687.
Rivier, M., Safonova, I., Lebrun, P., Griffiths, C. E., Ailhaud, G., & Michel, S. (1998). Differential expression of peroxisome proliferator-activated receptor subtypes during the differentiation of human keratinocytes. J Invest Dermatol, 111(6), 1116-1121.
Rothnagel, J. A., Traupe, H., Wojcik, S., Huber, M., Hohl, D., Pittelkow, M. R., et al. (1994). Mutations in the rod domain of keratin 2e in patients with ichthyosis bullosa of Siemens. Nat Genet, 7(4), 485-490.
Russell, L. E., Harrison, W. J., Bahta, A. W., Zouboulis, C. C., Burrin, J. M., & Philpott, M. P. (2007). Characterization of liver X receptor expression and function in human skin and the pilosebaceous unit. Exp Dermatol, 16(10), 844-852.
Russell, L. J., DiGiovanna, J. J., Rogers, G. R., Steinert, P. M., Hashem, N., Compton, J. G., et al. (1995). Mutations in the gene for transglutaminase 1 in autosomal recessive lamellar ichthyosis. Nat Genet, 9(3), 279-283.
Sakai, K., Akiyama, M., Sugiyama-Nakagiri, Y., McMillan, J. R., Sawamura, D., & Shimizu, H. (2007). Localization of ABCA12 from Golgi apparatus to lamellar granules in human upper epidermal keratinocytes. Exp Dermatol, 16(11), 920-926.
Sakai, K., Akiyama, M., Yanagi, T., McMillan, J. R., Suzuki, T., Tsukamoto, K., et al. (2009). ABCA12 is a major causative gene for non-bullous congenital ichthyosiform erythroderma. J Invest Dermatol, 129(9), 2306-2309.
Schmitz, G., & Muller, G. (1991). Structure and function of lamellar bodies, lipid-protein complexes involved in storage and secretion of cellular lipids. J Lipid Res, 32(10), 1539-1570.
Schmuth, M., Haqq, C. M., Cairns, W. J., Holder, J. C., Dorsam, S., Chang, S., et al. (2004). Peroxisome proliferator-activated receptor (PPAR)-beta/delta stimulates differentiation and lipid accumulation in keratinocytes. J Invest Dermatol, 122(4), 971-983.
Schmuth, M., Jiang, Y. J., Dubrac, S., Elias, P. M., & Feingold, K. R. (2008). Thematic review series: skin lipids. Peroxisome proliferator-activated receptors and liver X receptors in epidermal biology. J Lipid Res, 49(3), 499-509.
Sethuraman, G., Khaitan, B. K., Dash, S. S., Chandramohan, K., Sharma, V. K., Kabra, M., et al. (2008). Ichthyosiform erythroderma with rickets: report of five cases. Br J Dermatol, 158(3), 603-606.
Shalita, A. R. (1987). Mucocutaneous and systemic toxicity of retinoids: monitoring and management. Dermatologica, 175 Suppl 1, 151-157.
Shulenin, S., Nogee, L. M., Annilo, T., Wert, S. E., Whitsett, J. A., & Dean, M. (2004). ABCA3 gene mutations in newborns with fatal surfactant deficiency. N Engl J Med, 350(13), 1296-1303.
Simon, M., Jonca, N., Guerrin, M., Haftek, M., Bernard, D., Caubet, C., et al. (2001). Refined characterization of corneodesmosin proteolysis during terminal differentiation of human epidermis and its relationship to desquamation. J Biol Chem, 276(23), 20292-20299.
Singh, S., Bhura, M., Maheshwari, A., Kumar, A., Singh, C. P., & Pandey, S. S. (2001). Successful treatment of harlequin ichthyosis with acitretin. Int J Dermatol, 40(7), 472-473.
Smith, F. J., Irvine, A. D., Terron-Kwiatkowski, A., Sandilands, A., Campbell, L. E., Zhao, Y., et al. (2006). Loss-of-function mutations in the gene encoding filaggrin cause ichthyosis vulgaris. Nat Genet, 38(3), 337-342.
Smyth, I., Hacking, D. F., Hilton, A. A., Mukhamedova, N., Meikle, P. J., Ellis, S., et al. (2008). A mouse model of harlequin ichthyosis delineates a key role for Abca12 in lipid homeostasis. PLoS Genet, 4(9), e1000192.
Sneddon, I. B. (1955). Acquired ichthyosis in Hodgkin's disease. Br Med J, 1(4916), 763-764.
Sondell, B., Thornell, L. E., & Egelrud, T. (1995). Evidence that stratum corneum chymotryptic enzyme is transported to the stratum corneum extracellular space via lamellar bodies. J Invest Dermatol, 104(5), 819-823.
Stefkova, J., Poledne, R., & Hubacek, J. A. (2004). ATP-binding cassette (ABC) transporters in human metabolism and diseases. Physiol Res, 53(3), 235-243.
Steinert, P. M., Cantieri, J. S., Teller, D. C., Lonsdale-Eccles, J. D., & Dale, B. A. (1981). Characterization of a class of cationic proteins that specifically interact with intermediate filaments. Proc Natl Acad Sci U S A, 78(7), 4097-4101.
Steven, A. C., & Steinert, P. M. (1994). Protein composition of cornified cell envelopes of epidermal keratinocytes. J Cell Sci, 107 ( Pt 2), 693-700.
Strautnieks, S. S., Bull, L. N., Knisely, A. S., Kocoshis, S. A., Dahl, N., Arnell, H., et al. (1998). A gene encoding a liver-specific ABC transporter is mutated in progressive familial intrahepatic cholestasis. Nat Genet, 20(3), 233-238.
Sybert, V. P., Dale, B. A., & Holbrook, K. A. (1985). Ichthyosis vulgaris: identification of a defect in synthesis of filaggrin correlated with an absence of keratohyaline granules. J Invest Dermatol, 84(3), 191-194.
Taylor, E. M., Broughton, B. C., Botta, E., Stefanini, M., Sarasin, A., Jaspers, N. G., et al. (1997). Xeroderma pigmentosum and trichothiodystrophy are associated with different mutations in the XPD (ERCC2) repair/transcription gene. Proc Natl Acad Sci U S A, 94(16), 8658-8663.
Teraoka, S. N., Telatar, M., Becker-Catania, S., Liang, T., Onengut, S., Tolun, A., et al. (1999). Splicing defects in the ataxia-telangiectasia gene, ATM: underlying mutations and consequences. Am J Hum Genet, 64(6), 1617-1631.
Thacher, T. D., Fischer, P. R., Pettifor, J. M., & Darmstadt, G. L. (2004). Nutritional rickets in ichthyosis and response to calcipotriene. Pediatrics, 114(1), e119-123.
Thomas, A. C., Cullup, T., Norgett, E. E., Hill, T., Barton, S., Dale, B. A., et al. (2006). ABCA12 is the major harlequin ichthyosis gene. J Invest Dermatol, 126(11), 2408-2413.
Thomas, A. C., Sinclair, C., Mahmud, N., Cullup, T., Mellerio, J. E., Harper, J., et al. (2008). Novel and recurring ABCA12 mutations associated with harlequin ichthyosis: implications for prenatal diagnosis. Br J Dermatol, 158(3), 611-613.
Thomas, A. C., Tattersall, D., Norgett, E. E., O'Toole, E. A., & Kelsell, D. P. (2009). Premature terminal differentiation and a reduction in specific proteases associated with loss of ABCA12 in Harlequin ichthyosis. Am J Pathol, 174(3), 970-978.
Thomas, P. M., Cote, G. J., Wohllk, N., Haddad, B., Mathew, P. M., Rabl, W., et al. (1995). Mutations in the sulfonylurea receptor gene in familial persistent hyperinsulinemic hypoglycemia of infancy. Science, 268(5209), 426-429.
Traupe, H. (1989). The ichthyoses : a guide to clinical diagnosis, genetic counseling, and therapy. Berlin ; New York: Springer-Verlag.
Uitto, J., Pfendner, E., & Jackson, L. G. (2003). Probing the fetal genome: progress in non-invasive prenatal diagnosis. Trends Mol Med, 9(8), 339-343.
Vohra, N., Rochelson, B., & Smith-Levitin, M. (2003). Three-dimensional sonographic findings in congenital (harlequin) ichthyosis. J Ultrasound Med, 22(7), 737-739.
Wada, M., Toh, S., Taniguchi, K., Nakamura, T., Uchiumi, T., Kohno, K., et al. (1998). Mutations in the canilicular multispecific organic anion transporter (cMOAT) gene, a novel ABC transporter, in patients with hyperbilirubinemia II/Dubin-Johnson syndrome. Hum Mol Genet, 7(2), 203-207.
Walker, J. E., Saraste, M., Runswick, M. J., & Gay, N. J. (1982). Distantly related sequences in the alpha- and beta-subunits of ATP synthase, myosin, kinases and other ATP-requiring enzymes and a common nucleotide binding fold. EMBO J, 1(8), 945-951.
Waring, J. I. (1932). Early mention of a Harlequin fetus in America. Archives of Pediatrics and Adolescent Medicine, 43(2), 442.
Webster, D., France, J. T., Shapiro, L. J., & Weiss, R. (1978). X-linked ichthyosis due to steroid-sulphatase deficiency. Lancet, 1(8055), 70-72.
Weeda, G., Eveno, E., Donker, I., Vermeulen, W., Chevallier-Lagente, O., Taieb, A., et al. (1997). A mutation in the XPB/ERCC3 DNA repair transcription gene, associated with trichothiodystrophy. Am J Hum Genet, 60(2), 320-329.
Westergaard, M., Henningsen, J., Johansen, C., Rasmussen, S., Svendsen, M. L., Jensen, U. B., et al. (2003). Expression and localization of peroxisome proliferator-activated receptors and nuclear factor kappaB in normal and lesional psoriatic skin. J Invest Dermatol, 121(5), 1104-1117.
Willy, P. J., Umesono, K., Ong, E. S., Evans, R. M., Heyman, R. A., & Mangelsdorf, D. J. (1995). LXR, a nuclear receptor that defines a distinct retinoid response pathway. Genes Dev, 9(9), 1033-1045.
Wolff, K., Goldsmith, L. A., Goldsmith, L., Gilchrest, B., Katz, S., Paller, A., et al. (2007). Fitzpatrick's Dermatology In General Medicine, Seventh Edition: Two Volumes: McGraw-Hill Companies,Inc.
Woodcock-Mitchell, J., Eichner, R., Nelson, W. G., & Sun, T. T. (1982). Immunolocalization of keratin polypeptides in human epidermis using monoclonal antibodies. J Cell Biol, 95(2 Pt 1), 580-588.
Yamano, G., Funahashi, H., Kawanami, O., Zhao, L. X., Ban, N., Uchida, Y., et al. (2001). ABCA3 is a lamellar body membrane protein in human lung alveolar type II cells. FEBS Lett, 508(2), 221-225.
Yanagi, T., Akiyama, M., Nishihara, H., Ishikawa, J., Sakai, K., Miyamura, Y., et al. (2010). Self-improvement of keratinocyte differentiation defects during skin maturation in ABCA12-deficient harlequin ichthyosis model mice. Am J Pathol, 177(1), 106-118.
Yanagi, T., Akiyama, M., Nishihara, H., Sakai, K., Nishie, W., Tanaka, S., et al. (2008). Harlequin ichthyosis model mouse reveals alveolar collapse and severe fetal skin barrier defects. Hum Mol Genet, 17(19), 3075-3083.







IAAFVKKLVYEKDLRLHEYM 	Canis lupus familiaris
IAAFVKKLVYEKDLRLHEYM 	Bos taurus
IAAFVKKLVYEKDLRLHEYM 	Mus musculus
IADFVKTLVQEKDLRLYEYM 	Gallus gallus
IADFVKKLVHERELRLHEYM 	Danio rerio
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